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“If we knew what it was we were doing, it would not be
called research, would it?”
Attributed to Albert Einstein
I am delighted to welcome you to the ninth edition of the RCSIsmj.
This year we received an unprecedented number of fabulous
submissions from the RCSI student body, and as a result were able
to fill a larger issue than ever before with high-quality pieces. I am
confident that you will enjoy their work and learn a great deal from
it. Our training has deeply instilled in us the concept of
evidence-based decision-making, and we are introduced to research
as an educational tool from the very beginning of medical school.
Still, participation in the ‘publish or perish’ world of medical
research can be extremely daunting for young scientists. The
RCSIsmj aims to ease students at all levels of their training into the
research and publication process in a collaborative, collegial
environment. The result is the Journal you hold in your hands, but
also (we hope) the initiation of several early physician-scientist
careers. The RCSIsmj is a student-run organisation; all of the content
published within is written, reviewed, selected, and edited by
students, and our journal clubs are organised and presented by
students for discussion with our peers. We are extraordinarily
grateful for the support and assistance we receive from the Dean’s
office in the RCSI, and from the faculty who take time out of their
busy schedules to participate in journal activities. This publication
would not be possible without any of them.
Though my involvement with the RCSIsmj has come to an end, I am
excited to watch the Journal continue to grow and evolve under the
guidance of the next generations of students. I hope that through
their involvement they find, as I have, the confidence to dive head
first into the challenging and rewarding world of medical research.
As we wade through electronic journals, PowerPoint presentations,
and modern mobile applications in the course of our medical
education, the increased influence of modern science and
technology makes it all too easy to think of medicine as a pure
science. In this issue of the RCSIsmj, Vincent Healy’s review of the
quest to build an ‘artificial womb’ and Jenna Geers’ discussion of
incorporating whole genomic sequencing in the clinic exemplify
how modern technology and science have changed the face of
medicine. Reviews of relatively well-studied topics such as
fibromyalgia by Ghaleb Halaseh, diabetes by Samar Atteih, and
antibiotics by Stephanie Tung highlight how our approach to
diseases that are well understood continues to be moulded as our
knowledge grows.
In addition to discussing advances in science, in this issue we also
reflect the other side – that is, the art – of medicine. Travel briefs by
Luke Gin and Amenah Dhanoon illustrate the true essence of
medicine in nations dealing with difficult situations (such as Nepal
and Syria, respectively), while Danielle Wuebbolt’s visit to Shanghai
demonstrates how culture affects medicine. Jessica Suddaby
examines the challenges and opportunities facing refugee and
migrant healthcare in Europe, Katie Dunleavy et al. discuss the
rotavirus burden and impact of vaccination in Uganda, and Naomi
O’Sullivan takes us beyond our shrinking world to discuss medicine
in space! The concepts of medicine as an art and science collide as
Amelia Reid explores changing attitudes to communication, Michael
Bravo argues for ‘sharing and caring’ in the world of scientific and
medical literature, and Deirdre Harford, in her prize winning essay,
deliberates on the ethics associated with the use of untested drugs
in the treatment of the Ebola virus. Apart from reflecting how the
world continues to evolve, they also serve as a reminder that
humanity and the art of medicine are still very much alive and well,
and not merely romantic rhetoric.
There is something to learn from every patient and every moment
in medicine, and (we hope) in every page of this Journal. The pieces
within exemplify the need to constantly evaluate our actions and
motivations, particularly in how we balance science and art. Though
our world continues to evolve, and science continues to advance,
medicine desperately requires both and has since the time of
Hippocrates. After all, “wherever the art of medicine is loved, there
is also a love of humanity.”
Mohit Butaney
Editor-in-Chief, RCSIsmj 2015-2016
Natalie Achamallah
Director, RCSIsmj 2015-2016
Medicine: science or art?
Director’s welcome
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Gene editing allows sections of DNA from a genome to be precisely
replaced or removed using ‘molecular scissors’. Techniques such as
CRISPR-Cas9 can modify genomes of living organisms at precise
locations in more specific and more cost-effective ways than were
previously possible.1 In the future, these tools also hold the potential to
be applied clinically to prevent or treat lethal and/or seriously
debilitating genetic diseases. Gene editing of somatic cells is currently in
clinical development for a variety of conditions, including HIV and
leukaemia.2 Human germline editing, which involves altering genes in
sperm, eggs or embryos, holds the possibility of not only correcting
genes that cause disease, but also of passing those genetic fixes on to
future generations. In April 2015, researchers in China announced that
they had attempted to use CRISPR-Cas9 to edit non-viable human
embryos with a debilitating disease. The experiment was partially
successful, but the team concluded that there are still hurdles to
overcome before CRISPR is safe for clinical use.3 The announcement was
welcomed by some in the scientific community as a major step forward
in eradicating debilitating human disease. Although these embryos were
non-viable – they could not result in a pregnancy – a public outcry
arose that the scientists had taken an alarming step towards the
creation of ‘designer babies’.4 Then, in February 2016, the Human
Fertilisation and Embryo Authority (HFEA) in the United Kingdom
approved an application from Dr Kathy Niakan of the Francis Crick
Institute to renew her laboratory’s research licence to include gene
editing of embryos. In its approval, the HFEA stated that no research
using gene editing could take place without research ethics approval,
and that it is illegal to transfer any embryo used in research to a woman
for treatment.5 Around the world, laws and guidelines vary widely about
whether germline, or hereditary, research is allowed. Some ban any
research; some allow only lab research but not pregnancies; and, some
have no policies.
Questions
1. Should a temporary or permanent global ban on human germline
editing be introduced and, if so, on what basis?
2. Is there an ethical difference between using gene editing for the
avoidance of severe inherited diseases or for ‘enhancement’ of
human capabilities?
Ethics Challenge
2016/2017
GENE EDITING
This is the eighth instalment of the RCSIsmj Ethics Challenge.
The editorial staff would like to congratulate Deirdre Harford
on her winning essay in the 2015/2016 Ethics Challenge. Please
see page 6 for her submission.
We invite students to submit an essay discussing the ethical
questions raised in the scenario presented. Medical ethics is an
essential aspect of the medical curriculum and we hope to
encourage RCSI students to think critically about ethical situations
that arise during their education and subsequent careers. All essays
will be reviewed by a faculty panel of experts and the winning essay
will be published in the 2017 print edition of the RCSIsmj. The
deadline for submission of entries will be the same as the general
submission deadline for the 2017 edition of the RCSIsmj. Please visit
our website at www.rcsismj.com for specific dates. Please contact us
at editorsmj@rcsi.ie with any questions or concerns.
Submission guidelines
Please construct a lucid, structured and well-presented discourse
for the issues raised by this scenario. Please ensure that you have
addressed all the questions highlighted and discuss these ethical
issues academically, making sure to reference when necessary.
Your paper should not exceed 2,000 words.
Your essay will be evaluated on three major criteria:
1. Ability to identify the ethical issues raised.
2. Fluency of your arguments.
3. Academic quality with regard to depth of research,
appropriateness of references and quality of sources.
Good luck!
The winning entry will be presented with a prize at the launch
of the next issue.
References
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Introduction
The 2015/2016 RCSIsmj Ethics Challenge presents the dilemma
surrounding Ebola treatments and their distribution.1 Mapp
Biopharmaceuticals, an American pharmaceutical company, has
developed a number of promising but untested vaccines for
treatment of the virus.2 With rising incidence and high mortality
rates, the WHO decided to back the use of ZMapp, an untested
Ebola intervention, in humans.3
Faced with this multi-faceted outbreak, we find ourselves placing
under the microscope our principles with regard to clinical trials,
intervention availability and duty of care beliefs. Further ethical
questions arose following news that American missionaries who
became infected while providing care to Ebola patients4 received
ZMapp treatment and subsequently recovered, having been
selected over Africans to receive the treatment.1 This article aims to
examine the ethical grounds for providing patients with an untested
drug for diseases such as Ebola, and the distribution, prioritisation
and criteria for deciding the recipients of said treatment.
Providing Ebola patients with an untested drug
“Never mind that they haven’t been tested for safety. Believe me, I’d
run for the freezer and ask for forgiveness instead of permission.”5
Erica Ollmann Saphire, Scripps Research Institute, San Diego.
In the face of a crisis of this scale, parameters of right and wrong
became less well defined and the magnitude of the disaster forced
healthcare professionals to re-evaluate previously held values and
principles. 
Traditionally, medical practice hangs on the four ethical principles
from the work of Beauchamp and Childress, who believed that it is
“legitimate and rewarding” to apply general ethical principles to
medicine.6 This framework sets out the following:
Beneficence: providing benefits and balancing them with risks
High mortality rates, as high as 70%, fuelled the WHO’s decision to
offer untested drugs,3 as conventional care failed to produce
acceptable clinical outcomes.7,8
ETHICS CHALLENGE WINNER 2015/2016
The use of untested drugs in the
treatment of the Ebola virus
Deirdre Harford
RCSI medical student
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As with all communicable diseases, containment is of the utmost
importance, and therefore co-operation with health authorities,
for instance regarding sanitation laws such as burial practices,9-11 is
a top priority. Decisions about experimental treatments may
damage the trust placed in a system and thereby jeopardise such
protocols,10 should the experimental treatments prove to be
harmful or of no benefit.
However, some argue that on a public level, distribution of an
experimental drug through a “transparent and equitable process”
may rebuild and fortify the trust placed in health systems.12 It is
also true that in return for any form of compliance or trust on the
patient’s side, they expect the provision of respectable standards
of care.13
Writing for the Journal of Medical Ethics, Angus Dawson described
the use of ZMmapp as clearly following “directly from a
physician’s general duty to do what is best for their patients,
which is already explicitly endorsed by the Helsinki
Declaration”.14,15
Respect for autonomy: respecting the capacity of autonomous
persons to make decisions
Ethical medicine recognises that a patient’s ability to think and act
independently is what facilitates all other morals in life, and is
therefore prioritised.16 It is questionable how informed a generally
disadvantaged population – particularly with regard to education –
can be about Ebola treatments. Indeed, one of the most
contentious issues surrounding the Ebola outbreak is its
geographical location. Many of the organisations tackling the
outbreak believe that bringing an untested drug into a population
that is already distrustful of the teams providing help is unfeasible.5
In their report, the WHO recommended that the limited supply of
ZMapp should generate as much data as possible, with a moral
obligation being placed on the collection and free distribution of
this data.17 In other words, as close as is possible to a clinical trial
should be conducted given the circumstances. To fulfil these
criteria while respecting autonomy, clear explanations of these
trials and informed consent from patients is vital.17
This outbreak has highlighted the need for trust, and for public
understanding of treatment evaluation, and the necessity of
conducting ethical research and subsequent interventions under
crisis conditions.18
Non-maleficence: avoiding causation of harm
Our duty of primum non nocere is in jeopardy when we
experiment with untested drugs on patients,19 which is bad
practice under usual circumstances. This potential harm not only
threatens the patient, but also wider society.18 The
consequences of unprecedented harm from use of an untested
drug could jeopardise both the outbreak response (as the trust
of patients and the public is lost) and efforts to develop future
treatments.18 However, the lack of a definitive treatment equates
to a limited incentive to present for medical help,20 which
causes harm to patients who may nevertheless benefit from
supportive care.
Many of the organisations tackling the
outbreak believe that bringing an untested
drug into a population that is already
distrustful of the teams providing 
help is unfeasible.
Justice: fairly distributing risks and benefits
In the midst of an outbreak such as Ebola, there is still an
obligation to ensure that all societies benefit equally. The
development of stable, functional health systems offering a
respectable level of care ensures that all communities obtain fair
benefits from research during this epidemic, regardless of where
this research is carried out.21 Offering an untested drug, under as
close to clinical trial conditions as possible, challenges this
principle.
In order for clinical research to be ethical, it requires equipoise – a
state of genuine uncertainty regarding comparative therapeutic
merits. However, if it becomes known that one treatment is of
superior therapeutic merit (with conventional care proving to be of
little benefit), there is an ethical obligation to offer the superior
treatment.22 ZMapp is considered a more acceptable treatment
than whole-blood transfusions from convalescent survivors.20 While
ZMapp has not as yet proven superior therapeutic merit, one
would be acting ethically to offer ZMapp as soon as such a
conclusion could be drawn.
If an untested drug were solely used in the seriously ill, it might
become more difficult to identify severe side effects associated with
the drug.18 It has been argued that the experience in the first two
people treated with ZMapp eliminated the possibility of a
universally severe adverse response; however, as medics struggle to
satisfy the principle of justice, one approach to investigating
promising drugs for patients with Ebola would be to allow limited
emergency use alongside studies in healthy volunteers to satisfy
concerns about toxicity and adverse events. Under these
circumstances, the provision of this untested drug is not
unreasonable.18
Is it ethical to give an untested drug to healthcare
professionals first?
Perhaps the most controversial aspect of the current Ebola
outbreak is the fact that the treatment, albeit untested, was first
offered to white, western healthcare workers.1,23 A case in
Germany in 2009 saw a researcher become exposed to Ebola
following a needlestick injury.5 She remained asymptomatic after
receiving immediate medical attention, with the vesicular
stomatitis virus (VSV) vaccine rushed to Hamburg for her
treatment. Whether the vaccine worked cannot be determined,5
as it is impossible to know whether she would have become
infected otherwise. Such a response would not have been feasible
in a developing country, demonstrating the inequitable risk
distribution among healthcare workers and the general
Ebola-affected population.
RCSIsmjethics challenge
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Reciprocity and consequentialism
The ZMapp debate draws upon many complex arguments as to
why we treat first responders first. It is often argued that as
health professionals place themselves in harm’s way to care for
patients, and could help more once recovered, we have a duty
of care to them.21,24,25 The present Ebola outbreak is occurring in
three of the world’s poorest countries, with not only the lowest
per capita gross national incomes, but also extremely low
physician ratios: fewer than 0.1 physician per 10,000 persons.26
Therefore, many draw on the principles of reciprocity (receiving
help from others, having provided help for others) and
consequentialism (the consequences of actions provide the basis
for their judgement) to justify the prioritisation of healthcare
workers.21 In contrast, some believe that good medical ethics
needs to focus on public health and societal perspectives, instead
of allowing individualistic values to dominate the Ebola
discussion.14 However, it is widely accepted that healthcare
workers are financially comfortable and well connected within
the medical field.21 Their prioritisation may be seen as a source
of tension as we preferentially treat the privileged. This is an
especially contentious issue when one considers those who
provide care without being health professionals.21
Populations who are terrified by Ebola,
and who lack trust in healthcare workers
and public authorities following civil
wars, cannot be assumed to have the
capacity to provide informed consent.
Informed consent
Despite this, to repeat what was done in Germany in 2009 for
hundreds of people at a time in African countries is virtually
impossible,27 not least due to issues of informed consent.5
Populations who are terrified by Ebola, and who lack trust in
healthcare workers and public authorities following civil wars,
cannot be assumed to have the capacity to provide informed
consent.7 Therefore, it could be considered unethical to offer an
untested treatment to these people. When recipients are
healthcare workers, whose ability to understand risks is
presumably high, the decision to prioritise them seems more
ethically correct.10
There is still an influential school of thought which holds that
the drug should be given on a first-come, first-served basis.12
According to this approach, prioritising access to experimental
drugs in certain populations (healthcare workers) or countries
(Western Hemisphere) promotes inequitable access to resources
and is therefore unacceptable. In prioritising certain groups, we
arguably negate the principles of distributive and social justice,
which we previously achieved. This is of particular concern in
places where human rights violations frequently occur, such as
those countries affected by Ebola.12
What ethical criteria should be used to decide which
healthcare professionals receive the drug?
If one accepts that the limited, untested treatment should be
offered to healthcare workers exclusively, another aspect of the
Ebola ethics dilemma unfolds. The WHO report sets out criteria
regarding which healthcare professionals should receive the
limited ZMapp supplies. Such guidelines include transparency
about all aspects of care – informed consent, freedom of choice,
confidentiality, respect for the person, preservation of dignity
and involvement of the community.17 Nearly all of these
guidelines focus on individualistic considerations.14 Indeed, one
could consider the focus on autonomy of the patient
inappropriate for those victims of Ebola who have limited
capacity to provide consent.14 Arguably, one should prioritise
those who can debate the risks and benefits of treatment and
provide the most informed consent.
The criteria provided also failed to address the ethical objectives
of promoting patient benefits and protecting patients from
harm.14 Perhaps those who are most likely to make a recovery
should receive the drug.
Ethical Ebola research
If the use of ZMapp is limited to healthcare workers, expansion
of its use without additional testing would be irresponsible.21
Moreover, it would be careless to use the small amount of
experimental interventions possible without any collection of
systematic data about its drug profile.21 Given this social
backdrop, it is ethical for the treatment to be provided to those
from whom we can generate the most data efficiently and
under the safest experimental conditions.
When untested drugs such as ZMapp are used in this Ebola
emergency, it is important that research ethics are upheld to
avoid exploitation of affected individuals and communities. The
eight ethical principles for research as outlined by Emanuel et al.
must be met to facilitate supply of the drug:21
  informed consent;
  collaborative partnership;
  social value;
  scientific validity;
  fair selection of study population;
  favourable risk–benefit ratio;
  independent review; and,
  respect for recruited participants and study communities.
Any discussion regarding possible treatment programmes
highlights that the identification of target groups may require
improved viral transmission surveillance systems and a better
understanding of Ebola transmission.28
RCSIsmjethics challenge
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Conclusion
Despite there being compelling arguments for the immediate and
widespread use of ZMapp in times of global crises, closer inspection
of the situation indicates that this would be not only unfeasible but
unethical. Any global epidemic with a 70% mortality rate7 poses
momentous problems, but these were exacerbated further by the
geographical and cultural setting of this virus.
It would be reasonable to conclude that, given the
circumstances of this illness, an untested drug may be ethically
employed for compassionate use in conjunction with other
trials.18 As soon as a proven treatment (such as ZMapp if proven
efficacious), becomes available, global expansion of the
treatment group is morally imperative.
Regardless, the controversy surrounding the prioritisation of
white healthcare workers and accessing Ebola interventions
continues.
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A rare case of post-gastric
bypass hypoglycaemia
Abstract
A 46-year-old woman with a history of Roux-en-Y gastric bypass (RYGB) surgery in 2010 was
referred to the hepatobiliary oncology clinic in the University of Colorado Hospital in May
2013 with frequent episodes of post-prandial hypoglycaemia with neurogenic and
neuroglycopenic symptoms. Findings in her biochemical profile, a 72-hour fast, and a mixed
meal test were all negative. Subsequent CT abdomen and endoscopic ultrasound did not
identify pancreatic lesions. Interventional radiology (IR) hepatic venous sampling with calcium
gluconate localised excess insulin production to the tail of the pancreas. Medical
management with acarbose and octreotide was commenced, but due to progressive
symptoms and life-threatening episodes of hypoglycaemia, the pancreas was surgically
resected. Pathology failed to show neoplastic tissue; histology demonstrated mild hyperplasia
and hypertrophy, although within normal limits. A diagnosis of nesidioblastosis – a rare
disease that causes pancreatic hyperfunction in the absence of an insulinoma and with
evidence of hyperplasia – was made. It is a leading cause of hyperinsulinaemic hypoglycaemia
in childhood, but causes <5% of cases in adults. Although the exact pathogenesis is not
understood, nesidioblastosis is increasingly recognised as a late complication of bariatric
surgery, where it is termed “post-gastric bypass hypoglycaemia” to distinguish from other
entities associated with nesidioblastosis.
Royal College of Surgeons in Ireland Student Medical Journal. 2016;1:10-12.
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Introduction
Patients experiencing episodes of hypoglycaemia
may experience a broad range of symptoms. These
can be either neurogenic or neuroglycopenic (Table
1). The presence of hypoglycaemic symptoms, low
measured glucose levels, and relief of symptoms
with glucose administration – Whipple’s triad –
suggests true hypoglycaemia and is a diagnostic
hallmark for insulin-secreting tumours (insulinomas).
Differential diagnoses for true hypoglycaemia are
categorised as endogenous or exogenous in origin
(Table 2). The most common cause in non-diabetic
and otherwise healthy adults is an insulinoma, a rare
tumour with an incidence of four cases per million
person-years.1 Approximately 90% of these are
benign and 90% are solitary.2 Diagnostic
investigations include a 24-hour fast, 72-hour fast,
and assay for insulin antibodies. C-peptide,
proinsulin, and insulin levels can be measured to
rule out factitious hypoglycaemia. Imaging includes
CT abdomen and endoscopic ultrasound, with a
combined sensitivity of >90%.3 An octreotide scan
may show somatostatin receptor-positive tumours
and interventional radiology (IR) hepatic venous
sampling with calcium gluconate localises regions of
pancreatic hyperfunction. Surgical resection of the
affected pancreas is the gold standard, with a cure
rate of 97.5%.4 Surgical options include enucleation,
distal resection, total pancreatic resection and
duodenopancreatectomy (Whipple’s procedure).
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Table 1: Symptoms of hypoglycaemia.
Neurogenic features                        Neuroglycopenic features
• Sweating                                       • Dizziness
• Palpitations                                    • Double vision
• Tremors                                         • Blurry vision
• Anxiety                                          • Weakness
                                                         • Coma
Table 2: Causes of hypoglycaemia in non-diabetic patients.
Endogenous                                           Exogenous
• Pancreatic β-cell tumour                           • Factitious hypoglycaemia
• Post-gastric bypass                              • Sulfonylurea induced
dumping syndrome                             
• Noninsulinoma pancreatogenous 
hypoglycaemia 
(adult nesidioblastosis)
• Post-gastric bypass hypoglycaemia 
(adult nesidioblastosis)
• Autoimmune insulin syndrome
Case report
A 46-year-old Caucasian woman with a history of Roux-en-Y gastric
bypass (RYGB) surgery in 2010 was referred to the hepatobiliary oncology
clinic in the University of Colorado Hospital in May 2013 with frequent
episodes of post-prandial hypoglycaemia accompanied by neurogenic
and neuroglycopenic symptoms. She reported sweating, tremors,
palpitations, weakness, and dizziness, which came on approximately two
hours after consuming simple sugars. The episodes had increased in
frequency, requiring several emergency department visits. She denied
pain, changes in appetite, or weight loss, but reported eating more
frequently to prevent episodes from occurring. Her past medical history
was significant for Graves’ disease, systemic lupus erythematosus,
seizures, and asthma. Physical examination revealed no abnormalities.
Blood investigations including insulin, proinsulin, C-peptide, and
sulfonylurea were all within normal limits, ruling out exogenous causes of
hypoglycaemia. She was negative for insulin antibodies. Both 24- and
72-hour fasts were conducted with negative results. Imaging with CT
abdomen was unremarkable. The patient was managed conservatively
with an α-glucosidase inhibitor (acarbose 25mg) and frequent
low-carbohydrate meals, but intolerance of acarbose necessitated
replacement with a somatostatin analogue (octreotide 100mcg three
times daily). She responded well initially, but by March 2014 her
octreotide dose was increased to 200mcg three times daily and she was
still experiencing weekly episodes of hypoglycaemia. She reported a
blood glucose of 1.44mmol/l with her latest episode, and had fallen on
several occasions due to weakness or loss of consciousness. An octreotide
scan failed to localise somatostatin receptor-positive tumour cells, but IR
hepatic venous sampling with calcium gluconate showed over a six-fold
rise in insulin levels localised to the pancreatic tail. A CT abdomen and
endoscopic ultrasound in April and May 2015, respectively, were both
unremarkable. Hepatic venous sampling was repeated and confirmed
previous findings. It was then decided that due to the very low reported
insulin levels with each episode, and the increasing risk of fall-related
injury, the benefits of surgery outweighed the risks. The patient was
scheduled for a distal pancreatectomy and splenectomy.
Outcome
In August 2015 the patient had her spleen and two-thirds of her
pancreas removed. Pathological examination of pancreatic tissue ruled
out neoplasm and all sampled lymph nodes were negative. Hyperplasia
and hypertrophy in the pancreatic tissue were present but within normal
limits. She was discharged on day six postoperatively after an uneventful
recovery and reported no further episodes of hypoglycaemia, with all
measured glucose levels above 4.4mmol/l.
Discussion
Nesidioblastosis is a rare disorder first described by George Laidlaw in
19385 as neoformation of Langerhans islets in the pancreatic ductal
epithelium. Initially observed in neonates and now recognised as the
primary cause of hyperinsulinaemic hypoglycaemia in childhood,6 it is
rare in adults and accounts for <5% of cases.7 RYGB surgery was first
associated with adult onset nesidioblastosis in 2005; fewer than 100
cases of post-gastric bypass nesidioblastosis have been identified as of
November 2014.8 Nesidioblastosis should be included as a differential
diagnosis in hyperinsulinaemic hypoglycaemia, with a negative 72-hour
fast and unremarkable findings on imaging.
IR hepatic venous sampling with calcium stimulation test is a useful
investigation when other imaging modalities fail to localise a pancreatic
lesion. The technique involves placing a catheter in the right hepatic
vein, and performing a pancreatic angiography via the femoral artery.
Calcium gluconate is then injected into the selectively catheterised
gastroduodenal, proximal splenic, and superior mesenteric arteries.
Venous samples are collected at 0, 30, 60, and 120 seconds for each site.
Five minutes are allowed between each injection. A greater than
two-fold rise in insulin levels within 30-120 seconds is recorded as a
positive result in the distribution of the relevant artery.9 This technique
can thus indicate pancreatic hyperfunction and suggest either an
insulinoma or (less commonly) nesidioblastosis, as well as guiding the
surgical approach for resection.10
Nesidioblastosis is diagnosed based on the absence of an insulinoma and
the presence of islet cell hyperplasia on histological examination. It is
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important to note that the diagnostic criteria for hyperplasia are not
universally agreed upon; Rindi et al. define hyperplasia in adults as an
expansion of the endocrine cell mass to more than 2% of total pancreas
mass.11 Due to the impracticalities of conducting detailed pancreatic
morphometry of a sample, the diagnosis may often be subjective.
However, most would regard an increase in islet numbers as evidence of
hyperplasia.11 Four major criteria have been proposed to diagnose
nesidioblastosis:
1. Exclusion of insulinoma by macroscopic, microscopic and
immunohistochemical examinations.
2. Multiple β-cells with enlarged, hyperchromatic nuclei and abundant
clear cytoplasm (β-cell hyperplasia and hypertrophy).
3. Islets with normal spatial distribution of various cell types.
4. No proliferative activity of endocrine cells.3
Utilisation of this criterion may help to improve diagnostic
consistency. The recommended management of post-gastric bypass
surgery hypoglycaemia is with frequent, low-carbohydrate diet or
medical management (α-glucosidase inhibitors, diazoxide,
octreotide). If these fail, reversal of gastric bypass can be performed.
Often symptoms persist; in an attempt to preserve pancreatic
function, a partial pancreatectomy may be performed, but
symptoms often return and necessitate further surgery.8
Conclusion
Nesidioblastosis is a rare cause of hyperinsulinaemic hypoglycaemia in
adults and can occur as a late complication of RYGB surgery. Diagnosis
must be suspected when 72-hour fast is negative and imaging fails to
identify insulinoma, and is established when pathological assessment
confirms absence of insulinoma and presence of pancreatic hyperplasia.
A multidisciplinary approach becomes necessary when the diagnosis is
unclear and investigations suggest a rare pathology; as in this case,
involvement of endocrinologists, general surgeons, interventional
radiologists and pathologists can ensure that an adequate management
plan is put in place to bring about the best possible patient outcomes.
Typically, management is dietary and medical, but surgery may be
considered in refractory cases such as this one. Where surgery is
deemed necessary, IR hepatic venous sampling may localise the site of
pancreatic hyperfunction to determine the extent of surgical resection.
As our case demonstrates, the subjective and impractical nature of
pathological assessment can show hyperplasia and hypertrophy to be
within normal limits, thus making definitive diagnosis of nesidioblastosis
a technical difficulty. Implementation of established diagnostic criteria
can help to resolve this issue and improve inter-observer consistency.
Further research and long-term studies are needed to understand the
pathogenesis of post-gastric bypass hypoglycaemia and the therapeutic
outcome, as this has implications for the future of gastric bypass surgery
as an option for weight loss.
Rachel MacCann
RCSI medical student
Introduction
Castleman’s disease (CD), or giant lymph node
hyperplasia, is a rare disorder first described by
Castleman et al. in 1956.1 CD is separated into
localised unicentric disease, with solitary
hyperplastic mediastinal lymph nodes, or
multicentric disease (MCD). Histologically, CD is
divided into the hyalinised vascular form and a
plasma cell variant, the former being more
common in localised disease, and the latter more
common in MCD. Mixed forms of CD have also
been documented.2
MCD is characterised by polylymphadenopathy
and inflammatory manifestations including fevers,
malaise, wasting, hypoalbuminaemia,
cytopaenias, and hyponatraemia. These
symptoms are a result of inflammatory cytokine
overproduction, especially IL-6 (Figure 1).2 The
diagnosis of MCD requires the clinical features of
active disease described above plus pathologic
confirmation on biopsy.
In HIV-infected patients, MCD is usually caused by
Kaposi’s sarcoma-associated herpesvirus (KSHV),
also called human herpesvirus-8 (HHV-8). This virus
encodes a homologue of interleukin 6 (vIL-6),
which may mediate the systemic features of MCD.
Symptomatic patients with HHV-8-positive MCD
have HHV-8 viral loads that are exponentially
greater than asymptomatic HHV-8-positive patients
(Table 1). In accordance with this, the increased
viral load correlates with increased serum levels of
IL-6.3 This virus predisposes patients to much
higher risk of other malignancies, including
Kaposi’s sarcoma (KS) (13% increased risk)2 and
primary effusion lymphoma.
Kicking up a cytokine storm:
an unusual presentation of
Castleman’s disease
Abstract 
Castleman’s disease (CD) is a rare lymphoproliferative disorder that can be separated into
localised disease and multicentric Castleman’s disease (MCD). Kaposi’s sarcoma-associated
herpesvirus (KSHV), also known as human herpesvirus-8 (HHV-8) is the causal agent for Kaposi’s
sarcoma (KS) and MCD in human immunodeficiency virus (HIV)-infected patients. This virus
encodes a homologue of interleukin 6 (vIL-6), which may mediate some systemic features of
MCD. A 58-year-old man presented to the infectious disease department with a three-day
history of dyspnoea, fever, and cough. He had a history of HIV and had been on antiretroviral
treatment for the previous year. Despite compliance, his CD4 count had dropped and he was
found to have widespread lymphadenopathy and pancytopaenia on admission. Biopsy showed
the presence of KS and it was decided to treat him for an ‘MCD-like’ syndrome based on his
clinical presentation. The patient responded well to treatment with rituximab, an agent used
for MCD, and his haematological profile improved. This case lends support to the theory that
some patients with HIV and HHV-8 co-infection, but without MCD, can develop severe systemic
inflammatory symptoms associated with elevated levels of HHV-8 vIL-6, IL-6 and HHV-8 viral
loads. It additionally illustrates the challenges faced in the diagnosis of this unusual form of
MCD in patients with HIV. Most importantly, this case highlights the importance of a thorough
history and examination in eliciting the clues to diagnosis in the face of these challenges.
Royal College of Surgeons in Ireland Student Medical Journal. 2016;1:13-17.
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There is evidence that MCD has become more common since the
advent of combination antiretroviral therapy,5 affirming the theory
that immune-overactivation rather than immunosuppression leads to
MCD. Like MCD that is unrelated to HHV-8, the clinical presentation
of HHV-8-associated MCD is dominated by systemic inflammatory
symptoms and polylymphadenopathy. It is diagnosed upon lymph
node biopsy and has a fluctuating course, which, if untreated,
proves fatal. This report discusses the presentation of a new variant
of HHV-8-associated MCD and the difficulties faced in diagnosis and
management.
The case
A 58-year-old Caucasian gentleman presented to St George’s
Hospital in London with a three-day history of dyspnoea, fever, and
cough. This was on a background history of community-acquired
pneumonia five weeks previously, for which he had been successfully
treated at the same hospital.
Past medical history was significant for HIV, diagnosed 13 months
previously, and he was being treated with antiretroviral medications
– specifically, oral combined tenefovir and emtricitabine (Truvada®;
Gilead Sciences, Foster City, CA, USA), and darunavir. However, his
CD4 count had decreased over the previous year from 800 to 285
cells/mm3, despite compliance with his medications. Other medical
history included a parietal skull fracture three years previously
following a fall, hypothyroidism, for which he took 100mcg
levothyroxine once daily, and depression, for which he took 37.5mg
venlafaxine once daily. His father passed away from lung cancer at
the age of 83 and his mother passed away from a cerebral sarcoma
aged 50. He was a non-smoker and non-drinker, who lived alone
and worked as an optometrist.
On examination, he appeared pale and dyspnoeic. Auscultation of
the lungs elicited increased vocal fremitus and crackles of the right
lower zone. A full blood count revealed low neutrophil and platelet
counts, and C-reactive protein (CRP) was elevated. X-ray findings
were consistent with right lower lobe pneumonia. He was
commenced on an amoxicillin and doxycycline antibiotic regimen
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FIGURE 1: Castleman’s disease variants.
IL-6 production
HHV-8 + HHV-8 -
Multicentric
Castleman’s disease
(MCD)
Unicentric
Castleman’s
disease (UC)
Castleman’s
lymph node
Fever
At least three of the following symptoms:
Peripheral lymphadenopathy
Enlarged spleen
Oedema
Pleural effusion
Ascites
Cough
Nasal obstruction
Xerostomia
Rash
Central neurologic symptoms
Jaundice
Autoimmune haemolytic anaemia
Increased serum C-reactive protein level >20mg/L in the absence
of any other aetiology
HIV = human immunodeficiency virus; MCD = multicentric
Castleman’s disease.
Table 1: Definition of a HIV MCD attack.4
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with 30mg prednisolone. Upon completion of his treatment course,
his chest symptoms resolved but his platelets remained remarkably low
and CRP remained elevated. He became progressively fatigued and his
blood profile failed to improve despite medical treatment, prompting
a re-evaluation of his initial diagnosis.
Further questioning uncovered a four-month history of fatigue, night
sweats, and weight loss. Repeat bloods revealed worsening
pancytopaenia in addition to persistently elevated CRP, lactate
dehydrogenase (LDH) and hyponatraemia. CT showed widespread
lymphadenopathy and splenomegaly. Based on these findings, and as
a result of immunosuppression because of his low CD4 count, a
diagnosis of immune thrombocytopaenia (ITP) was made. He was
commenced on ITP-specific therapy, which consisted of platelet
transfusion, intravenous immunoglobulin (IVIG) and glucocorticoids
(prednisolone 30mg once daily) in an effort to raise his platelet count.
His antiretroviral medication was switched from a darunavir-based
regimen to raltegravir 400mg twice daily in an effort to improve his
CD4 count.
Two weeks after his admission, the patient developed a palpable light
brown lesion on his right forearm measuring 6cm by 7cm in diameter.
Following a cervical lymph node biopsy, a histological diagnosis of
HHV-8-positive KS was made (Figure 2). A plan was made to
commence chemotherapy treatment once his platelet levels could be
raised to a level above 50 x 109/L with his ITP-specific therapy.
However, following a five-day treatment course, his platelet levels
failed to respond. As a result, he was initiated on a weekly romiplostim
regimen with continuation of prednisolone.
This also failed to improve his condition, so a discussion between the
departments of haematology, infectious diseases, and oncology was
held. This patient’s clinical and haematological presentation fit the
diagnosis of MCD, yet the tissues obtained for histological diagnosis
were only positive for HHV-8 and not for MCD (Figure 3). It was
FIGURE 2: Cervical lymph node biopsy from patient with a CD31 positive stain showing: a) lymph node follicle with KS x20 magnification; b) KS with
HHV-8 x20 magnification; c) lymph node follicle with KS x200 magnification; and, d) KS cell with HHV-8 x200 magnification. Typical histologic
findings in KS include: proliferation of spindle cells; prominent, slitlike vascular spaces; and, extravasated red blood cells. KS = Kaposi’s sarcoma.
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hypothesised that the patient’s symptoms of lymphadenopathy and
inflammation might not be caused by HHV-8–MCD, but might instead
result from HHV-8 lytic activation and consequent cytokine production.
The patient was found to have a substantial elevation of vIL-6 and hIL-6,
and so he was proposed to have a rare and newly described syndrome
called ‘KSHV inflammatory cytokine syndrome’ (KICS) (Table 2).6 Due to
its relatively new classification, the treatment approach for KICS is still
largely theoretical and based on MCD treatment. Our patient was
started on a trial of rituximab 375mg/m2 once weekly for four weeks.
His first dose was well tolerated and his platelets increased from 22 x
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FIGURE 3: Lymph node biopsy demonstrating the histological appearance of MCD: a) haematoxylin and eosin-stained section of lymph node (100×
magnification) showing the concentric layering of lymphocytes in the mantle zone of the lymphoid follicle – ‘onion-ring’ appearance; and, b) HHV-8
immunohistochemical stain showing mantle zone concentricity and distinct HHV-8 positive nuclear staining of lymphoid cells in the mantle zone
(100× magnification). MCD = multicentric Castleman’s disease.7
Table 2: Working case definition of KSHV (HHV-8) inflammatory cytokine syndrome.5
1. Clinical manifestations
a. Symptoms
Fever
Fatigue
Oedema
Cachexia
Respiratory symptoms (including cough, dyspnoea, airway
hyperreactivity)
Gastrointestinal disturbance (including nausea, anorexia, abdominal
discomfort, altered bowel habit)
Arthralgia and myalgia
Altered mental state
Neuropathy with or without pain
b. Laboratory abnormalities
Anaemia
Thrombocytopaenia
Hypoalbuminaemia
Hyponatraemia
c. Radiologic abnormalities
Lymphadenopathy
Splenomegaly
Hepatomegaly
Body cavity effusions
2. Evidence of systemic inflammation
Elevated C-reactive protein (≥3g/dL)
3. Evidence of KSHV lytic activity
Elevated KSHV viral load in peripheral blood mononuclear cells (≥100 copies/106 cells)
4. No evidence of KSHV-associated Castleman’s disease
Exclusion of MCD requires pathologic assessment of lymph node, bone marrow, or spleen
The working case definition of KICS requires the presence of at least two clinical manifestations drawn from at least two categories (1a, b, and c), together
with each of the criteria in 2, 3, and 4. Clinical manifestations for the working definition are drawn from the initial case series and from findings commonly
seen in KSHV–MCD (HHV-8–MCD).
A B
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109/L prior to treatment to 69 x 109/L following treatment. His
haemogloblin levels and white cell count also improved, and CRP began
to show a downward trend. For the first time since admission, the
patient showed encouraging clinical improvement and was discharged
home, with the plan to return for his remaining three rituximab
treatments. At the most recent follow-up he had symptomatically
improved and was tolerating rituximab.
Discussion
The differential diagnosis of fever and adenopathy in HIV-infected
patients, even with other laboratory abnormalities, is broad. As a
result, HHV-8–MCD can be difficult to diagnose and is often missed.
This is an unusual case of a HIV-infected patient who had
lymphadenopathy, severe inflammatory symptoms, KS and
pancytopaenia, but in whom a histological diagnosis of MCD could
not be made. Recently, another HHV-8-associated condition, KICS, has
been described.4 Its clinical manifestations resemble those of
HHV8–MCD but, as seen in this case, the histological changes of
HHV-8–MCD are absent. Patients with KICS exhibit elevated HHV-8
viral loads and elevation of vIL-6, a homologue of human interleukin-6
and IL-10 comparable to those seen in HHV-8–MCD.8 The pathological
evolution of this syndrome and its relationship with HHV-8–MCD
remains to be elucidated. No standardised therapy exists for MCD,
and only one RCT has been conducted for MCD treatment.9
Management thus far has been guided by case reports or
observational studies, and usually involves a combination of
immunotherapy, chemotherapy and antiviral agents. Treatment
selection depends upon whether the patient is HIV/HHV-8 positive,
and on the clinical aggressiveness of the disease. Concurrent
combination antiretroviral therapy (HAART) is generally used in
HIV-infected patients. Prompt therapy must be instituted to avoid
potentially fatal complications from organ failure and infections.6
Rituximab, a humanised monoclonal antibody against the B-cell
antigen CD20, has been shown to be effective in MCD treatment.10
Two prospective phase II studies have shown a significant reduction in
symptoms and decreased HHV-8 viral load.10,4 Other case reports have
used a successful combination of rituximab and liposomal doxorubicin
to kill KS spindle cells. It is on the basis of these studies and previous
case reports that this therapy was commenced with this patient.
Furthermore, the patient’s positive response to his rituximab treatment
strengthens the theory of a KICS diagnosis for our patient.
Conclusion
CD and its associations are broad and complex in their presentation
and diagnosis. KICS demonstrates that the clinical manifestations of
HHV-8 infection may vary and sometimes overlap. Future work to
establish the incidence of this syndrome and its ideal treatment, and
to clarify how it differs from MCD or KS, is crucial. Additionally, this
case reminds us to consider an IL-6-related inflammatory syndrome in
critically ill patients with HIV and KSHV co-infection.2
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Background
Necrotising soft tissue infections (NSTIs) encompass
a relatively broad spectrum of potentially
life-threatening infections, including necrotising
forms of cellulitis, fasciitis, and myositis. NSTIs can be
classified according to the depth of tissue
involvement, severity of infection, and causative
organism. The most commonly used classification
describes type I polymicrobial infections (especially
anaerobes), type II monomicrobial infections (most
commonly group A β-haemolytic streptococci such
as S. pyogenes and, increasingly, Staphylococcus
aureus), and type III infections (gram-negative
aquatic organisms).1NSTIs are uncommon, with
recent reports estimating up to 1,500 cases in the
United States annually.1,2 Predisposing factors include
diabetes and other chronic diseases, traumatic
injuries (with or without skin injury), and intravenous
(IV) drug use. An association with non-steroidal
anti-inflammatory drug (NSAID) use has been
described, but remains controversial.1 Virtually all
untreated cases are fatal, and mortality with
treatment approaches 35%.2
Case
We describe a 68-year-old male who self-presented
to the emergency department with abrasions and
pain in his left leg along the anterior tibia, medial
knee and medial thigh, from a three-foot fall from
a wooden ladder the previous evening. Following
the injury, the patient self-administered povidone
iodine ointment, cetrimide 0.5% (w/w) cream,
chlorhexidine gluconate 0.1% (w/w), and
mentholatum to the wound. He complained that
he had been awakened from sleep with severe
pain and swelling in the leg, and that he “felt
unwell”.
Toxic shock syndrome
complicated by necrotising
fasciitis: back to basics
Abstract
Necrotising soft tissue infections (NSTIs) are uncommon but potentially fatal, and both their
recognition and management represent significant challenges for clinicians. A 68-year-old
male presented to the emergency department complaining of pain in his left lower limb
following abrasion injuries sustained from a fall off a wooden ladder the previous evening. His
injuries extended from the left anterior tibia up along the medial aspect of the left knee and
thigh, and showed erythema, induration, and vesiculation. The patient had a history of
hypertension and hypercholesterolaemia. On examination, he was hypotensive, tachycardic,
and hypothermic. He rapidly deteriorated and developed acute kidney injury secondary to
septic hypovolaemia, requiring haemodynamic support, long-term intravenous antibiotics,
several surgical debridements, dialysis, and skin grafts, but he subsequently made a full
recovery. The clinical, laboratory, and radiological findings in NSTIs can vary significantly, and
definitive diagnosis is made by surgical exploration. Pain out of proportion to clinical findings,
rapid clinical deterioration, and signs of systemic involvement are important clues for the
clinician. This case demonstrates how rapid diagnosis and multidisciplinary management (in
which surgery is the cornerstone) can lead to the most favourable outcome for patients.
Royal College of Surgeons in Ireland Student Medical Journal. 2016;1:18-22.
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The patient had a high BMI, but past medical history was significant
only for alcohol use (approximately 50 units of alcohol weekly) and
ongoing hypertension and hypercholesterolaemia. On examination,
the patient was profoundly hypotensive (66/43mmHg), tachycardic
(95bpm), and hypothermic (34.6ºC). He appeared pale and
clammy, but was oriented to person, place, and time with a GCS of
15/15. Examination of the left lower limb revealed leg weakness,
well-demarcated pretibial erythema with warmth and tenderness
distally, and a hemi-circumferential area of yellow discolouration,
overlying vesiculation, and induration on the medial thigh. This
region was exceptionally tender. Clinically, necrotising fasciitis was
suspected and initial management involved IV fluid resuscitation,
analgesics, and clindamycin. Laboratory results (Table 1) indicated a
non-oliguric acute kidney injury (AKI) secondary to hypoperfusion
caused by septic shock and a likely hypovolaemic hyponatraemia.
The patient remained hypotensive despite ongoing fluid
resuscitation. Blood, urine, and vesicular fluid samples were sent to
the laboratory for culture. Piperacillin-tazobactam, vancomycin, and
gentamicin were commenced, and the patient was transferred to
the intensive therapy unit (ITU), where he was intubated and
mechanically ventilated. A CT scan showed evidence of infection but
no direct evidence of necrotising fasciitis (Figure 1). With this
diagnosis unconfirmed, antibiotic treatment was escalated to a
combination of clindamycin, piperacillin-tazobactam, linezolid, and
ciprofloxacin to provide broad-spectrum cover for group A
β-haemolytic streptococci (GAS), Panton-Valentin leukocidin-positive
methicillin-resistant Staphylococcus aureus, gram-negative bacilli, and
anaerobes. Due to ongoing hypotension and the associated AKI, the
patient was started on inotropes and placed on continuous
veno-venous haemodialysis (CVVH). He received prophylaxis for
venous thromboembolism with unfractionated heparin, and was
taken to theatre for a decompressive fasciotomy; no evidence of
Table 1: Relevant laboratory results.
Test                                                    Result                                               Flag                                                  Reference interval
Sodium                                               123mmol/L                                       L                                                       133-146mmol/L
Lactate, serum                                    6.4mmol/L                                        H                                                       0-1.8mmol/L 
Urea, serum                                        14.2mmol/L                                      H                                                       2.5-8.5mmol/L
Creatinine, serum                               188µmol/L                                        H                                                       64-104µmol/L
WCC                                                  20.1x109/L                                        H                                                       4.0-11.0x109/L
CRP                                                    378mg/L                                           H                                                       0-5mg/L
                                                                                   
WCC: White cell count; CRP: C-reactive protein.
FIGURE 1: CT femur. Marked oedema and stranding within the subcutaneous
tissues of the left lower extremity, with fluid tracking along the intermuscular
planes of the medial and posterior compartments. No dominant focal fluid
collection to suggest a discrete abscess. No air within the soft tissues.
FIGURE 2: CT femur. Views of the legs demonstrate left thigh medial
fasciotomy. No evidence of subcutaneous emphysema or collection
visualised within the scan range (to mid calf). There is a vac 
dressing in situ.
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necrotising fasciitis was found intraoperatively. However, theatre
samples grew GAS and vesicular fluid cultured Staphylococcus
aureus. A diagnosis of toxic shock syndrome (TSS) was made on
the basis of his clinical picture and microbiology results.
In the following days, the patient’s blood pressure and renal
function proved too unstable to reduce CVVH. He developed
profuse diarrhoea (Clostridium difficile negative), and wound
appearance continued to worsen. Questions arose concerning the
patient’s immunological status, due to the extent and severity of
the infection. HbA1c levels proved normal, and HIV tests were
negative. Given the lack of a history of recurrent soft tissue or
respiratory tract infections, normal immunoglobulin levels and
serum protein electrophoresis results, hypogammaglobulinaemia
was outruled. However, a positive GAS culture, without an
associated rise in the antistreptolysin O titre (ASOT), indicated a
possible functional humoral defect. In the context of a worrying
clinical picture and suspected GAS-induced sepsis, the patient
was given high-dose IV immunoglobulin (IVIG) with
pre-administration of antihistamines, hydrocortisone, and
anti-inflammatories. CT imaging of the abdomen and left leg
remained unremarkable (Figure 2).
By day seven, increasing urine output indicated improving renal
function, and the patient was able to maintain blood pressure
without inotropic support. However, he developed bilateral
pleural effusions with significant peripheral oedema, likely from
fluid loading, and evidence of cholestasis (elevated alkaline
phosphatase (ALP) and bilirubin), likely secondary to antibiotic
treatment; no liver or biliary abnormalities were noted on
ultrasound. As a result, linezolid and piperacillin-tazobactam were
discontinued, daptomycin was commenced and the patient
continued on clindamycin.
The patient continued to improve, and was successfully
extubated on day nine. However, blood cultures grew Klebsiella
pneumoniae, while Candida spp. was cultured from the tip of a
FIGURE 4: Anterior view of the patient’s left leg following surgical skin
grafting.
FIGURE 3: Lateral (top) and medial (bottom) views of the patient’s left
leg following debridement, prior to skin grafting.
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right jugular line. Aztreonam and caspofungin were added to the
antimicrobial regimen. 
Over the following ten days the patient deteriorated, became
pyrexic, required re-intubation and a further dose of IVIG. His
wounds began to show evidence of necrotic tissue. Surgical
exploration confirmed the presence of necrotic change of the
subcutaneous tissues and fascia, and a diagnosis of necrotising
fasciitis was made. The patient underwent a total of four
debridements over the next few days before it could be
confirmed that no involved tissue remained (Figure 3). While at
times agitated, the patient began to show significant clinical
improvement, and was systemically stable and suitable for
surgical skin grafting by day 26 of hospital stay; extensive skin
grafts were required along his upper medial thigh (Figure 4). The
patient was transferred out of the ITU on day 27 and recovered
on the ward, completing three weeks of physiotherapy before
being discharged home.
Discussion
This patient presents a classic example of TSS complicated by
necrotising fasciitis. The microbial aetiology – GAS with synergistic
Staphylococcus aureus – and the previously healthy patient’s history
of a minor injury with skin breach were consistent with that of most
type II NSTIs described in the literature.3
While most infections evolve over a period of two or three days,
GAS has been shown to be particularly aggressive;3 in this case, the
patient was in septic shock less than 12 hours following the initial
injury. Many factors, including advanced age and comorbidities,
have been shown to adversely affect patient outcome, but delayed
surgical intervention is the most important factor leading to
increased mortality.4,5 However, neither surgery nor antimicrobial
therapy alone are sufficient in patient management.6 It has been
well documented that early and complete surgical debridement,
appropriate antimicrobial therapy, and physiological support and
monitoring provide the best chance for patient recovery.2,7 Novel
Table 2: Common features of necrotising fasciitis.
Symptoms3,7                   Clinical findings3,7                 Laboratory studies2              Radiological imaging10         Surgical exploration2,7
Extreme pain,                  Rapid progression                  Evidence of sepsis                 Early changes are similar        Easy blunt dissection of 
disproportional to            of clinical manifestations         (elevated lactate, WCC,        to those in cellulitis:               the subcutaneous tissues 
clinical findings                                                               CRP, altered electrolytes,       soft tissue thickening,             from deep fascia 
                                                                                      abnormal renal or                 increased opacity                    ('finger test')
                                                                                      liver profiles)
Rapid progression            Tenderness and oedema        WCC >15.4*109/L                 Subcutaneous emphysema,    Gray, swollen tissue/fascia 
and spread of                  past the apparent area            and serum sodium                 may track along fascial           
lesions, erythema,            of erythema                            <135mmol/L                         plains
and tenderness                                                                                                             
Systemic symptoms         Supralesional vesiculation,      LRINEC score >8 suggests     Fluid or air collections in        Lack of bleeding, 
of infection/toxicity:        bullous formation                   high risk of NSTI                    subfascial planes                     thrombosis of vessels
fever, fatigue                                                                                                              
                                                                                                                                    
                                        
                                        Indurated, hard, wooden                                                    Dermal thickening                  Thin exudate, lack of
                                        feeling of subcutaneous                                                                                                    excessive pus
                                        tissue; inability to feel                                                                                                         
                                        underlying muscle groups                                                    
                                        Signs of sepsis: tachycardia,                                                 Inflammatory fat stranding
                                        hypotension, hypothermia                                                   
                                        or fever, end organ
                                        dysfunction
                                         
Abbreviations: WCC – white cell count; CRP – C-reactive protein; LRINEC score – laboratory risk indicator for necrotising fasciitis score (variables include
WCC, haemoglobin, sodium, glucose, serum creatinine and C-reactive protein); NSTI – necrotising soft tissue infection.
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but controversial therapies include IVIG8 and hyperbaric oxygen.2
IVIG was used in this patient based on evidence that suggests its
usefulness in GAS-induced sepsis.8 Importantly, this case shows
excellent patient management by the multidisciplinary clinicians
involved and demonstrates the benefit of early senior clinical input.
Emergency physicians recognised sepsis, suspected necrotising
fasciitis, provided appropriate resuscitation, and referred to ITU
when septic shock developed. From the outset, the patient received
input from emergency, surgery, microbiology, critical care, renal,
radiology and immunology experts, demonstrating a co-ordinated
multidisciplinary approach to patient management. Early diagnosis,
while of paramount importance, can be challenging even for
experienced physicians. NSTIs can resemble simple cellulitis in the
early stages, and overlying skin changes may not necessarily reflect
the ongoing extensive subcutaneous disease process.4 Clinical
presentation may vary depending on various factors, including time
of presentation within the natural history of infection, and microbial
aetiology.3 Scoring systems to aid in diagnosis are typically more
useful for ruling out an NSTI, or discriminating between necrotising
and non-necrotising forms, than for confirming it.2 Additionally,
radiological signs may be absent or non-specific; for example, gas in
the fascial planes (while highly specific) is not a sensitive finding.2
The direct visualisation of the subcutaneous tissues and fascial planes
during surgical exploration remains the most important feature of
an NSTI, and is the only way to make a definitive diagnosis.7 Thus,
maintaining a high index of clinical suspicion is crucial, and in
suspected cases, surgical intervention should not be delayed while
awaiting laboratory, microbiological, or radiological studies. Some of
the important surgical findings and supporting clinical, laboratory
and radiological evidence are summarised in Table 2.
Conclusion
While uncommon, NSTIs can affect healthy individuals as well as
at-risk groups, and are rapidly fatal if not promptly diagnosed and
treated. Appropriate patient management requires multidisciplinary
care, and core principles are early surgical debridement,
broad-spectrum antibiotic therapy, and organ and haemodynamic
support. These interventions crucially depend on high clinical
suspicion and early diagnosis.
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Introduction
Coarctation of the aorta (CoA) is a common
condition,1 accounting for 5-8% of all congenital
heart conditions,2 and can be one of the most
fatal congenital heart defects depending on its
classification.3 The danger of CoA is further
emphasised by its subtlety, as it can easily be
missed; a Swedish study showed that of 104
missed diagnoses of duct-dependent cardiac
defects, CoA was the most common at 64/104
(62%).4
The pathogenesis of CoA is currently unknown,
but it is known to be associated with aortic
valvular defects and, most commonly, Turner’s
syndrome, among many other syndromes. The
main pathology underlying this condition is the
narrowing of the aorta either proximal to or at
A missed coarctation
Abstract
Coarctation of the aorta (CoA) is a very dangerous congenital heart defect, with many
patients presenting in the neonatal period with heart failure. This defect is especially serious
since many cases are missed at birth due to inaccurate examination or lack of screening.
Recommended pulse oximetry and blood pressure screening is currently not a mandatory
screen in the HSE guidelines for newborn checks, but provides a much-needed support to
clinical skills in detecting a CoA defect. This is the case describing a nine-day-old boy whose
cardiac condition was misdiagnosed, leading to preventable and potentially fatal
consequences. His defect was missed at both a newborn assessment and his presentation to
Cavan General Hospital. He presented to Cavan General Hospital with upper extremity
cyanosis and discolouration, pale trunk and legs, and tachypnoea. After clinical assessment,
the impression was septicaemia on underlying congenital heart disease (CHD), and he was
then transferred to Our Lady’s Children’s Hospital Crumlin (OLCHC). Upon examination and
screening, he was determined to have CoA, which was successfully repaired surgically with
end-to-end anastomosis with patent ductus arteriosus (PDA) ligation. This case highlights the
importance of complete paediatric examinations and the necessity for pulse oximetry and
blood pressure screening for CoA to prevent future complications.
Royal College of Surgeons in Ireland Student Medical Journal. 2016;1:23-6.
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the junction with the ductus arteriosus (pre-ductal/ductal) or distal
to the ductus arteriosus (post-ductal), as shown in Figure 1.
Pre-ductal and ductal coarctations are duct dependent and have a
worse prognosis due to ductus arteriosus closure at about seven
days postnatally, leading to cardiac decompensation.3 Postnatally
diagnosed pre-ductal CoA typically presents at approximately seven
days postnatally1 with cardiogenic shock or signs of heart failure,
typically central cyanosis, breathlessness, and systemic oedema.2
This presentation is associated with a mortality rate of approximately
13.6%.1 Post-ductal CoA patients typically have the classic sign of rib
notching and pulsations due to intercostal collateral circulation.
Non-duct-dependent children may never experience symptoms until
adulthood due to collateral circulation through intercostal arteries,
but eventually experience cardiac decompensation.3 Management of
a duct-dependent coarctation requires immediate administration of
prostaglandin E1 to maintain the ductus arteriosus. The ductus
arteriosus is the primary means of perfusion to the lower extremities,
especially in very narrow coarctations.3 If prostaglandin E1 is not
administered, death is nearly certain from cardiogenic shock.
Dobutamine must also be given to maintain cardiac output in heart
failure. Management of post-ductal coarctation presentation is
dependent on the severity of narrowing and symptoms. Surgery is
always required for pre-ductal CoA, while patients with post-ductal
CoA should have surgery prior to decompensation to increase life
expectancy.5 The common types of surgical intervention in
pre-ductal and post-ductal CoA repair include stent placement,
end-to-end anastomosis, and catheter balloon aortoplasty with
concurrent patent ductus arteriosus (PDA) ligation.5 A comparison of
both classifications based on presentation age, signs and
Table 1: Comparison of pre-ductal and post-ductal CoA.
Comparative qualities                           Pre-ductal/ductal CoA                                                Post-ductal CoA
Age                                                         Neonatal presentation                                                  Adolescent/adult presentation
Symptoms/signs                                     Cyanosis when DA closes                                             Cyanosis during exercise/stress
                                                              Dyspnoea, tachypnoea                                                 Dyspnoea, tachypnoea
                                                              Loss of consciousness                                                   Loss of consciousness
                                                              Absent femoral pulses                                                  Rib notching and pulsations
                                                              Plethora of upper extremity                                         Upper extremity hypertension
                                                              Upper extremity hypertension                                      Possible cardiogenic shock
                                                              Decreased lower extremity perfusion
                                                              Cardiogenic shock
Investigations                                          Pulse oximetry of four limbs                                         Pulse oximetry of four limbs
                                                              Blood pressure of four limbs                                         Blood pressure of four limbs
                                                              VBG – metabolic acidosis                                             ABG – metabolic acidosis
                                                              CXR – cardiomegaly                                                     CXR – cardiomegaly
                                                              ECG – arrhythmia                                                         ECG – arrhythmia and RVH/LVH
                                                              ECHO – RVH                                                                ECHO – RVH and LVH
                                                                                                                                                  CT or MRI angiography
Management                                          Alprostadil/Prostin                                                        Dobutamine
                                                              Dobutamine                                                                 High flow oxygen
                                                              CPAP and intubation (if needed)                                  Diuretics – if fluid overloaded
                                                              Diuretics – if fluid overloaded                                       NPO prep. for surgery
                                                              NPO prep. for surgery                                                  Anti-hypertensive medication
                                                              Anti-hypertensive medication
                                                              
Abbreviations: CoA – coarctation of the aorta; DA – ductus arteriosus; VBG – venous blood gas; ABG – arterial blood gas; 
CXR – chest x-ray; ECG – electrocardiogram; ECHO – echocardiogram; RVH – right ventricular hypertrophy;
LVH – left ventricular hypertrophy; CPAP – continuous positive airway pressure; NPO – nil per os.
FIGURE 1: Comparison between pre-ductal (left) and post-ductal
(right) coarctation of the aorta. Image courtesy of Catherine Tennant,
RCSI medical student.
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management can be seen in Table 1. Failure to operate on CoA in
both pre- and post-ductal cases has been shown to result in 75%
mortality by the age of 46 years, with an average life expectancy of
35 years.5 These statistics emphasise the need for early detection and
intervention. The purpose of this article is to present a rare case of
missed CoA, and emphasise the importance of complete
examinations, maintaining suspicion of CoA, and screening, both at
neonatal check-ups and upon presentation to hospital.
The case
A nine-day-old baby boy presented to Cavan General Hospital in
Cavan, Ireland, with a one-hour history of blue/purple facial and
upper extremity colour and pallor of the trunk and lower
extremities associated with fast, deep breathing. On the previous
night, he had been normally active and feeding, with his last feed
at 6.00pm, but the parents noted fatigue and irritability with
feeding. At about 4.00am, he was noted to have a purplish blue
face and upper chest, with pale trunk and legs. He was tired,
floppy, cold, sweating, and taking fast, deep breaths. He was
immediately brought by ambulance to Cavan General Hospital and
admitted to the neonatal ICU. He spent one day there, initiated on
antibiotics and intubated due to continuous positive airway
pressure (CPAP) intolerance. He had multiple cyanotic episodes
lasting 15-20 minutes every three hours while at Cavan General
Hospital. He was noted to have passed bowel motions and to have
urinated at normal frequency and colour with no pain. He had no
past medical history of any illness or medication use. Birth weight
was 3.78kg at 40+2 gestation without complications pre- or
postnatally.
Initial examination only revealed cyanotic features in the upper
extremity, pale and cold lower extremities, with weak peripheral
pulses and a continuous systolic murmur. There was noted
increased work of breathing but no wheeze, consolidation, or
crepitations in both lung fields. Temperature was recorded at
38.2ºC. Full blood count revealed WBC of 14.2 x 109/L (ref.
4.0-11.0), which is slightly raised, but not entirely suggestive of
severe infection. Arterial blood gases revealed combined metabolic
and respiratory acidosis with severe deoxygenation: pH 7.22;
PaCO2 6.3kPa; PaO2 4.2kPa; and, HCO3 19.2mEq/L. Chest x-ray
revealed cardiomegaly.
Initial impression led to a diagnosis of sepsis compounded by
underlying decompensated congenital heart disease, with triple
antibiotics implemented but with no relief. He also received
prostaglandin E1 and dobutamine to maintain perfusion and
cardiac output, but remained cyanotic with low oxygen saturations.
He received morphine for pain relief and eventually required
nasogastric (NG) tube feed and ventilated intubation at FiO2 30%
due to CPAP intolerance. After hours of no improvement, he was
urgently transferred to Our Lady’s Children’s Hospital Crumlin
(OLCHC) for tertiary care. This diagnosis of pre-ductal coarctation
of the aorta was due to his classical findings of breathlessness and
cyanosis. A successful urgent end-to-end anastomosis repair of the
coarctation and PDA ligation was performed. Postoperative
echocardiogram revealed left and right ventricular hypertrophy and
postoperative gradient of 19mmHg, much decreased from its
previous coarced state. He was also initiated on morphine for pain
relief, paracetamol to continue closure of the PDA, furosemide with
spironolactone to decrease fluid overload, and clonidine for
hypertension. He began to improve with no cyanotic episodes on
close observation, and was then discharged with daily medication
to combat further ventricular hypertrophy and prevent heart failure.
Discussion
While this case’s end results were good, with no immediately
noticeable neurological or pulmonary damage, this missed
diagnosis is a failure from the physician’s point of view. Palpating
femoral pulses is a necessary part of the paediatric exam and may
appear to be relatively simple, but children may be irritated by
finger pressure into the sensitive inguinal area, making it difficult to
appreciate. Due to either lack of clinical experience or
circumstances, many physicians have missed congenital heart
abnormalities, specifically CoA. One study showed that 21/22
infants presenting and diagnosed with CoA had weak or absent
femoral pulses.1 However, femoral pulse palpation should not be
the only screening tool for CoA, as a PDA can possibly provide
enough blood volume from the right ventricle to create a palpable
pulse.6 While a normal femoral pulse may appear to be a good sign
of perfusion, it also masks the hidden danger of a coarctation. One
study showed that 22/83 misdiagnosed infants were readmitted
with circulatory failure and 3/83 died from CoA.7 If CoA does not
present in earlier life, adults may go untreated for hypertension,
resulting in stroke or cardiac failure, with most patients dying
before the age of 46 years.5 This emphasises the importance of
diagnosing CoA at birth and not waiting for hospital admission
with cardiogenic shock. Simply put, doctors are fallible and can
miss diagnoses. This does not mean that the physicians involved in
the missed diagnoses are necessarily poor or lazy; other
investigations supporting clinical skills may be necessary to
diagnose CoA. It is also difficult to assess the sensitivity of palpating
femoral pulses for CoA versus lack of experience, given the
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expertise required for confidence at this examination. A secondary
assessment for CoA is to use pulse oximetry and measure blood
pressure on all four limbs to find CoA, and this has been a
recommended evidence-based screening method in previous
studies.5,6 A noticeably diminished blood oxygen saturation of the
lower versus upper limbs should trigger a diagnostic
echocardiography or CT scan.5 Pulse oximetry screening (POS) and
four-limb blood pressure measurements are easy to perform,
non-invasive, and require little economic input due to the use of
previously stocked equipment for which little training is required.
Neither femoral pulse palpation nor POS are sensitive enough to
rule out CoA, but together this combination provides the best
screening tool for CoA in the newborn. The largest expense and
greatest barrier to using both POS and femoral pulse palpation is
extra time spent by the physician or nurse to perform these
screening procedures. A POS and blood pressure screen algorithm
is provided by the Health Service Executive, but is not a mandatory
part of newborn testing.8 Currently, the only required newborn
screens are bloodspot and hearing test,9 but CoA screening should
be done to prevent fatal complications in the young infant as it is
both non-invasive and potentially life saving. Pulse oximetry and
blood pressure screening of newborns appears to satisfy each of the
Wilson and Jungner Screening Criteria from the evidence listed
above.10 Other investigations to diagnose CoA have been explored,
but with little success. 
Antenatal echocardiogram screening for CoA has been shown to
have modest results in improving outcome, but is not sensitive
enough to stand alone as a diagnostic tool.1
A major limitation to antenatal echocardiogram screening is also
the heavy expense on the healthcare system. Pulse oximetry and
blood pressure screening, in addition to femoral pulse palpation,
require a commitment of a great deal of time on already
time-pressured physicians, but should be used like the standardised
heel-prick test to recognise this potentially fatal condition.
Conclusion
This is a lesson in the importance of paediatric physical
examinations and investigations, both at the first neonatal check
and at subsequent checks. This case also shows the necessity of
detecting CoA as early as possible, and the importance of pulse
oximetry and blood pressure screening in early life. While CoA
patient signs may be missed by multiple physicians, this does not
excuse the use of simple, non-invasive screening in addition to
femoral pulse palpation to identify CoA in the newborn stage.
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Introduction
Smoking is the single most important preventable
cause of illness, chronic disability, and death in
Ireland.1,2 According to the Health Survey Ireland
2015, 23% of the Irish population are smokers.2
Smokers lose an average of 10-15 years from their
life expectancy;1 according to the HSE website on
smoking cessation, “one in every two smokers will
die of tobacco-related disease”.3,4 Every year, there
are over 5,000 deaths due to tobacco in Ireland.2
To combat this problem, healthcare professionals
(HCPs) are encouraged to provide cessation advice
to patients who are smokers. Based on a Cochrane
review in 2008, brief cessation advice provided by
doctors increases the possibility of smokers being
successful in quitting.5 The Health Survey Ireland
2015 reported that a “majority (63%) of smokers
are trying to, planning to or considering quitting”.2
However, there is a low prevalence of provision of
cessation advice by HCPs, in Ireland and more
widely. An Irish study (2012) found that 61% of
hospitalised patients were asked about smoking
status, and only 44% of current smokers received
advice from HCPs.6 This was also recently explored
in another Irish study (2014) carried out in two
large Irish university teaching hospitals, which
reported that 62% of inpatients did not receive
smoking cessation advice, despite 55% being
interested in quitting when asked.7 In a German
study, only 39% of patients who smoked recalled
being counselled to quit,8 while only 10.5% of
general practitioners in Montreal and 22.6% of
university hospital physicians in Turkey offered
smoking cessation advice.9,10 Use of the Ottawa
Model for Smoking Cessation (OMSC) has been
proposed to accomplish a systematic approach to
the delivery of cessation advice by HCPs to patients
Exploring the views of
healthcare professionals on
increasing smoking cessation
advice for patients
Abstract
Background: Smoking cessation advice provided by healthcare professionals can be effective
in increasing smoking cessation among patients. Any successful intervention will require staff
knowledge of local barriers to implementation. However, the views of Irish healthcare
professionals on increasing the provision of smoking cessation advice and the associated
barriers remain unexplored.
Aims: To explore the views of Irish healthcare professionals on barriers to increasing smoking
cessation advice for patients in a large Irish university teaching hospital.
Method: Semi-structured interviews were conducted separately with 16 healthcare
professionals in a large Irish university teaching hospital.
Results: The main barriers identified were patient and staff attitudes, time and service
constraints, information not readily available, and issues and opinions on a smoke-free
campus policy in a hospital setting.
Conclusion: Our results revealed several barriers, expressed by Irish healthcare professionals,
to providing smoking cessation advice to patients. This supports the need to implement a
multi-component intervention in a hospital setting to improve the rate of provision of
smoking cessation advice in patients by healthcare professionals.
Royal College of Surgeons in Ireland Student Medical Journal. 2016;1:27-32.
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in an Irish hospital setting. A study evaluating the OMSC showed that
69% of smokers receiving the OMSC intervention achieved six-month
continuous abstinence, suggesting that it is a successful cessation
model.11 A cross-sectional study in Japan reported HCPs lacking
knowledge and training, and patients’ unwillingness to quit, as
potential barriers to smoking cessation care.12 In the UK, a qualitative
study showed that patients were more likely to consider cessation
when referred to a separate specialist smoking cessation centre, and
this service was favoured by HCPs because they felt that they lacked
the time and expertise to intervene during daily practice.13 The views
of HCPs on increasing the provision of smoking cessation advice in
Ireland are not well elucidated. This study aims to explore the views of
HCPs on  current barriers to the provision of cessation advice to
patients, and their recommendations on how to increase such advice,
in a large university teaching hospital.
Methods
Participants and setting
Venue-based and snowball sampling methods were employed,
whereby 16 HCPs were recruited from Beaumont Hospital. Once a
HCP was interviewed, they then recommended two to three others
who might consider participating in the project. Each HCP was
contacted in turn, and the researcher (SYH) met those who agreed to
participate, and conducted the interviews within the allocated
timeframe. Participants were selected and interviewed if they fulfilled
the criteria: a healthcare professional working in an environment
where they would have daily contact with patients. Interview
appointments were arranged from July 4-11, 2012. HCPs were
categorised as doctors, surgeons, nurses and allied HCPs to ensure
anonymity.
Procedure
Ethical approval was given by the Beaumont Hospital Ethics (Medical
Research) Committee. Each participant was given a leaflet about the
study and its purpose, and a consent form to sign prior to the
interview. A set list of open-ended questions was used to maintain
consistency (Figure 1). All participants were interviewed by the same
interviewer. Each session lasted 15-30 minutes, and was recorded
with the respondent’s permission. Participants were questioned on
their smoking status, whether they routinely provide cessation
advice, barriers to delivering such advice to patients, and
recommendations.
Analysis
Digital recordings were analysed and fully transcribed. A thematic
Page 28 | Volume 9: Number 1. 2016
  Do you smoke?
  Do you routinely record patients’ smoking status?
  Do you routinely provide patients who are smokers with smoking  
cessation advice?
  Do you follow up on all these patients that you provide with
smoking cessation advice?
  On average, how many years of life would you estimate for
smokers to lose in comparison to non-smokers?
  Do you refer patients to a community smoking cessation
programme or any other that is similar?
  Are you familiar with the 5As model, 5Rs model or the Ottawa
model?
  If the 5As model were implemented in this hospital, do you think
it would be effective?
  If the 5Rs model were implemented in this hospital, do you think
it would be effective?
  What do you think about the Ottawa model, if it were to be
implemented in this hospital?
  Do you think practice-based supports such as stickers on a
patient’s chart, or posters or emails, would increase the rate of
delivery of smoking cessation advice to patients?
  Do you think brief smoking cessation advice from a healthcare
professional is effective in increasing quit rates?
  How long do you think brief smoking cessation advice should
take?
  Present results suggest that 10-15 minutes is the optimal length
for provision of smoking cessation advice. How realistic do you
think this is? What do you think of this?
  Do you have any other recommendations for improving the rate
of recording patients’ smoking status and providing smoking
cessation advice?
  What do you think about this hospital as a smoke-free campus?
Would that help patients?
  In this hospital, what systematic barriers do you and your staff
experience in terms of recording patients’ smoking status and
providing smoking cessation advice?
FIGURE 1: List of interview questions.
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analysis was done to identify the main themes (barriers and
recommendations) relating to smoking cessation from interview
transcripts. Significant key words, phrases and quotes from
transcripts were identified and marked with ‘descriptive tags’ or
codes by a researcher (SYH). Coded transcripts were then reviewed
by another researcher (MB) to ensure the reliability of the first
author’s (SYH) codings and to see if any further themes could be
detected in the transcripts. Once both researchers (SYH, MB) agreed
on the codings, all codes that were thematically similar were
grouped together and labelled as a category, which became the
organising themes of our analysis.
Results
HCP recruitment and participation
Of the 26 HCPs approached, 16 agreed to participate. Of the 10
that declined to participate, eight stated that they were busy and
two did not respond to the emails. The HCPs who participated were
doctors (n=6), surgeons (n=2), nurses (n=5) and allied HCPs (n=3),
none of whom currently smoked. One nurse had stopped smoking
11 years previously (Figure 2).
Current practice
Most HCPs (75%; 12/16) routinely recorded patients’ smoking
status on admission, 18.75% (3/16) did not do this routinely, and
6.25% (1/16) did not record patients’ smoking status at all. The
18.75% (3/16) of participants recorded smoking status when
reminded to do so (i.e., on admission note or social history), or
when it was relevant to the patient’s medical condition (i.e., if the
patient had a respiratory condition).
Only 43.75% (7/16) of the interviewed participants provided
smoking cessation advice to patients routinely, 37.5% (6/16) did not
routinely provide it, and 18.75% (3/16) did not provide it at all. The
time spent for provision of cessation advice was less than five minutes.
“We would contact the smoking cessation officer, but we don’t offer
advice for patients who come in.” (Interview 3 – nurse)
“We would [provide cessation advice] in young breast cancer patients
who are getting better and will live a long life, but if it’s somebody who
is quite sick and palliative, it’s not really considered important to do
that.” (Interview 10 – allied healthcare professional)
“I am not sure whether everyone does anything other than record [smoking
status] as part of the history that they take.” (Interview 6 – doctor)
There was also lack of routine documentation of patients’ smoking
history by staff. According to one nurse, patients’ smoking history
was not “written in black and white” and there was no “specific
column for it”.
“Sometimes it’s pack years, sometimes it’s ‘ex-smoker gave up 15 years
ago’, but not the amount. Maybe [it would be documented more] if
there was a routine hospital policy on how you document and to always
document it.” (Interview 10 – allied HCP)
Barriers to delivering smoking cessation advice
All HCPs interviewed viewed the provision of smoking cessation
advice as effective in increasing quit rates among patients. However,
several barriers were reported when providing patients with such
advice.
1. Patient and staff attitudes
Participants said that it can be difficult to encourage patients to quit
smoking when they have no intentions of quitting at all.
“When you start talking to a patient about smoking, you can see them
shut off. Most patients when asked, they smile and, it’s like, ‘I suppose
FIGURE 2: Flow chart illustrating recruitment of HCPs.
Total HCPs approached
(n=26) HCPs that declined (n=10)
Busy (n=8)
Did not respond to emails 
(n=2)
Doctors (n=6)
Surgeons (n=2)
Nurses (n=5)
Allied HCPs (n=3)
Total HCPs who participated
(n=16)
RCSIsmjoriginal article
you are going to give me a lecture now’…” (Interview 6 – doctor)
It was also voiced that patients come to the hospital for specific
medical problems and not smoking cessation, making it difficult for
HCPs to initiate.
“The patient didn’t come to quit smoking, they came for [a different]
problem, so it won’t have an impact.” (Interview 1 – surgeon)
One noted that there was no routine management for smoking
cessation.
“It was maybe done once or twice during a patient’s stay. I haven’t
seen it done any more.” (Interview 13 – doctor)
With regard to staff attitudes, participants felt that there was a
“huge lack of awareness”, as most doctors “don’t know the actual
process of referring someone for smoking cessation”. Furthermore,
most HCPs do not think that this is their primary goal, and believe
that they are not the “primary people” to give cessation advice.
Both of these factors contributed greatly to the lack of provision of
cessation advice to patients.
“They are not coming to me actually to see that [smoking cessation],
they are coming to me to diagnose a tumour, or treat their COPD with
whatever medication. That is what I’m supposed to do as a doctor.”
(Interview 15 – doctor)
The lack of knowledge among junior staff also contributed to a lack
of provision of smoking cessation advice. This resulted in HCPs not
providing cessation advice routinely or intensively in the hospital.
Another doctor suggested that staff should be educated on “actual
smoking-related illnesses and the latest figures on how smoking
impacts on patients” in addition to cessation advice.
“I think [smoking cessation advice] needs to come from all members of
the teams, because I think just one advising them to stop smoking is
not helpful.” (Interview 11 – allied HCP)
2. Time and service constraints
Most respondents viewed time as a major factor in providing brief
cessation advice to patients.
“We just lack time to talk to patients.” (Interview 14 – doctor)
“You have to do so much work. There is no time to spend per patient to
give cessation advice.” (Interview 1 – surgeon)
Having a part-time smoking cessation officer (three days per week)
was among the barriers faced by HCPs, as referrals made were “not
always consistent” (Interview 15 – doctor).
One nurse voiced the opinion that there should be immediate
access to a cessation officer at all times.
“You can’t send people over and say ‘we will have them talk to you
tomorrow’.” (Inter view 3 – nurse)
One surgeon suggested that a smoking cessation clinic should be
available in the hospital for patients willing to quit (Interview 1 –
surgeon). With the heavy workload and the time constraints every
HCP has, having a smoking cessation clinic where patients could be
followed up consistently and seen primarily for cessation would be a
great improvement. Facilities such as community smoking cessation
programmes, support groups and follow-up services for patients on
pharmacotherapy for cessation are unavailable, affecting the quit
rates among patients.
“I think it’s important when a patient avails of a service, they should be
followed up within six months.” (Interview 16 – allied HCP)
“There are no community cessation programmes and facilities
available.” (Interview 15 – doctor)
Staff shortages in the hospital contributed to inconsistent provision
of cessation advice. One nurse suggested that having a cessation
nurse assigned to wards to follow up on patients would improve the
rate of delivering cessation advice.
“I think if someone was assigned specifically, a nurse to go around and
check what patients are smokers and sit down [with them], maybe that
will help.” (Interview 5 – nurse)
3. Information not readily available
One practical barrier expressed by participants was a lack of
availability of information on smoking cessation. Without
information leaflets and posters readily available throughout the
hospital, HCPs can only provide cessation advice verbally.
“There aren’t any information leaflets and things like that. So maybe if
there were leaflets on the wards, it might help inpatients as well.”
(Interview 8 – doctor)
“When you are in A&E admitting patients, you always ask about
smoking history and it’s at the forefront of your mind ... By the time
they make it to the wards, it’s forgotten, and you deal with their acute
problems.” (Interview 8 – doctor)
4. Smoke-free campus
During the study period, the hospital had just implemented a
smoke-free campus policy and experienced several issues. Patients
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smoking in a hospital affects not only their health, but also subjects
non-smoking parties to passive smoking, so with the hospital being
designated a smoke-free campus, there would have to be an increase
in the rate of provision of cessation advice and encouraging patients
to quit smoking. Hospital staff would also theoretically be motivated
and encouraged to quit smoking, as there is a “restriction they have
to respect” (Interview 1 – surgeon). However, the idea of the
smoke-free campus was not supported by all. One doctor said it “is
not fair for the palliative patients”, despite helping other patients with
smoking cessation, and suggested that exceptions should be made
for these patients (Interview 9 – doctor).
Discussion
This is the first qualitative study to explore the views of HCPs in
Ireland on the barriers to increasing smoking cessation advice for
patients. The main barriers identified from our study were time and
service constraints, patient and staff attitudes, information not readily
available, and issues with the smoke-free campus policy. Time
constraint was viewed as the major barrier to the provision of
smoking cessation advice to patients by HCPs. In an Irish study, 74%
of nurses had no time to provide cessation advice to patients.14 In
another study, smoking cessation counselling was perceived as too
time-consuming by physicians.8 According to Duffy et al., having
trained nurses to deliver cessation care to patients is ideal, as nurses
are well informed on patients’ medical conditions, nursing time is
more cost-effective compared to physician time, and nurses have
access to and immediate rapport with patients.15 Future research
should investigate the suitability of nurses to deliver cessation care.
Another barrier perceived was that HCPs underestimate the relevance
of cessation advice to the patients and do not regard it as their
primary goal and priority. This was reflected in other research: 76.3%
of physical therapists asked patients’ smoking status but only 21.6%
reported assisting patients to quit smoking (due to lack of training).16
Despite HCPs being aware of the importance of smoking cessation,
there is a lack of knowledge as regards counselling patients. Desalu et
al. found that 67% of physicians were aware of smoking cessation but
only 30.3% had knowledge on cessation counselling and 66.3% had
poor knowledge of interventions.17 An Irish study reported that 65%
of nurses lacked training in delivering cessation advice.14 Smoking
patients who received cessation advice from two or more types of
HCP had an almost three-fold increase in quit attempts and readiness
to quit in the next six months.18
With regard to patient attitudes, patient resistance or unwillingness to
quit smoking was also among the barriers. Dentists and general
practitioners in the UK reported patient resistance as a barrier.19,20
However, Duffy et al. reported that only 17% of inpatient veteran
smokers received advice, despite more than two-thirds being
motivated to quit.15 In Ireland, Bartels et al. reported that 40% of
smokers would like to receive cessation advice.6 A further barrier
identified was the lack of a facility to follow up patients who had
received smoking cessation advice from HCPs. It has been
demonstrated previously that cessation rates were higher in groups
receiving extended counselling (22% versus 20% in the control
group) and follow-up (28% versus 24% in the control group)
compared with those receiving brief advice.21 Training residents and
labelling medical records with reminders has more than doubled the
percentage (from 9% to 23%) of patients receiving advice.22
Intervention, including a follow-up call, showed a rise in the
six-month continuous abstinence rate (29.4% vs. 18.3%).11 Rigotti et
al. confirmed that intensive intervention with follow-up support
increased cessation rates.23 Multi-component interventions that
increase provision of cessation advice have demonstrated some
success. Freund et al. implemented a multi-strategic approach, which
involved seven broad intervention strategy areas, and this was
effective in increasing hospital smoking care delivery and provision of
nicotine replacement therapy.24 A further multi-strategic intervention
trial showed that improving the routine provision of cessation care
practices in a hospital setting is achievable.25 This confirms the need
for multi-component intervention to increase the efficiency of
provision of cessation advice in a hospital setting.
This study has several limitations. Results were based on interview
sessions with HCPs, leading to recollections and biases of individuals
affecting the data’s accuracy. The sample size was 16 HCPs from a
single large university teaching hospital, suggesting that the sample
may not be representative of the entire HCP population. However,
the HCPs interviewed are involved with patients directly in their
clinical practice and would be the ones providing cessation advice
directly.
Conclusion
This study investigated the views of HCPs on increasing smoking
cessation advice for patients. We identified several barriers expressed
by HCPs to providing cessation advice to patients. With the
knowledge of these barriers, we are able to understand and overcome
them, and to personalise and improve the provision of smoking
cessation advice to patients, thus increasing smoking cessation rates.
Overall, this supports the need to implement a multi-component,
hospital-based intervention, or specialist cessation care, to promote
and increase the rate of provision of smoking cessation advice to
patients by HCPs.
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Introduction
An estimated 246,660 new cases of invasive
breast cancer are expected to be diagnosed in
2016 in the United States alone.1 While the exact
aetiology is unclear, certain risk factors have been
identified, with the majority related to prolonged
oestrogen exposure. Risk factors include genetics,
family history, increasing age, early menarche,
late menopause, and high levels of sex steroid
hormones (e.g., for women on the oral
contraceptive pill or on hormone replacement
therapy).2 Pertaining to genetics, those with
BRCA 1 and 2 mutations are at a greatly
increased risk, with some opting for prophylactic
mastectomies and/or bilateral salpingo-
oophorectomies in order to reduce their risk.3,4
Other rare genetic mutations – such as
phosphatase and tensin homologue (PTEN)
mutations in Cowden syndrome and p53
mutations in Li Fraumeni syndrome – have also
been implicated.5,6 More recent studies have led
to the discovery of various subtypes of breast
cancer, and have elucidated the roles of different
hormones and oncogenic mutations.
Subtypes
Four well-defined subtypes, based on cell
receptor expression, have been identified:
basal-like; human epidermal growth factor
receptor 2 (HER2) enriched; luminal A; and,
luminal B. Luminal A breast cancers are ER and
progesterone receptor (PR) positive and HER2
negative. Luminal B tumour cells are hormone
An investigation of
responsiveness to PI3K
inhibition in breast cancer
cells expressing high levels of
androgen receptor
Abstract
Introduction: Approximately 75% of breast cancers express androgen receptor (AR). There is
conflicting evidence regarding the role of androgen signalling and breast cancer survival; a
number of studies suggest a protective function but, more recently, AR has been shown to
drive oestrogen receptor (ER) gene expression in ER-negative apocrine (AR positive, triple
negative) breast cancer. This concept is echoed by a number of studies that have focused on
the oncogenic potential of the AR. In this study, we evaluated responsiveness to PI3K
inhibition in a series of breast cancer cell lines expressing varying levels of AR. 
Methods: IC50 values for the pan-class I PI3K inhibitor BEZ235 were established in a range of
breast cancer cells in vitro. BEZ235 inhibits phosphorylation of Akt and also blocks the mTOR
pathway. MTS assays were optimised and suitable drug concentrations were then evaluated.
Endocrine-sensitive (MCF7) and -resistant (LetR, ZR75.1) cell lines were assessed. 
Results: MCF7 cells had an IC50 of 0.01031M, ZR75.1 cells had an IC50 of 0.001064M, and
LetR cells had an IC50 of 0.001826M. 
Conclusion: Low-AR expression MCF7 cells were found to be much less sensitive to PI3K
inhibition than the high-AR cell lines. AR could be used to identify endocrine-resistant
patients who would benefit from second-line PI3K inhibitor therapy.
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receptor (ER and PR) and HER2 positive. The HER2-enriched subtype
is hormone receptor (ER and PR) negative with HER2 amplification.
Basal-like tumour cells are hormone receptor (ER and PR) and HER2
negative, and are so-called ‘triple negative’ tumours.7 Subtype is a
prognostic factor; luminal A tumours account for about 72.7% of
breast tumours in the United States and have a better prognosis
than luminal B (4.6%), triple negative (12.2%) and HER2-enriched
tumours (12%), with the latter three being more clinically
aggressive.8 These subtypes are also useful in patient management
and treatment choice.
Breast cancer management
Treatment is determined by stage of disease, size of tumour, tumour
subtype, and patient age. Surgery remains the mainstay of breast
cancer treatment, with radiotherapy, chemotherapy and endocrine
therapy used as adjuvants. Endocrine therapy is highly dependent
on the molecular profile of the tumour.9 ER-positive tumours can be
successfully treated with complete oestrogen antagonists such as
fulvestrant, selective oestrogen receptor modifiers (SERMs) such as
tamoxifen, or therapies that prevent the synthesis of oestrogen, e.g.,
aromatase inhibitors (AIs) such as anastrozole.10 The stage of breast
cancer is essential in determining optimal treatment. Non-invasive
breast cancers are usually treated with breast-conserving surgery
(BCS) and prophylactic radiation; invasive carcinoma, on the other
hand, may require mastectomy, almost always requires a sentinel
lymph node biopsy, and requires axillary clearance if there is nodal
involvement.9 Adjuvant endocrine treatment methods for both
invasive and non-invasive carcinomas vary depending on
menopausal status. Studies suggest that premenopausal patients
receive tamoxifen as first-line therapy, ovarian ablation as a suitable
second-line therapy, and an AI as a third-line therapy.11 However, for
postmenopausal women there is more variability in treatment
methods. Five years of treatment with tamoxifen has until recently
been seen as first-line therapy, followed by AIs as second-line
therapy, and a switch to another AI as third-line therapy.12,13 The use
of AIs for five years instead of tamoxifen is also commonly accepted,
especially in patients with high recurrence risks.9 There has been
prolonged debate over whether tamoxifen or an AI should be used
as first-line therapy in postmenopausal women, with tamoxifen
usually favoured in practice.9 However, the Arimidex, Tamoxifen,
Alone or in Combination (ATAC) trial showed that AIs compare
favourably to tamoxifen in disease-free survival, withdrawals and
side effects associated with tamoxifen’s partial agonist activity on the
ER (including vaginal discharge, thromboembolic disorders, and
endometrial cancer),13 suggesting that AIs should be seen as a
first-line treatment.
Role of androgen receptors
There is now an increased recognition of the role of androgen
receptors (ARs) in breast cancer, with about 60-70% AR positivity.14
The effects of ARs seem to vary based on the subtype in question.
ARs suggest good prognoses in ER-positive breast cancers, where
they help to balance oestradiol-induced cell proliferation.7,15
However, in certain classes of ER-negative cancers, AR expression has
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been linked to poor prognosis along with increased proliferation,
particularly in the molecular apocrine subtype, which is ER negative
but AR positive.15 Therefore, AR has become a possible target in the
treatment of breast cancer.
PI3 kinase link with androgen receptors
Because increased AR levels in certain cancers are a sign of poor
prognosis, current studies focus on factors that could cause
abnormalities in normal AR functioning. Of interest, a recent study
reported a link between kinase domain PI3K mutations and
increased AR levels.16 The PI3K pathway has also been linked with
survival of letrozole-resistant (LetR) cell lines;17 in addition, an
association has been established between the PI3K and other
growth factor pathways with ligand-independent activation of the
AR. Relapses after successful inhibition of the AR have been
attributed to this.18 By this logic, an inhibition of the PI3 kinase
pathway could be used as treatment for AR-positive tumours that do
not respond well to conventional endocrine treatment.
BEZ235 mechanism of action
BEZ235 is a pan-class PI3K inhibitor, which has been shown to
inhibit the PI3K/Akt/Mammalian target of rapamycin kinase
pathway. It works by binding to the adenosine triphosphate (ATP)
cleft of these enzymes, competitively preventing binding of ATP. The
PI3K pathway has been implicated in various cancers, and therefore
its inhibition by BEZ235 is a possible treatment option for various
cancers.19 The mechanism of action can be seen in Figure 1.
Hypothesis
Breast cancer cells that express high levels of AR will exhibit greater
sensitivity to the pan-class I PI3K BEZ235 (provided by Novartis).
Aims
1. Define the IC50 of BEZ235 for each of the following breast cancer
cell lines:
• MCF7 – endocrine sensitive;
• ZR75.1 – endocrine sensitive; and,
• LetR – endocrine resistant.
The endocrine-sensitive cells are highly responsive to treatment by
AI and tamoxifen, while the endocrine-resistant cell line is
unresponsive despite being ER positive.
2. Evaluate if AR is wild-type or mutated in cells with varying
sensitivity to BEZ235.
Materials and methods
Cell models
Previous work has shown that LetR cells express higher levels of AR
than the sensitive MCF7 and MCF7aro cells (MCF7 cells
overexpressing the enzyme aromatase) (Figure 2).
The control line used was ZR75.1 cells, which have a luminal A
profile like MCF7, but exhibit much higher levels of AR.20
Cell culture
All cell culture work was carried out in a sterile fume hood with
laminar airflow. All methods were performed using aseptic
technique. Cells were maintained in an incubator at 37°C with a
humid 5% (v/v) CO2 atmosphere.
Routine passaging of cells in vitro
Cells were grown in T-75cm2 filtered tissue culture flasks (Sarstedt;
Germany) and passaged when approximately 80% confluent.
Maintenance work was carried out by removing the old media and
washing cells with 5ml phosphate buffered saline (PBS; Oxoid Limited;
Basingstoke, Hampshire, England). 2ml of 0.05% trypsin (v/v) 0.02%
EDTA (v/v) solution (Sigma Aldrich) was used to detach cells from
growing surface, for incubation for five minutes at 37°C. Trypsin was
neutralised with 5ml of phenol red-free Minimum Essential Medium
(PRFMEM; Gibco LifeSciences) and the cell suspension was transferred
from the flask to a 15ml tube for centrifugation at 1,000rpm for three
minutes at room temperature. The pellet was then re-suspended in the
appropriate volume of suitable media and sub-cultured at a lower
confluency into a T-75 flask.
Endocrine treatment of cells
MCF7 cells express ER and PR, are negative for HER2 amplification,
and were obtained from the American Type Culture Collection
(ATCC). These were maintained in minimum essential media (Sigma
Aldrich; Germany), supplemented with 10% (w/v) foetal calf serum
FIGURE 2: Western blot showing higher levels of AR in the letrozole-resistant
(LetR) compared with the parental endocrine-sensitive MCF7aro cells.
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(FCS) (Sigma Aldrich) and 2mmol/l L-glutamine (Sigma Aldrich),
along with 1% (w/v) Penicillin Streptomycin (Pen/Strep).
LetR cells were created by long-term treatment (>3 months) of
MCF7aro cells with letrozole (Novartis; Basel, Switzerland). Cells
were cultured in PRFMEM containing 10% (w/v) charcoal dextran
stripped-FCS, androstenedione (10-9M; Sigma Aldrich), letrozole
(10-6M) and G418 (200g/ml).
ZR75.1 cells were maintained in RPMI 1640 media (Sigma Aldrich)
and supplemented with 10% (w/v) FCS, 1mmol/l L-glutamine
(Sigma Aldrich) and 1% (w/v) Pen/Strep.
Cell counting
The cell pellet was re-suspended after centrifuging in 10ml of
media. 15µl of this suspension was transferred to a 1.5ml Eppendorf
tube along with 15µl of trypan blue (Sigma Aldrich). 10µl of this
mixture was then pipetted onto a haemocytometer (Marienfeld
Superior; Germany). Cells were counted manually under the
microscope in each of the four 4x4 grids on the haemocytometer
and averaged. The appropriate volume of cell suspension was
calculated and seeded into a suitable culture plate for its purpose.
Cell proliferation assay
Cells were cultured, trypsinised, counted and seeded at a defined
concentration. 50µl of the cell suspension was placed in each well at
3x103 cells per well. Cells were plated into a 96-well plate (Greiner
Bio-One; Germany). Dimethyl sulfoxide (DMSO) was used as the
vehicle control.
Method development for IC50
The IC50 is a measure of the effectiveness of a compound in
inhibiting biological or biochemical function. This quantitative
measure indicates how much of a particular drug/inhibitor
compound is needed to inhibit a given biological process by half, in
this case cell viability.
Optimisation
Cell concentration per well, drug concentration and treatment
duration were optimised over a series of preliminary phases.
Stage 1: During the exploratory stage of the research the optimal
cell concentration for treatment was determined. Cells were initially
seeded at 1×103 and treated with BEZ235 and DMSO (control
treatment) at varying concentrations for 24 hours.
Stage 2: This was the drug concentration optimisation stage.
Following an evaluation of the results, the cells were seeded at
3×103 cells per well and treated for 24 hours using the same
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FIGURE 3: Graph showing IC50 for MCF-7.
FIGURE 4: Graph showing IC50 for ZR75.1.
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concentrations as in Stage 1. Insolubility of BEZ235 at high
concentrations led to an adjustment of drug concentrations.
Stage 3: Final changes were made and cells were seeded at 3×103
cells. The duration of the treatment was also adjusted to 48 hours to
allow enough cell growth that would display adequate differences
between the drug and control treatments.
DNA isolation
DNA extraction was carried out with a DNeasy Kit (Qiagen). Pellets
were harvested from six-well plates on which cells had been
cultured. Pellets were stored in Eppendorf containers in a freezer at
-81°C until DNA isolation was ready to be carried out. Cells were
re-suspended in 200µl of PBS and 20µl of proteinase K was added.
200µl of Buffer AL was added, the mixture was homogenised by
vortexing and incubated for 10 minutes at 56°C. 200µl of ethanol
was added to the mixture, followed by further vortexing. The
mixture was transferred to a spin column and placed in a 2ml
collection tube. It was centrifuged at 8,000rpm for one minute, with
the flow-through subsequently discarded. This step was repeated
after the addition of Buffer AW1. Buffer AW2 was added to the spin
column and centrifuged for three minutes at 14,000rpm. 
The flow-through was discarded once again and the spin column
was transferred to a 1.5ml microcentrifuge tube. DNA was eluted by
adding 200µl Buffer AE to the centre of the spin column. The DNA
was incubated at room temperature for one minute and centrifuged
again at 8,000rpm. This step was repeated once again to optimise
the yield.
Results
IC50 curves were graphed using the software GraphPad Prism 5.
LetR and ZR75.1 cells (IC50: 0.001826 and 0.001064, respectively),
which have high levels of AR, were more responsive to BEZ235 than
the MCF7 cell line (IC50: 0.0103) (Table 1; Figure 3; Figure 4;
Figure 5; Table 2).
Discussion
We compared the responsiveness to treatment with BEZ235 in
ZR75.1 and LetR vs MCF7 cell lines. High levels of AR expression
equated to greater sensitivity to PI3K/mTOR pathway disruption
by BEZ235. This effect was seen when comparing IC50s for the
cell lines with higher AR levels (ZR75.1 and LetR) with the IC50
for MCF7 cells, which express low levels of AR. The fact that
ZR75.1 cells and MCF7 cells primarily differ in their expression
of the AR further reinforces this point.
Most work on adjuvant treatment of breast cancer currently
focuses on the role of ER, PR, and HER2, as these are the most
commonly expressed hormone receptors in breast tumours.
However, the role of the AR should not be understated, as it is
becoming increasingly evident that the AR plays a role in the
development, progression and prognosis of breast cancer. The
results from this experiment indicate that there are interplays
downstream in the signalling cascade, which could affect
treatment response. This study shows the role of the AR in the
PI3K pathway, which could be just one of many; however, we
can ascertain that exploration of the AR in breast cancer could
lead to a whole new realm of therapeutic options for patients.
Assessment of AR expression could indicate which patients
would benefit from PI3K inhibitors; this accentuates the need to
develop a wider range of endocrine therapies and explore
factors that can be used to optimise treatment for individual
patients.
Conclusion
Clinical studies are currently being carried out in order to
determine the tolerability of BEZ235 and its efficacy as an
anti-tumour drug.21 However, there has not been much research
done investigating the relationship and interplay between AR
levels and the PI3K/mTOR pathway. 
More research must be carried out in order to discover factors
that could help to select the best therapies for individuals based
on their tumour’s receptor profile, particularly with regard to AR
expression.
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Abstract 
Rotavirus is an RNA virus that causes diarrhoeal disease and represents a significant cause of
hospitalisation and death in children under five worldwide. The disease burden is particularly
high in developing countries, including those in sub-Saharan Africa, where the population is
young, sanitation is often poor and access to healthcare limited. Vaccination against the virus
has been available since 2006, but population vaccination schedules have not yet been
introduced worldwide. Vaccination programmes, including those in several sub-Saharan
countries, have been successful in significantly relieving the burden of disease. Uganda, which
has one of the highest rotavirus-associated death rates in the world, is scheduled to introduce
the vaccine into its national schedule during 2016. As such, it seems an appropriate time to
assess the current epidemiological status of rotavirus infection in Uganda, and to discuss
important factors that must be considered in the implementation of the vaccine. These factors
include cost-effectiveness and a dosing schedule for maximal efficacy, while minimising
potential dangerous side effects like intussusception. If implemented properly and effectively,
the rotavirus vaccine stands to save millions of lives in Uganda and around the world.
Royal College of Surgeons in Ireland Student Medical Journal. 2016;1:39-43.
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Introduction
Rotavirus is the leading cause of diarrhoeal illness
in children under five, killing over 450,000
children annually.1,2 Infection with the virus
occurs in all parts of the world; however, the
burden of disease and death is greatest in Asia
and Africa.3,4 In these regions, the threat of
rotavirus is most substantial because of the lack
of supportive care, such as rehydration and
electrolyte therapy, often due to poor healthcare
infrastructure and lack of funding.1,5,6 It is
thought that the virus is transmitted via the
hands of contaminated individuals, as countries
with improved sanitation systems exhibit
significantly decreased rates of infection. In
Uganda, where 49% of the population is under
15 years of age, rotavirus is a significant cause of
childhood mortality and poses a substantial
healthcare burden.7 Newly developed and
licensed rotavirus vaccines have proven
successful in developing countries, and have the
potential to help abate Ugandan childhood
mortality.1,2,6,8 This paper will review the
epidemiology of rotavirus infection in Uganda
and explore the potential benefits of the
introduction of a national vaccination
programme.
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Rotavirus
Rotavirus is a double-stranded RNA virus whose serotypes are
determined by the proteins VP7 (G protein) and VP4 (P protein).
These antigens are located on the outer capsid of the virus and elicit
an antibody-mediated response, which facilitates partial humoral
immune protection.1,9 A Cochrane review by Soares-Weiser et al.
reported the presence of approximately 15 G and 26 P antigen
types in human rotavirus strains, theoretically producing 390
(15Gx26P) combinations of various viral subtypes.2 This large
genetic diversity results from point mutations creating new G or P
antigens, reassortment of related strains causing antigenic shift, and
crossing of animal strains with the capability to infect humans. Only
five strains have been associated with the majority of human
infections: G1P[8]; G2P[4]; G3P[8]; G4P[8]; and G9P[8].1,2,9,10
Course of infection
Rotavirus is transmitted through the faecal-oral route, frequently due
to inadequate hygiene, especially when preparing food. Following
ingestion, the virus enters the villi of the epithelial cells lining the
small intestine and replicates. The virus inhibits absorption of vital
nutrients, including glucose and sodium, which subsequently causes
luminal water retention and diarrhoea. Although humoral immunity
increases with repeated infection, it fails to achieve complete
protection, thus allowing re-infection at any age.1 The average
incubation period for rotavirus is 48 hours, with fever and vomiting
developing thereafter. Watery diarrhoea typically begins 24-48 hours
after initial symptoms present, with up to 20 bowel movements per
day. The illness typically lasts for three to eight days, with primary
complications of dehydration, electrolyte imbalances and metabolic
acidosis,5 which can be exacerbated in areas lacking access to basic
medical care.3 Enzyme-linked immunoassay (EIA) and latex
agglutination remain the laboratory diagnostic tools of choice for
identification of rotavirus viral antigens in stool samples.1,5 Most
deaths caused by rotavirus are seen in young children in developing
countries in Asia and Africa; Angola and Uganda have the highest
mortality rates in the world at 1.9% and 2.3%, respectively.3
Uganda and rotavirus
Uganda is a landlocked country located in East Africa with a
population of approximately 35 million.11 The life expectancy at
birth in Uganda is 57 and its under-five mortality rate is ranked
thirtieth in the world at 74 deaths per thousand.11 In 2013, 8,383
deaths were reported in children under four from diarrhoeal disease,
which is the sixth leading cause of death in children under five in
Uganda and accounts for 8% of deaths in this age group.7,12
Uganda has an estimated annual incidence of 10,944 non-severe
and 576 severe cases of rotavirus per 100,000 people aged one to
59.13 A study conducted at the Mulago National Referral Hospital in
Kampala showed that rotavirus accounted for 32.8% of cases of
acute diarrhoea in children, most of whom were between three and
23 months old.14 Another 2010 study by Nakawesi et al. at the same
hospital found that rotavirus accounted for almost half of the cases
of acute diarrhoeal hospitalisations in children.15 This figure is
consistent with WHO global networks for surveillance of rotavirus
data, and the actual figure is likely somewhere between 30 and
50%.15
Increased prevalence of rotavirus in Uganda
Nakawesi et al. also observed that breastfeeding children were 2.5
times more likely to contract rotavirus than those who did not.
This is in contrast to previously published data, which suggested
that breastfeeding confers some protection against contracting the
virus.16,17 Nakawesi et al. explained the contrasting result of their
study by hypothesising that the majority of infants included in
their study were not exclusively breastfed, and therefore did not
consume enough breastmilk to confer immunity.15 However, in a
2011 matched case-control study performed at the same hospital,
breastfeeding failed to show protection against rotavirus
infection.18
The authors also found that dehydration in children resulted in a
two-fold risk of contracting rotavirus. This finding corroborates
previous literature and speaks to the higher disease burden in
low-income countries, where there is more limited access to clean
water for rehydration therapy.15 Studies conducted in sub-Saharan
Africa (excluding Uganda) have also found that nutritional status,
disease during the dry season, and age under two years are linked
to the prevalence of rotavirus. Interestingly, no association between
rotavirus and HIV has been found, and children infected with HIV
have been shown to mount a similar seroresponse to rotavirus
infection as those not infected with HIV, and to clear the virus
effectively.15,19-21
Sanitation is also an important factor contributing to disease
burden. A study of the microbial risks to human health in the water
in the Bwaise III slum in Kampala estimated that 20% of infections
were due to rotavirus contamination, mainly from exposure to open
surface water drainage channels.22 This study also found that the
total disease burden from water-borne pathogens was 680
disability-adjusted life years (DALYs) per 1,000 persons per year. This
is several orders of magnitude higher than the WHO reference level
of tolerable risk.22
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Rotavirus vaccine
Medically, rotavirus gastroenteritis has no cure, although
supportive therapy is frequently employed and typically includes
fluid replacement and electrolyte replenishment.1 Two rotavirus
vaccines have been approved and are used worldwide: RV1
(Rotarix®) by GlaxoSmithKline and RV5 (RotaTeq®) by Merck.1,6,23
RV1 is a monovalent, attenuated rotavirus vaccine of the common
G1P strain. RV5 is a pentavalent vaccine derived from five naturally
occurring bovine strains, which have undergone genomic
reassortment to introduce features of the human rotavirus strains.
Four of the strains express G1, G2, G3 and G4 human rotavirus
surface proteins. The fifth strain expresses the P(8) surface proteins
from human rotavirus strains.2,6 The vaccines were initially tested in
developed countries, but recent concerns have arisen about the
effectiveness of the vaccines within countries in Africa and Asia,
which have the highest incidence of disease.24,25 Strain diversity in
Africa is much more heterogeneic than Asia; predominant strains
include G1, G9, G2, P[8], P[6], and P[4] P proteins.26 Although
some variation exists between vaccine strains and circulating
strains, evidence suggests that rotavirus vaccines provide both
heterotypic and homotypic protection. However, the vaccine is less
effective in developing countries.2,10,25 Currently, 79 countries have
implemented rotavirus vaccination programmes. Financial aid from
the Global Alliance for Vaccines and Immunization (GAVI) has
enabled the implementation of rotavirus vaccine programmes in
many low-income African countries. However, countries such as
Uganda, which has one of the highest burdens of disease, have
only recently planned a national rotavirus vaccination
programme.3,6,27
Vaccination strategies
Several evidence- and population-based strategies can be
employed to attenuate the disease burden of rotavirus in Uganda.
Introduction of a national rotavirus vaccination schedule offers the
opportunity to reduce rotavirus-related disease. Of the ten
countries comprising East Africa, eight have already incorporated
the rotavirus vaccine into their national immunisation
programmes. Uganda has yet to implement the vaccine, although
according to the WHO Ugandan National Planning Cycles,
introduction of the vaccine is planned for April 2016.28 Uganda has
shown a preference towards the monovalent RV1 Rotarix vaccine,
as have a majority of developing countries, due to longer shelf life
and a shorter dosing schedule.29 The WHO recommends that
rotavirus vaccines should be included in all national immunisation
programmes, particularly in South Asian, Southeast Asian, and
sub-Saharan African countries.29 The cost-effectiveness of a new
health intervention is an important factor requiring consideration
by decision-makers prior to its introduction.13 Reports on the
cost-effectiveness of introducing the rotavirus vaccine in Uganda
estimate that approximately four million cases of rotavirus and
70,236 rotavirus-related deaths from 2016 through to 2035 would
be avoided,30 with an estimated cost per DALY averted of $34 USD
in Uganda.13 Vaccines could potentially prevent 4.4 million
DALYs.30 Administered orally, these vaccines are 85-98% effective
in preventing severe rotavirus disease in infants and young
children.31 RotaTeq (RV5) is given in three doses at ages two
months, four months, and six months, while Rotarix (RV1) is given
in two doses at ages two months and four months. The timing of
the vaccines tends to differ between middle to upper-income
countries and lower-income countries, since access to healthcare has
greater barriers in low-income countries, making the Rotarix
two-dose vaccine more appealing, with a higher chance of complete
dosing. This is primarily due to existing vaccination schedules, and
the logistics of delivering and storing multiple vaccines. In many
low-income countries, poor health service access precludes some
children from timely vaccination. The WHO rotavirus position urges
countries to consider providing rotavirus vaccination to these
children, even if it would be later than recommended.32 In
low-income countries with a high burden of rotavirus disease, the
protection provided by the licensed vaccines is lower (39% for
RotaTeq and 49% for Rotarix) than that reported in high-income
countries (about 85% for RotaTeq and 82% for Rotarix).8
A birth dose strategy for rotavirus vaccination may have the
potential to address these challenges.33 Rotavirus infection occurs
at a younger age in low-income countries and early infection is
often associated with more severe disease.34,35 Administration of
the first dose of the vaccine at six weeks of age leaves a gap in
protection. A birth dose would bridge this gap, and potentially
enhance coverage and timeliness of vaccine completion,
particularly in countries with immunisation-related challenges.36
Additionally, intestinal barriers to vaccine efficacy, such as
interference from breastmilk antibodies or environmental
enteropathy, may be limited if the vaccine is administered at birth
when breast milk intake is still low and intestinal microbiota has
not yet been established.33,37,38,39 Intussusception is considered rare
in the first two months of life, so it is thought that administration
of a birth dose could also improve the safety profile of rotavirus
vaccines.33 Neonatal and infant vaccination with the RV3-BB
rotavirus vaccine was found to be well tolerated and
immunogenic.33
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Abstract
Fibromyalgia is a chronic condition characterised by widespread musculoskeletal pain and somatic
symptoms of fatigue, depression and sleep disturbance. For years, patients presenting with
longstanding regional pain were given a label of ‘chronic pain’. To date, the exact
pathophysiological mechanism underlying the development of fibromyalgia has not been fully
elucidated, although many theories have been put forth in the literature. The most prominent
theory describes an underlying central neuropathophysiology characterised by altered pain
processing. The use of novel functional imaging studies has provided us with potentially the most
objective evidence to date of the mechanism of central sensitisation, which remains the most
widely accepted theory to date. However, the most recent literature describes widespread small
nerve fibre pathology, consistent with significant reports of peripheral neuropathic symptoms in
patients with fibromyalgia. Other theories under investigation include roles for immune system
abnormalities such as elevated levels of cytokines and hypoactivity of the hypothalamus-
pituitary-adrenal (HPA) axis. There is also much debate regarding the role of vitamin D deficiency,
with some studies suggesting a correlation between low levels of vitamin D and patient-reported
pain scores. This review will discuss some of the prominent theories about fibromyalgia and the
current recommendations for management of the disease.
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Background
Fibromyalgia is a chronic condition characterised by widespread
musculoskeletal pain with multiple soft tissue tender points
symmetrically distributed across the body. Allodynia,
hyperalgesia, fatigue, sleep disturbances, and neurocognitive
impairment are also features of the condition, which affects
2-3% of the population, predominantly middle-aged females.1,2
For years, patients presenting with longstanding regional pain
for which a definite cause could not be identified, and for which
inflammatory and biochemical markers were negative, were
simply given a label of ‘chronic pain’, or diagnoses ranging from
temporomandibular joint syndrome, to irritable bowel
syndrome, to simply chronic back pain.3
A more coherent picture is now being drawn, with recent
studies suggesting that syndromes characterised by chronic
regional pain are not separate entities, but different
manifestations of a sole central neuropathophysiology. This
shifts the historical blame from a local pathologic process,
corresponding to the region of pain, to the central nervous
system.3 Other prominent theories describe a potential link
between hypoactivity of the hypothalamus-pituitary-adrenal
(HPA) axis and fibromyalgia.4,5 The roles of the immune system
and vitamin D levels have also been extensively explored.6-11
In 1990, The American College of Rheumatology (ACR) released
a set of diagnostic criteria for fibromyalgia. These included both
a history of widespread pain – which is defined as pain above
and below the waist, on both sides and in the axial skeleton – as
well as at least 11 out of 18 identified tender points.12
However, this ignored major manifestations of fibromyalgia such
as psychiatric and sleep disturbances. In 2010, these criteria
were revised to include such manifestations, causing the ratio of
women to men affected to fall from 10:1 to 2:1, which is in line
with many other chronic pain disorders.13 In 2011 the criteria
were further revised, eliminating physician assessment scores
entirely. 
This most recent set of diagnostic guidelines includes the
widespread pain index (WPI) scored from 0-19, indicating the
number of areas of self-reported pain over the previous week,
along with a symptom severity score involving self-reported
fatigue, waking unrefreshed, cognitive disturbance, headaches,
abdominal cramps and depression.14
Pathophysiology theories
The exact aetiology of fibromyalgia is currently unknown, but
underlying pathophysiological mechanisms of central
sensitisation, imbalances in systemic levels of pro-inflammatory
and anti-inflammatory cytokines, and disturbances in the HPA
axis are becoming more evident.4,5,10,11 Together with the two
characteristic symptoms of allodynia and diffuse hyperalgesia,
these theories are in line with the notion of an underlying
central nervous system pathology in pain processing.13
Data from these studies are adding to
an already impressive volume of
evidence that points towards an
underlying enhancement of pain
processing in fibromyalgia.
Central nervous system
Studies have shown that patients with fibromyalgia have a lower
pain threshold, with greater pain scores in response to heat,
cold, electrical and pressure stimuli. Furthermore, these patients
do not exhibit the typical exercise-induced analgesic
response.15,16 However, these studies are often scrutinised for
the lack of an objective pain scale, often resorting to
patient-reported pain as a data reference.17,18
With the use of functional magnetic resonance imaging (fMRI)
and positron emission tomography, regions of the brain central
to pain processing, such as the insula and the anterior cingulate
cortex, have been identified.19,20 In one study, fMRI
demonstrated a decreased activation of the rostral anterior
cingulate cortex (rACC) in patients with fibromyalgia as
compared to controls. The rACC region is made up of a high
density of opioid receptors, and is a vital descending inhibitory
system.19 This dysfunction is in line with other reports regarding
the inefficacy of opioids as a treatment in fibromyalgia.21,22 In
another study using fMRI, patients with fibromyalgia produced a
cerebral response to the application of a mild stimulus
equivalent to that of the control group’s response to a stimulus
of twice the magnitude.23 In one study of 10 patients with
chronic regional pain syndrome, also characterised by altered
pain processing, Freund et al. demonstrated enhanced cerebral
response with the use of functional imaging.24 Data from these
studies are adding to an already impressive volume of evidence
that points towards an underlying enhancement of pain
processing in fibromyalgia.
The use of structural imaging has also allowed for the
demonstration of morphological changes in the brain: one study
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reported significant grey matter volume loss in patients with
fibromyalgia.25 However, depression is a common psychiatric
comorbidity in fibromyalgia, and is also associated with a higher
rate of grey matter volume loss. When depression was
controlled for in other fibromyalgia studies, this association lost
its significance.26,27
Neurotransmitter levels have also been shown to be significantly
altered in fibromyalgia, with an increase in those associated with
pain transmission (such as glutamate, nerve growth factor,
substance P, and the action of serotonin on the 5HT-2a/3a
receptors). This is accompanied by a decrease in
pain-attenuating neurotransmitters such as norepinephrine,
gamma-aminobutyric acid (GABA), and serotonin acting on the
5HT-1a/1b receptors.13,28-30
One system that appears to be working paradoxically in
fibromyalgia is the endogenous opioid system, which is
normally responsible for inhibiting pain. There appears to be an
increase in endogenous opioid activity, with concomitant
decrease in μ-opioid receptor availability.13,31 This is in line with
promising results produced by clinical trials on the use of
naltrexone, an opioid antagonist, as a treatment modality in
fibromyalgia.32,33
The pathophysiology of fibromyalgia is complex, however, and
there is minimal but consistently growing evidence that
peripheral nervous system abnormalities may also play a role.
Peripheral nervous system
Peripheral neuropathic symptoms described as ‘pins and
needles’, and ‘hot’ and ‘tingling’ sensations are prevalent in
fibromyalgia, with studies reporting 76-95% of patients using
those terms as symptom descriptors.10,34,35 This is in keeping
with other diseases with proven peripheral neuropathic
pathology, such as diabetes mellitus, in which 66% of patients
have a sensory neuropathy.36
Epidermal nerve fibre density has been shown to be a reliable
indicator for the presence of small nerve fibre pathology, with
one study reporting a diagnostic efficiency of 88%.37 Several
studies have demonstrated the presence of this pathology by
obtaining skin biopsies from patients with fibromyalgia.
However, these studies have not controlled for the potential
deconditioning and lack of physical activity in this cohort, which
may confound these findings.38,39
Immune system dysregulation
Despite cementing its status as a disease of non-inflammatory
aetiology, multiple studies have reported imbalances of cytokine
levels in fibromyalgia.11,40-43 Cytokines, some of the immune
system’s chemical messengers, can be divided into pro- and
anti-inflammatory, with IL-1, IL-6 and IL-8 being some of the
more prominent pro-inflammatory biomessengers.11
Several studies have reported increased levels of
pro-inflammatory cytokines in fibromyalgia.11,42,44 In studies of
patients receiving IL-2/LAK (lymphokine activated killer) cell
therapy and IFN-alpha for renal cell carcinoma45 and chronic
hepatitis,46 respectively, classical symptoms of fibromyalgia such
as diffuse pain and sleep disturbance developed. However, up to
one-quarter of patients on interferon therapy will develop
depressive symptoms, which include diffuse pain and sleep
disturbance. No correction for depression was made, and thus
further research into this relationship is needed.47 Furthermore,
the literature has reported elevated levels of IL-8 in patients with
fibromyalgia.48 While IL-8 has been shown to be implicated in
the enhancement of anterior cingulate cortex processing in
animals with chronic inflammatory pain, it did not display a
significant association with clinical pain in fibromyalgia.49 Acute
stress has been shown to be associated with higher IL-8 levels,
which may account for the observed relationship.50 The number
of studies on anti-inflammatory cytokines pales in comparison,
with conflicting results reported. One study reports a positive
association between IL-4 gene polymorphism and fibromyalgia,
while others found none.51,52 Another study reported low levels
of Th2 cytokines such as IL-4, IL-5 and IL-13.40,41 A search of the
literature produced no evidence to support a role of IL-10, the
body’s major inflammatory cytokine, in fibromyalgia. Until a
decade ago, the dichotomy of Th1/Th2 cell balance dominated
the immunology realm. However, Th17, a recently discovered
subtype of T helper cells, has demonstrated a role in the
development of autoimmune pathologies such as multiple
sclerosis and psoriasis.53 The major cytokine secreted by the
Th17 cell, IL-17, has also been shown to be elevated in
fibromyalgia.44 Furthermore, one study by Kim et al.
demonstrated a role for IL-17 in mediating pain hypersensitivity.
However, further research is needed into the exact role of this
cytokine in fibromyalgia.54
It is known that cytokines can sensitise nociceptors and
potentially modulate the HPA axis, but it is unclear how this
would lead to central sensitisation.40,55 Rodriguez-Pinto et al.
have proposed the use of cytokine and chemokine levels as
possible biomarkers of fibromyalgia, with implications for
fostering future treatments.40
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The role of vitamin D
Vitamin D deficiency has been implicated as a potential
component in the pathogenesis of a host of conditions, ranging
from multiple sclerosis and inflammatory bowel disease to
Parkinson’s disease and depression.56-58 In exploring the
relationship between vitamin D deficiency and fibromyalgia, the
literature suffers from conflicting reports regarding both the
strength of association and the implications of vitamin D
supplementation as a potential treatment modality.6-9,56-61
Vitamin D has well known anti-inflammatory properties, and low
level states have been postulated to increase levels of
inflammatory cytokines, resulting in increased central
sensitisation to mechanical pain. The central nervous system
mechanisms of attenuating or suppressing pain are theorised to
become dysfunctional if vitamin D levels are low.8,60,61
In one study, 69.3% of patients who met the 1990 ACR criteria
for fibromyalgia were found to have low levels of vitamin D.56
These results were similar to those obtained by von Kanel et al.,
which found that 71% of chronic pain patients were vitamin D
deficient.8 While one randomised controlled trial found no
significant difference in vitamin D levels between patients with
fibromyalgia and controls, the expected rise of vitamin D levels
in the summer was absent in those with fibromyalgia.6
Armstrong et al. reported a significant association in
fibromyalgia patients between low vitamin D levels and anxiety
or depression. Both these findings can potentially be explained
by a lack of sun exposure, prevalent in patients with
fibromyalgia due to the impact of disease on patient activity.56
Evidence has also shown that by supplementing vitamin D,
symptoms of pain in fibromyalgia were reduced.9 Another study
suggested a role for low levels of vitamin D in augmenting
central sensitivity to physically evoked pain, which actively
involves centres of the brain that are distinct from those
involved in spontaneous pain.8
Managing fibromyalgia
The literature on fibromyalgia management is currently
dominated by trials of complementary and alternative therapies,
underlining the limitations of modern medicine in treating
fibromyalgia.62,63
Management of fibromyalgia must be carried out in a primary
care setting, unless clinically indicated otherwise. Patients whose
diagnoses are in question or who are refractory to initial therapy
warrant a referral to the relevant departments, such as
rheumatology, for further investigation.64,65 The general
consensus among clinicians on the initial approach to
fibromyalgia includes pharmacological monotherapy in addition
to non-pharmacological treatments such as patient education,
cognitive behavioural therapy and exercise.
Non-pharmacological therapy has been reported to have effects
of larger magnitude than its pharmacological counterpart.13,64,66
Historical editorials held that informing patients of their
fibromyalgia diagnosis would lead to a rise in patient access to
healthcare services, placing further stress on the system.67
However, recent studies show that a diagnosis is often followed
by a sharp decline in access to healthcare, fewer referrals, fewer
drug prescriptions, and less diagnostic testing.68,69
A diagnosis often provides a source of relief to patients who
have been suffering from an ‘invisible disorder’ that is widely
misunderstood by both the public and clinicians.13 Highlighting
this knowledge gap, Jay et al. reported receiving a patient
referred by a primary physician for “fibromyalgia of the right
shoulder”.70
Secondary fibromyalgia
Patients with fibromyalgia can be categorised clinically into two
groups – one in which no biological evidence of inflammation
can be found, and another in which a concomitant
inflammatory condition such as rheumatoid or osteoarthritis
exists. The latter is also known as ‘secondary fibromyalgia’.13,71,72
In the latter subset of patients, it has been proven that pain
eventually centralises and becomes unresponsive to peripherally
directed treatment modalities, such as NSAIDs and opioids, and
more responsive to centrally acting treatments. It has been
proposed that this centralisation of the pain appears to be
driven by continuing peripheral nociceptive input.3,13,66
As such, identifying individuals at risk of developing this
centralised pain state and intensively treating them at the time
of these acute pain episodes could be essential to ‘preventing’
the development of fibromyalgia. By shifting the research
landscape from the management of symptoms of fibromyalgia
to prevention, our ability to combat fibromyalgia may
potentially improve.13
Conclusion
Numerous studies to date have attempted to outline the
mechanisms underlying fibromyalgia. The use of novel diagnostic
imaging such as fMRI and positron emission tomography has
provided potentially the best objective evidence to date of the
mechanisms of central sensitisation in fibromyalgia.19,23 However,
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The road to the gold standard:
whole genome sequencing 
in the clinic
Abstract 
Costs and time involved in generating whole genome sequences with next-generation
technology are continually dropping, and in this regard are nearing feasibility in clinical
settings. The most significant obstacles to clinical application now derive from the massive
amounts of data generated by each genome sequenced. Storage, analysis and interpretation
pose technical and knowledge-based challenges to researchers, who must also confront ethical,
legal and social issues raised by mass (electronic) storage and sharing of inherently identifiable
data. Medical genomics as a field is still new. There is a dearth of established standards for the
return of results to clinicians and patients, and few evidence-based guidelines pertaining to
most of the variants identified by whole genome sequencing (WGS). However, the ability to
comprehensively identify all genomic variants holds thrilling opportunities for personalised
medicine. Platforms to integrate patients’ clinical information with their genomic data are being
developed and tested with promising results. The statistical power to associate genotypes with
phenotypes and clinical outcomes continues to rise; initiatives like the UK’s 100,000 Genomes
Project are paving the way for clinical adaptation. Currently, narrower targets than the whole
genome are more feasible in the clinic, but there is a reasonable expectation that it will
eventually become the ‘gold standard’ in personalised medicine.
Royal College of Surgeons in Ireland Student Medical Journal. 2016;1:51-6.
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Background
Next-generation sequencing (NGS) technologies can now
sequence the entire human genome in less than three days and,
according to industry claims, at a total cost of $1,000 USD or
less.1,2 This “massively parallel sequencing” generates short
“reads” or nucleotide sequences from a DNA sample and aligns
the reads against a standard reference genome in a
high-throughput process.2-4 Sequence variants are identified by
comparing the sample and reference genomes, and stored in a
variant call file (.vcf) containing the several million variants each
genome typically contains. Medical geneticists and clinicians then
compare the data with a genotype-phenotype database,
interpreting which are pathogenic and which are “actionable”
(have an established intervention and an agreed-upon policy on
whom to treat), and provide results to the patient.5 With the
ability to rapidly generate massive amounts of genomic data,
analysis of this data has now overtaken sequencing as the major
challenge and time-consuming process.
Genome analysis encounters technical, legal, ethical, and
interpretive obstacles.3,6-9 Since a complete, standardised, fully
annotated and linked genotype-phenotype database does not
exist, the reality is that the protocol above represents the ideal
model rather than the practical reality. It is statistically
challenging to assimilate enough evidence to determine
pathogenic significance for variants, particularly rare or unique
ones. This makes practical interpretation of variants
challenging.6,10,11 Several methods are being utilised to raise
statistical power but the problem persists, especially as there
often exists little to no information on phenotypic/clinical
presentations associated with specific variants.12
Training and education
To work with genomic technology, clinical laboratory staff must
be computationally skilled and adequately trained in sample and
data collection, preparation, analysis, and interpretation.
Pathologists play a crucial role in assessment of specimens;
recognising this, several major institutions have incorporated
genomics training into pathology residencies, along with online
resources and educational programmes to address the increasing
need for medical professionals competent in the growing field of
genomic medicine.12,13 There are also academic reviews written
specifically for clinicians on implanting current technology in
practice,14-16 and organisations such as the College of Genomic
Medicine aim to train and update practising clinicians in these
areas.17 Laboratories are certified – for example, by the Clinical
Laboratory Improvement Amendments programme – to ensure
the quality and reliability of sequencing and analysis. The
ultimate goal is to ensure downstream accuracy, identify
medically important variants, and maximise utility for clinicians
and patients.8,18
Challenges to evidence-based progress: 
ethical, legal, social
Data sharing and integration
Challenges to the uptake and widespread implementation of
WGS in clinical practice include formulating ethical policy for
conducting research, creating decision frameworks for clinical
practice, and overcoming institutional and practical inertia to
implement new technology.18 Issues of data sharing, the
electronic health record, and informed consent in a
technologically advanced era of healthcare information
assimilation and storage are particularly relevant to the
formulation of ethical policy. Decision frameworks require the
establishment of criteria for ‘actionability’ of variants for return to
clinicians, return to patients, and support in choosing
interventions,19 which in turn requires efficient and ethically
acceptable data sharing. Concerns about consent to long-term
(and possibly indefinite/irreversible) storage of genomic
information have resulted in the limitation of accessibility of
genomic data collected in these projects to very specific uses and
groups of people.20 Widespread accessibility of genomic
databases is difficult to arrange while respecting privacy and
confidentiality. Research on these ethical, legal, and social issues
has long been acknowledged as necessary and is funded
alongside empirical research.21
Statistical analysis identifying relationships between genotype and
disease alone is not adequate to create clinical guidance. Systems
biology and systems medicine aim to integrate data including
genomics, proteomics, and bioinformatics with clinical
observations. This is crucial in order to understand disease
aetiology, progression, and characteristics in the real world.11,20
Bioinformatics tools to integrate clinical, biological, and genomic
data are in development, and some of the early products show
great promise for personalising treatment, particularly in
oncology,22 but their use will grow slowly as the evidence base
from research and drug development gradually expands. Current
efforts like the electronic Medical Records and Genomics
(eMERGE) network aim to integrate the electronic health record
with compilations of biogenetic information in an ethically
competent manner, and to test frameworks for validating variants
Volume 9: Number 1. 2016 | Page 53
RCSIsmjreview
(including phenotypic associations) and returning findings to
clinicians and research participants/patients.19,23 The 100,000
Genomes Project is a nationwide effort by the National Health
Service in the UK to obtain and integrate clinical information with
whole genome sequences from patients with rare diseases and
their families, and patients with cancer. The aim is to improve
understanding of disease aetiology, identify and diagnose disease
where it exists, and optimise patient management including
treatment selection.24
Return of findings and evidence-based decisions
WGS invariably identifies variants in patients’ genomes not
related to the stated purpose of the test. These ‘incidental
findings’ can have a significant impact on patients’ well-being in
terms of future planning, healthcare decisions, and mental and
emotional health. The American College of Medical Genetics and
Genomics has released recommendations for return of incidental
findings from clinical WGS and whole exome sequencing (WES)
testing, but these guidelines have been accused of ignoring the
patient’s right to refuse the return of results. This ‘right not to
know’ presents a complex challenge to the establishment of
criteria and procedures for returning findings while providing the
full disclosure essential to patient autonomy.25-27 Several eMERGE
projects are examining this topic,19,23 and large-scale initiatives
including the Evaluation of Genomic Applications in Practice and
Prevention (EGAPP) produce evidence-based reviews on the
utilisation of genomic tests. These projects form part of a larger
effort to prime NGS technologies for regular clinical
implementation, as well as clinical decisions in utilising and
returning results to patients.
Physicians often rely on referral to or collaboration with medical
geneticists in providing care based on genomic testing; however,
demand for these specialists may soon overwhelm availability.27 In
cases where evidence-based decision-making is not possible,
clinicians must use their best judgment (or institutional policy,
where it exists) to decide what course of action to take based on
a patient’s genomic findings.26 ‘Early-adopter’ institutions will
continue to be essential in establishing, troubleshooting and
modelling use of genomic testing and utilisation in clinical
settings. They act as examples to convince institutional
stakeholders to fund genomic testing regimens – currently a
major obstacle to establishment of genomic testing in the clinic.18
Current practice and opportunities
Only in the past five years has the role of the non-exomic region of
the genome, previously considered ‘junk DNA’, begun to be
understood and explored, thanks to the results of the international
collaborative Encyclopedia of DNA Elements (ENCODE) project.28,29
An estimated 15% of Mendelian disorders arise from mutations
outside the exome.7 These variants, which are detectable only
through WGS or (limited) tests such as karyotyping, can have
significant functional effects, but are less straightforward to
understand and interpret.4,9,25,30 Once the impact of these
non-exomic variants is better elucidated, WGS will be ideal in
situations of clinical disease where WES, gene panels and other
technologies have failed to provide diagnostic and interventional
guidance. For this reason, WGS has already begun to be
implemented in specialist centres as a tool to help diagnose
paediatric pathologies believed to have a genetic component, but
which have failed to be elucidated after other extensive laboratory
and genetic tests.18,27 This currently limited clinical use of WGS is
largely overshadowed by its use in oncology.
Oncology
The affirmation that genome instability is a major contributor to
cancer development was a crucial result of early WGS
implementation in the field of oncology.30 In research and clinical
practice, genomes of tumour cells are sequenced and compared
to non-cancerous cells from the same individual.22 This allows
tracking of the genomic changes that occur between normal and
cancerous cells in an individual – ‘somatic variants’ – stored in
databases such as the Catalogue of Somatic Mutations in Cancer
(COSMIC) or The Cancer Genome Atlas (TCGA). Somatic variants
across individuals with tumours of varying types are compared to
reveal pathways leading to cancerous growth in specific types of
cancer, as well as commonalities between them.31 Variants found
can be looked up in cancer databases to determine whether they
are ‘druggable’ targets, which have responded well to a certain
pharmacological treatment. This is the idea behind personalised
cancer care – find the best treatment option based on an
individual’s profile of genomic, histological and other clinical
information to achieve the best outcomes (Figure 1).32
As tumours grow, subpopulations of cells diverge genetically, as
they acquire different mutations and continue to proliferate. This
‘intratumoural heterogeneity’ is at least partially responsible for
the phenomenon of treatment resistance. Metastatic tumours can
also develop differentially – ‘intertumoural heterogeneity’ – with
similar implications for treatment.33 The use of WGS and other
NGS technologies to comprehensively identify tumour
heterogeneity, and to identify treatment options based upon
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heterogeneity and temporal development of somatic mutations, is
currently being assessed in several different trials for clinical
feasibility.34,35 Histological assessment can provide a great deal of
practical information about a biopsy, and indeed is the standard
by which neoplasticity is determined, but it is subjective, and on
its own cannot capture the vast heterogeneity of the cancer
genome.
The genetic characterisation of an individual’s cancer is therefore
crucial for personalised diagnostic, prognostic and treatment
purposes.36 A recent study found that in 43% of tumours
examined, mutation similarities between tumours of different
anatomical sites and tissues of origin were more pronounced than
between different tumours of the same anatomical site of
origin.37,38
Trials testing the efficacy and feasibility of this concept –
recruiting cancer patients for treatment trials based on shared
genetic aberrations rather than site of origin – are underway.38
In addition to identification of appropriate treatment, early
detection of, and response to, cancer in an individual is crucial
for a good prognosis.33 Recent investigation of circulating
cell-free tumour DNA (ctDNA) as a cancer biomarker, and
sequencing of it to characterise tumours genetically, has yielded
cautiously optimistic results as a relatively non-invasive diagnostic
and monitoring tool for cancer progression and treatment
response. It can also be used to monitor cancers to assess
treatment resistance. Entire genomes can be sequenced with a
high enough sample titre of ctDNA.35,37,39,40 Albeit in the early
stages of research, this has exquisite potential to improve cancer
treatment and research in terms of quality and patient tolerability
if it proves effective and feasible.
FIGURE 1: A model for personalised cancer treatment using WGS data. Adapted and expanded from Simon and Roychowdhury (2013).40
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Summary
In theory, the ultra-systematic and comprehensive variant
identification of WGS eliminates much of the time and money cost
of running sequential single-gene tests. It is ideal for detecting the
maximum amount of genetic variants upon which to base
treatment consideration,32 and has the advantage of rarely needing
PCR or other techniques for amplification before sequencing –
making it intrinsically more accurate than WES or targeted
sequencing, which use enrichment techniques that could
potentially introduce amplification-related sequence errors.41
However, at present WGS is used (nearly) solely in research
settings. Too much data, with too little known about non-exomic
variants, is generated for clinical use. Outside of clinical trials,
WES or other targeted sequencing strategies are used in order to
generate data relevant to clinical interpretation and use.42
Realistically, targeted gene sequencing and/or WES will be
implemented before WGS in clinical contexts, as most anti-cancer
drugs (and drugs in general) target proteins altered by
aberrations in the exome.43 Costs and time involved in WGS will
continue to decrease as demand for the technology grows,
although the initial investment in equipment and staff training is
substantial. Individual institutions will only bear the costs to start
the programme once evidence-based reviews, public pressure,
and large-scale initiatives – like the 100,000 Genomes Project –
provide a great enough stimulus.24
In the short term, WGS will be almost exclusively used in clinical
trials and research, but the knowledge it produces will filter down
to inform and help interpret WES and other targeted clinical
genetic tests. WGS identification of pathogenic variants will also
continue to inform pharmaceutical development.21 Despite its
currently limited utility in the clinic, WGS is already informing
research and will firmly establish a supportive role in medicine in
the near future, with real potential to become the gold standard
in personalised and genetic medicine in the long term.
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Continuous glucose
monitoring: a sweet deal for
paediatric type 1 diabetics
Abstract
Children diagnosed with type 1 diabetes mellitus (T1DM) are at particular risk for long-term
complications, including diabetic retinopathy, neuropathy, and nephropathy. Over the last few
decades, clinical advancements in glucose monitoring and methods of insulin delivery have
improved quality of life in T1DM, making strict glycaemic control, which can reduce
long-term complication risk, more achievable. The continuous glucose monitor (CGM) is a
minimally invasive subcutaneous device, which assesses subcutaneous interstitial glucose levels
at five-minute intervals. Used in conjunction with multiple daily insulin injections, or
continuous subcutaneous insulin infusion via insulin pump, the CGM has been proven to
enhance metabolic control, reducing HbA1c levels as well as time spent in hypoglycaemia.
Furthermore, CGM allows for retrospective analysis of blood glucose trends by clinicians,
leading to individualised and precise management strategies. However, limitations to its use
include cost efficacy, sensor accuracy, and insertion site irritation. This review will discuss the
potential benefits and limitations of CGM use in a paediatric population, and the
recommendation that CGM be made available to any paediatric diabetic who requests its use.
Royal College of Surgeons in Ireland Student Medical Journal. 2016;1:57-61.
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Introduction
Type one diabetes mellitus (T1DM) is a chronic autoimmune
condition characterised by a total lack of insulin production by
pancreatic beta cells.1 In genetically susceptible individuals, an
interplay between genetic and environmental factors leads to the
early development of islet cell autoantibodies, which target
insulin-producing cells, thereby rendering individuals severely
glucose intolerant.2
Prior to the discovery of insulin, doctors could do little for children
diagnosed with T1DM. Changes in diet, including carbohydrate
restriction, had little impact on disease progression, and death
shortly followed diagnosis. When insulin was first derived from the
pancreases of cattle and pigs in 1921, the prognosis of T1DM
improved drastically. In 1978, biosynthetic human insulin was first
developed, with the advent of various slow- versus fast-acting insulin
types shortly thereafter.3
Nowadays, children diagnosed with T1DM are immediately
commenced on lifelong insulin therapy to prevent severe long-term
complications, such as neuropathies, retinopathies, nephropathies,
early cardiovascular disease, and death.3,4 Strict glycaemic control –
defined as glycosylated haemoglobin (HbA1c) levels <7%5 – has been
shown to significantly reduce the risk of these sequelae for the
estimated 500,000 children worldwide who currently live with T1DM.6
Over the last few decades, clinical advancements in glucose
monitoring and methods of insulin delivery have improved the
quality of life of people with type one diabetes, making strict
glycaemic control more achievable. This article reviews the literature
available on one relatively new advancement, the continuous glucose
monitor (CGM), which, when combined with insulin therapy, has the
potential to aid the paediatric population with T1DM to achieve
target management goals.
Management of paediatric diabetes mellitus
Management of T1DM can be broken down into two main
components: insulin analogue therapy; and, self-monitoring of blood
glucose (SMBG) levels.
Insulin analogue therapy consists of a basal dose of insulin to control
glycaemic levels throughout the day (‘background’ insulin), as well
as bolus doses of insulin taken for meals. Insulin is usually delivered
via one of two methods: multiple daily injections (MDI); or,
continuous subcutaneous insulin infusion (CSII) via an insulin pump.
While both methods have proven effective, multiple studies have
shown CSII to be superior to MDI in the paediatric population7,8 –
perhaps because it involves one needlestick every three days rather
than the four to eight daily injections required for MDI therapy.
SMBG uses finger-prick testing with a glucometer to analyse capillary
blood glucose levels. This has long been the gold standard for
diabetic self-testing because of its high accuracy rate. However,
glucometers only allow patients to assess glycaemic levels
periodically; therefore, their overall efficacy in contributing to
enhanced glycaemic control is highly user dependent.9 A more
recent technological advancement, the CGM, mitigates the
glucometer’s limitation of intermittent testing. This minimally
invasive device sits just beneath the skin and assesses subcutaneous
interstitial glucose levels at five-minute intervals, providing a
systematic flow of data, which can be used for both real-time and
retrospective analyses.
The majority of people with T1DM are diagnosed in childhood and
early adolescence,5 when strict glycaemic control is more difficult to
attain than in the adult population.10 Children and adolescents may
not understand the implications of the disease, and variations in
exercise and diet can make management difficult. In adolescents, this
is at least partly attributable to physiological changes and hormonal
fluctuations associated with puberty, which can affect insulin
absorption; additionally, psychological issues such as denial of the
illness in an attempt to fit in with peers can lead to poor adherence
to insulin therapy.11
While maintenance of normal blood glucose levels is crucial in
diabetes management, intensive insulin therapy increases the risk of
hypoglycaemia.12 Hyperglycaemia (capillary glucose levels >8mmol/l)
may lead to the abovementioned complications, but hypoglycaemia
(<4.0mmol/l) also poses a real threat, especially to the paediatric
population. Many of these episodes of hypoglycaemia occur at night,
during sleep.9 Although it is possible that a hypoglycaemic event will
awaken the patient, severe hypoglycaemia can rapidly lead to
convulsions, coma, and even death, if not treated promptly.13
Multiple episodes of hypoglycaemia may eventually result in a state
of ‘hypo-unawareness’, in which a diabetic patient does not realise
that their glucose levels are dangerously low. This is especially
common in the very young subset of patients, who may be unable
to adequately express their symptoms, even if aware of them.13 In
fact, the fear of hypoglycaemia has been shown to be a major
contributing deterrent to adequate control for people with type one
diabetes.12,14 The overall goal of intensive diabetes management is
therefore to reduce HbA1c levels without increasing the number of
hypoglycaemic events.
The advantages of continuous glucose monitoring
One undisputed advantage of CGM is improved metabolic control
and thus decreased risk of long-term complications. A meta-analysis
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of randomised controlled trials comparing CGM to SMBG in
paediatric T1DM patients indicates the potential of CGM use, with
either MDI or CSII, to effectively reduce HbA1c levels when
compared to SMBG;15 other independent studies show consistent
results.6,16,17 Studies also indicate significant decreases in
post-prandial and nocturnal glycaemic deviations when using the
CGM in combination with an insulin pump (known as a
sensor-augmented pump or SAP).18 When compared to MDI, SAP
use has also been shown to decrease HbA1c levels, with more
paediatric participants achieving their age-specific HbA1c targets.19
This can be explained in part by the use of alarms triggered by
hyperglycaemic excursions, which allow for improved daytime
dosing of insulin in response to hyperglycaemia.
In addition to this reduction in HbA1c levels, multiple studies have
shown that CGM use leads to a decreased number of hypoglycaemic
episodes and overall total amount of time spent in hypoglycaemia,
both daily and nocturnally.20,21 The use of alarms indicating
hypoglycaemic episodes may be partially responsible, although one
study found that over 50% of nighttime alarms fail to awaken
patients.22 Retrospective data analysis by clinicians leading to
adjustments in insulin dosages likely has a more profound effect on
these findings.14
Another important advantage of CGM use is enhancing the
understanding of T1DM and disease management by both real-time
and retrospective data analysis. Clinicians can make precise
adjustments to patient management after analysing trends in
glycaemic levels in response to exercise, food intake and even
examination stress (in adolescents).23 Seeing the effects that these
activities have on their glycaemic levels may inspire confidence and
independence in managing the illness for patients, who are at
increased risk of anxiety and depression,24 as well as for parents, who
bear the brunt of the work of diabetes management and are also at
increased risk.25,26 Psychological relief may also be conferred by
improved metabolic control, decreases in hypoglycaemia, and
real-time and retrospective data analysis allowing for better
management of the disease.27 All of these factors may contribute to
future maintenance of glycaemic control and quality of life.
Potential limitations to continuous glucose monitoring
Cost efficacy
The benefits of CGM are largely undisputed. Meta-analysis of studies
conducted in the United States has shown that CGM use is likely to
be the most cost-effective in a subset of patients with high baseline
HbA1c levels (indicating poor control) and in patients who are able
to use the CGM frequently (at least six days per week),28 although no
data is available on the paediatric subpopulation in particular.23
Due to variations in the literature, as well as the relatively recent
evidence indicating its effectiveness, health insurance reimbursement
and government funding of the devices have been restricted to a
large extent, although this is slowly beginning to change in much of
Europe.28 Unpublished analyses of cost-effectiveness in both Sweden
and the Netherlands found the cost-effectiveness to be
€36,000-52,000/QALY and €21,000/QALY, respectively, and the
CGM system is now reimbursed by these governments for patients
meeting certain criteria.23 The HSE long-term illness scheme currently
covers the cost of CGM sensors in the Republic of Ireland, and
reimbursement protocols vary throughout other European countries.29
If not reimbursed, maintenance of CGM is costly and may be a
deterrent to regular use, which as previously mentioned is vital to its
efficacy. Furthermore, for a few months after transition to CGM,
multiple appointments with a multidisciplinary diabetes team and
experts in CGM use are necessary. Although proven to be highly
beneficial, these appointments may also contribute to up-front (and
overall) costs.23
Sensor accuracy
The first CGM system – Medtronic’s Minimed system – was approved
in 1999.30 Initially used only for retrospective analysis, subsequent
generations of CGM devices have improved in accuracy, as well as
percent functioning, as measured by mean difference between
glycaemic sensor and reference levels. While sensors are 80-91%
accurate for levels in the hyperglycaemic range, and 73-76% for
those in the target range, the sensors are only 57-66% accurate at
indicating hypoglycaemia and potentially overestimate the frequency
of nocturnal hypoglycaemia.23 SMBG using glucometers has been
shown to have at least 97% accuracy for all three glycaemic states.23
For this reason, there is an ongoing need to calibrate the sensors
using glucometer testing at least every 12 hours.23 Due to the
potential for inaccurate readings, patients and guardians are
routinely instructed on the importance of confirming
hypo/hyperglycaemic episodes with finger stick testing before
treating either, to avoid unnecessary risk.23,31
General irritation by sensor site and ‘alarm fatigue’
Despite low rates of sensor site infection and cellulitis,14 skin irritation
from sensor adhesives, pain at insertion, retained subcutaneous
sensor tips, and annoyance at alarms have caused some concern
among patients and their parents/guardians.32 However, despite
these issues, overall satisfaction with CGM use is high among
patients and guardians.33
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Latest advancements, ongoing clinical trials and the
future of CGM
The journey to a closed loop system or ‘artificial pancreas’
The closed loop system or ‘artificial pancreas’, as regarded by some,
has been undergoing clinical trials for multiple years. Essentially, the
system is composed of CGM coupled with CSII via an insulin pump. 
The modified insulin pump uses specific algorithms to secrete
appropriate amounts of insulin in response to glucose level signals
from the CGM.34 In theory, this should obliterate the need for
manual boluses at meal times; however, available literature indicates
multiple limitations, the most prominent being lag time between
sensor signalling reaching the pump and actual changes in
glycaemic levels.34 Due to these limitations, the system is not
currently utilised clinically, and is unlikely to be for a number of
years.
MINIMED 640G by Medtronic
In 2014, Medtronic launched its Minimed 640G system, a
semi-closed loop system composed of an integrated insulin pump
and CGM sensor, modified to especially target nocturnal
hypoglycaemia. The CGM sensors detect when glucose levels are
falling below the normal range and send wireless signals to the
insulin pump to suspend the release of the maintenance dose of
insulin until glucose levels rise out of the danger zone, at which
point delivery is resumed.35
One significant benefit of this device is effectively reducing
nocturnal hypoglycaemic events35 (and the fear of them) without
the need of alarms to disturb the patient’s sleep. This encourages
intensive management of T1DM in the paediatric population,12 in
which hypo-unawareness is especially common.13 While no data is
yet available on the long-term benefits or risks of this particular
system, this is likely the most beneficial advancement to date in the
management of paediatric T1DM, and towards the development of
a fully automated, closed-loop system.
Conclusions
Paediatric patients with T1DM face the challenge of maintaining
glycaemic levels within target range throughout the day and night.
Findings that the paediatric population has overall higher HbA1c
levels and decreased control when compared to the adult
population10 make it vital to identify methods of increasing control
and reducing risk of long-term complications. CGM is effective in
reducing paediatric HbA1c levels, number of hypoglycaemic events,
and overall time spent in hypoglycaemia. Furthermore, CGM allows
for analysis of trends, which can be used by clinicians to alter patient
management for long-term benefit.14,21 Despite some limitations to its
use, it has been recommended that CGM be supplied to any
paediatric patient who desires it, and it is especially useful in those
with high baseline HbA1c levels, nocturnal hypoglycaemia, and those
capable of maintaining regular CGM use.23
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I eat, therefore I am: 
the gut–brain axis and
appetite control
Abstract
Traditionally, obesity has been viewed as a simple disease of excess calorific intake in the
context of a sedentary lifestyle. However, while an increase in energy consumption without
corresponding expenditure is a key force in the initial development of obesity, a number of
homeostatic mechanisms conspire to maintain high adiposity in individuals who are already
overweight. Both central neuronal mechanisms and peripheral endocrine signals drive
increased appetite and reduced metabolic rate in the obese. This prevents weight loss from
occurring as quickly as one would expect, and makes sustained weight loss of more than
15% almost impossible. Currently, the most effective therapy for obesity is bariatric surgery.
While previously believed to effect weight loss through malabsorption, restriction of
stomach capacity or both, it is now shown that these operations fundamentally change the
internal milieu of obese individuals, favouring weight loss and a reduction in appetite via
cumulative changes in neuroendocrine signalling. This has led to some exploration of
methods to directly affect the final common pathways in the brain and more efficiently
produce weight loss.
Royal College of Surgeons in Ireland Student Medical Journal. 2016;1:62-6.
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Introduction
Obesity is fast becoming a global epidemic. For the first time in
human history, more people are dying as a result of relative
calorie excess than of calorie deficit.1 In developing nations,
obesity and malnutrition coexist to create a ‘double burden’ of
disease on already stretched health systems.2 The traditional
medical approach of prescribing increased exercise and reduced
calorie intake, although shown to produce modest, clinically
significant weight loss (usually around 5-10%), is often difficult
for patients to adhere to in the first instance3 and is prone to
recidivism. The interest this creates in pharmacological and
surgical means of treating obesity has resulted in greater
understanding of how our appetite is regulated.
Acquisition of calories and nutrients necessary for survival creates
a powerful selection pressure on an organism. Evolution has
thereby resulted in a complex homeostatic network in individual
organisms to regulate appetite and prevent acute changes in
adiposity.4 In humans, powerful neuroendocrine interplay exists
between the digestive system, which initially receives and absorbs
nutrients ingested by the organism, the adipose organ, a large
endocrine organ involved in both energy storage and
anorexigenic signalling, and the brain, the centre of behaviour.5
Greater understanding of the crosstalk between these three
systems is required in order to facilitate the treatment of the
obese patient, and ultimately to reduce the level of obesity and
its concomitant complications in the future.
The lipostat hypothesis
Despite our general tendency to get bigger when calories are no
object, individually mammals tend to ‘guard’ their weight. A
number of experiments illustrate this: animals were either overfed
or underfed for a relatively short time frame, then allowed an ad
libitum diet. The animals exhibited compensatory behavioural and
metabolic changes to restore their original weight, suggesting
that there is a sliding set point, which internally monitors weight
gain and loss and prevents drastic changes. This ‘lipostat’ is
situated – like many homeostatic regulatory centres – in the
hypothalamus.6
The lipostat purposefully integrates the peripheral signals of
dietary intake and the central signals of satiety, and translates
them into appropriate behavioural, metabolic and appetite
changes, which maintain weight at its typical level. This is
important from a homeostatic perspective: a 1% miscalculation
of calorific intake or expenditure (around 20kcal a day, equivalent
to a single serving of cabbage) would result in the accumulation
of an extra 1kg a year or >50kg over the average adult lifespan.4
It also means that once the set point has been driven upwards (as
in obesity), the lipostat modifies energy expenditure and calorie
intake to maintain our internally determined weight. Therefore,
the traditional medical mantra of ‘eat less, move more’ may not
be sufficient for long-term, meaningful weight loss in those who
are clinically overweight/obese.
Peripheral signals: signs of dietary intake
Three separate organs act as peripheral nutrient sensors to the
hypothalamic centres involved in appetite: the stomach/small
intestine, the pancreas and the adipose organ. Each contributes
either to acute appetite regulation (satiety following a meal) or
the long-term control of eating. Signals may be endocrine, neural
or neuroendocrine in nature, and can be produced by direct
sensing of the relevant constituents of food (e.g., fatty acids) or
by mechanotransduction (stretch of the viscera leading to
relevant hormone release or neural afferent firing).7 This gives the
central integrating regions of the brain a sense of the volume and
type of meal that has been ingested.
Signals from the periphery are almost all stimulated by dietary
intake. A variety of mechanisms highlight the complexity of
appetite regulation; the major determinants of satiety from the
periphery, however, are anorexigenic (stimulate feelings of
fullness).8
Anorexigenic (appetite-suppressing) signals
Simple neuronal mechanisms act via the vagus nerve. Stretch of
the stomach increases the rate of vagal afferent firing, which is
processed initially in the nucleus tractus solitarius before
projecting to the hypothalamus. As the stomach stretches and
mechanotransduction increases, the feeling of fullness increases
proportionally.8
Neuroendocrine mechanisms also increase the activity of the
vagus nerve, either via receptors (e.g., CCK1 receptors
responding to cholecystokinin and leading to increased vagal
afferent firing) or by increasing gastric stretch, such as the
reduction of intestinal motility by peptide tyrosine tyrosine (PYY).
The central role of the vagus nerve in communicating satiety
signals from the gut is underlined by evidence that vagotomies in
animal models often result in a loss of anorexigenic hormone
signalling, resulting in overfeeding and weight gain.9
Hormones also act centrally to produce feelings of satiety.
Glucagon-like peptide 1 (GLP-1), perhaps better known as an
incretin since the addition of exenatide to the pharmacopoeia for
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diabetes, has an important role in generating central satiety.
Delivery of GLP-1 antagonists centrally promoted overeating in
experimental rodent models;10 additionally, the SCALE study
recently illustrated that the GLP-1 analogue ‘liraglutide’ produced
meaningful weight loss as an adjunct to diet and exercise.11
Pancreatic peptide (PP) also acts centrally via Y4 receptors and
increases proportionally with the calorie content of ingested food
boluses.7
Two hormones increase proportionally with fat mass: insulin, a
pancreatic hormone secreted in response to food ingestion, and
leptin, an adipokine directly secreted from adipose tissue. These
hormones act as acute and chronic negative feedback loops.7
Mice lacking leptin (ob/ob) are indistinguishable from their
heterozygote littermates at birth, but quickly gain weight
through massive overeating. Rarely, human obesity has been
shown to be associated with a loss of leptin function; however, in
the vast majority of patients leptin is massively oversecreted.12
This has important implications for how the hormone is sensed
centrally and reduces the lipostat’s ability to appreciate total fat
mass.
Orexigenic signals
There is a single orexigenic signal secreted in the periphery:
ghrelin, a peptide secreted from the stomach, acts on its receptor
(GHS-R) to stimulate appetite. Ghrelin levels are highest while
fasting and are higher in individuals who are chronically fasted
(such as those with anorexia nervosa and people on weight loss
diets). Ghrelin acts throughout the gut–brain axis to increase
gastric motility, gastric acid secretion and calorific intake.7
Central signals: our hedonistic brain
The brain is the integrative centre of the whole organism, allowing
appropriate responses to both external and internal stimuli. Two
important groups of neurons have been identified: an orexigenic
group, Agouti-related peptide/neuropeptide Y neurons
(AgRP/NPY); and, an anorexigenic group, pro-opiomelanocortin
neurons (POMC). AgRP neurons are stimulated by ghrelin and
inhibited by PYY, leptin and insulin. In POMC neurons the inverse
is true.13 This bimodal system of antagonistic neurons integrates
peripheral signals, producing an appropriate feeling of hunger or
fullness. The result is a sensitive homeostatic sensor, which
monitors input and modulates output by multiple efferent
pathways, such as the paraventricular hypothalamus, dorsomedial
hypothalamic nucleus and the limbic system.14
This acts via a second order set of neurons to alter metabolism by
regulating thyroid hormone signalling, and behaviour via
efferents to higher cortical centres.15,16 The cortex also plays a
role, with modifications in taste, smell and memory, all driven by
activity in the arcuate nucleus and circulating appetite-regulating
hormones.17
Alterations in signalling in the obese patient
So why, in spite of such overwhelmingly complex homeostatic
machinery, do people become obese? As individuals gain fat
mass, levels of insulin and leptin secretion increase. As is seen in
type II diabetes mellitus (T2DM), high circulating levels of insulin
result in tissue becoming resistant to its effects, and failure of
peripheral tissues to uptake glucose.18 A similar process occurs in
the central nervous system in regards to leptin: as higher levels
accumulate in the blood, the brain ceases to respond
appropriately, negating leptin’s influence as a satiety signal.12
Subsequently, as patients increase their energy expenditure
(exercise) or reduce calorie intake (diet) in order to lose weight,
GLP-1, PYY and other anorexigenic hormones are suppressed in
favour of ghrelin secretion.3 This acts via central mechanisms,
resulting in changes in behaviour and metabolism that prevent
effective weight loss, making it difficult for patients to attain
sustained and clinically meaningful changes in fat mass.
Bariatric surgery: anatomical or biochemical
intervention?
An emerging therapy for obesity is bariatric surgery, particularly
the Roux-en-Y gastric bypass. This procedure was developed to
produce weight loss through restriction of total stomach volume
(producing earlier vagal stimulation by stretch) and
malabsorption.3 However, it has since come to light that this
mechanism alone is unlikely to result in the sustained weight loss
seen in patients postoperatively. Some 85% of patients with
T2DM became normoglycaemic following the procedure,
independent of weight loss. This suggests that some change is
elicited in hormonal signalling and, ultimately, the gut–brain
axis.19
Weight loss following a Roux-en-Y gastric bypass is dissimilar
physiologically from weight loss due to starvation, exercise or
dieting. With the traditional ‘eat less, move more’ paradigm,
ghrelin increases and GLP-1 and PYY decrease to create an
appetite-stimulating hormonal milieu. Following Roux-en-Y the
inverse is true.20 The chance of a person having a significant
response to Roux-en-Y bypass, or losing a clinically significant
amount of weight following surgery, can be predicted with some
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accuracy by measuring these hormones. Leptin is reduced to
levels comparable to lean subjects, indicating a return to a
non-obese hormone profile.17 Finally, non-specific inhibition of
hormone signalling with somatostatin allows for an increase in
appetite as tested by an ad libitum meal.21
Unfortunately, this surgery also carries the risk of developing
malabsorption and dumping syndromes; thus, it is only reserved
for individuals with very high BMIs (40kg/m2 without
comorbidities or 35kg/m2 with comorbidities).22,23 Evidence is
beginning to accumulate for a less drastic operation, the sleeve
gastrectomy, which carries a lower risk of mortality and morbidity
but also has a reduced chance of producing sustained weight loss
and a change in obesity-related disease.24
Deep brain stimulation: neuromodulation of a final
common pathway
While the hormonal control elicited by gastric bypass is
impressive, researchers are now considering how best to
manipulate the final common pathway of satiety. Deep brain
stimulation (DBS) is currently indicated for a number of diseases
(notably Parkinson’s disease) with impressive reductions in
symptoms.25 This intervention requires stereotactic placement of
electrodes in the brain (around the lateral hypothalamus), but
eliminates the risk of malabsorption.26 It is arguably more precise
than the Roux-en-Y by consistently affecting the final common
pathway.
Although research is only beginning in this intriguing approach
to a common illness, results are reasonably promising. A 2013
pilot study of bilateral implantation of DBS electrodes (developed
for Parkinson’s disease) into the lateral hypothalamic nuclei of
three patients with intractable obesity was performed safely and
had some evidence of efficacy. A major limiting factor of this
study was that the electrodes that are produced for Parkinson’s
neuromodulation are too large to target the specific areas of the
lateral hypothalamus associated with appetite;27 however, as the
technology develops, more success may emerge from this
approach to the treatment of obesity. Additionally, a wide range
of alternative targets is being explored – such as elements of the
brain’s reward circuitry (nucleus accumbens) – suggesting new
directions for the future of bariatric surgery.28
Conclusions
Obesity has historically been associated with poor health.
Hippocrates reportedly stated: “Corpulence is not only a disease
itself, but the harbinger of others”. In the modern era of energy-
(and calorie-) sparing devices for work and easy availability of
calorie-dense foods, a veritable epidemic of ‘corpulence’ has
emerged.29,30 While the best solution to this problem is
prevention, there will inevitably be individuals who gain enough
weight to endanger their health.
Medical treatment of obesity has historically been simplistic and
has neglected the complexity of human biology and the powerful
homeostatic mechanisms to prevent sudden changes in
physiology. Prescription of diet and exercise will continue to be
the mainstay of treatment in the overweight, but an awareness of
the limitations of this strategy is an important consideration for
clinicians.
Understanding the gut–brain axis also allows for tailoring
treatment of the obese patient in novel ways, by using GLP-1
agonists as an adjunct for weight loss or utilising surgery
(bariatric or neurological) to fundamentally alter the
communication pathways between these organs, as discussed
above. Ultimately, this will produce a range of therapies that are:
a) effective; and, b) enduring in the fight against obesity,
reducing patient morbidity and mortality, and allowing
individuals to lead healthier, happier and longer lives.
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The artificial womb: 
bridging the gap between
embryo culture and 
the incubator
Abstract
Advances in life support devices and ex vivo embryo culture in artificial endometria present a
framework for the development of the artificial womb, a device capable of supporting
long-term extrauterine gestation. We review the potential medical impact of such
technology, proof-of-concept animal studies, related research, and emerging epigenetic,
neurologic and heritability challenges in supporting extrauterine culture and gestation.
Additional research is needed in a number of areas, particularly regarding poor outcomes in
embryo culture. In addition, we examine ethico-legal, social and fiscal considerations, with a
view towards preparing regulatory ethico-legal policies in anticipation of such technology.
Finally, stakeholder engagement is called for to see the integration and implementation of
existing technologies, and the development of the artificial womb as a clinical device of
promising utility.
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Opening
“[W]arm on their cushion of peritoneum and gorged
with blood-surrogate and hormones, the fetuses grew
and grew … ”
Brave New World, Aldous Huxley, 1931
Advances in in vitro fertilisation (IVF), foetal
incubation and neonatology continue to reduce
the essential time foetal gestation is required to
spend in utero. The prospective endpoint is
‘ectogenesis’, using an artificial womb as an
achievable life support device capable of
supporting in vitro gestation until viability, thus
bridging the gap between IVF and conventional
incubation in prematurity.1-11 In this article, we
examine the conceivable impacts, latest research,
and challenges of ectogenesis, and explore relevant
fiscal and ethico-legal considerations.
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Relevance and potential benefits
Due to the limitations of neonatal medicine and technology, at
present life is not viable outside the womb prior to approximately
23-24 weeks’ gestation.12 Thus, neonatology reviews are increasingly
calling for the development of an ‘artificial womb’ – a device capable
of supporting long-term extra-uterine gestation – to minimise the
morbidity and mortality of prematurity.1,3-6 Expert opinion holds that
such a device is feasible to support gestation from as early as 14 weeks
with modern knowledge and technology.1
Current challenges to foetal diagnostics and therapy in the uterine
environment include accessibility, therapeutic failure and
procedure-associated adverse events, such as miscarriage, at rates of
0.81% in amniocentesis13 or 1.6% in foetal transfusion,14 in the
developed world. In addition, owing to therapeutic limitations,
multi-foetal pregnancies and maternal-foetal disease may currently be
indications for termination.15 The total accessibility of the foetal
environment offered by ectogenesis creates significant potential for
novel solutions in minimally invasive foetal monitoring, surgical access
and delivery of therapeutics, all of which (potentially) function to
alleviate the morbidity and mortality associated with extreme
prematurity, structural anomalies and multi-foetal pregnancy. In
addition, strategic transfer to, or conception in, the artificial womb
could also significantly reduce the morbidity and mortality of
pregnancy; roughly 15% of all pregnancies involve potentially
life-threatening complications, resulting in 10 and 28 maternal deaths
annually per 100,000 pregnancies in the UK/Ireland and the US,
respectively.16,17
The artificial womb would obviate harmful environmental exposures,
including in utero infection and teratogens (e.g., foetal alcohol
syndrome). Eliminating just one common virus, cytomegalovirus,
could lead to substantial reductions in mortality, morbidity and
associated costs; 40,000 congenital cytomegalovirus infections in the
US are responsible for approximately 400 deaths and 8,000 serious
permanent neurodevelopmental and sensory disabilities annually.18
Total ectogenesis – denoting conception to delivery in the artificial
womb – could circumvent infertility, particularly due to uterine
absence or disease. Additionally, it could reduce international
surrogacy arrangements, which disproportionately rely on
socioeconomically vulnerable women.19 Readily available ectogenesis
could mitigate the considerable post-pregnancy morbidity for women,
including backache (45%), sexual dysfunction (20%), bowel problems
(17%) and urinary incontinence (11%) six months after delivery.20
Research and challenges in ectogenesis technologies
Proof-of-concept research
First attempted in 2003, total ectogenesis involves support from
embryo culture to full term. Liu et al. reported growing a mouse
embryo to term in a bioengineered uterus (albeit with deformities).
However, in a follow-up experiment, the group transferred murine
embryos grown on engineered uterine tissues (EUIs) to the abdominal
cavity – not the uterus – of adult mice at seven days, and left controls
in vitro. Four days short of term, researchers removed all embryos for
comparison; those in vitro had developed hearts, but died. However,
the embryos transferred were anatomically normal and apparently
healthy. In spite of such findings, Liu halted her experiments in
response to pressure from interest groups and ethical concerns.23-25
Such proof-of-concept research highlights challenges to the successful
application of ectogenesis in bridging the gap between embryo
culture and the incubation of mature foetuses. At present, devices
performing all the necessary functions of life support at later
gestations – incubation, gas exchange, waste removal and nutrition –
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Table 1: Timeline of assisted reproductive technologies.21,22
Research into extended foetal extrauterine life support in the 1990s successfully
incubated goat foetuses in artificial amniotic fluid.
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exist. Cardiorespiratory, gut, and kidney replicators are present in the
form of extracorporeal membranous oxygenation (ECMO), total
parenteral nutrition, and dialysis, respectively, and can be used in
conjunction with the previously listed life support mechanisms. These
devices have proven to be of immense clinical value; however,
research to implement their long-term integrated use in earlier
gestations has yet to progress beyond animal studies.7,25-27
Proof-of-concept research for extended foetal extrauterine life support
in the 1990s successfully incubated goat foetuses in artificial amniotic
fluid, providing gas exchange using extracorporeal supplies of blood
via umbilical access. Physiologic stability was maintained in foetuses of
120-128 days (of total gestation – approximately 150 days) for periods
in excess of 500 hours, with subsequently stable blood gas exchange
and survival upon removal. Results in similar animal studies clearly
indicate the viability of such devices in the extended extrauterine
incubation of a premature foetus utilising umbilical arteriovenous
ECMO.25-28
Device challenges and neuroplasticity
Assist devices currently undergoing development include the
ECMO-type neonatal oxygenator NeonatOx, which has been
successfully implemented with preterm lamb models. Its continued
refinement includes miniaturisation to rectify inappropriate shunt
fractions associated with congestive heart failure.3 Additional
challenges to clinical application of such a device include the potential
inflammatory and infectious sequelae of blood-priming to initiate the
circuit with non-foetal blood.3 Applicability to earlier generations or
total extrauterine gestation demands further research into the
integration of other life support functions, in order to more fully
recapitulate placental function of the maternal uterus.11
As incubator and life support technologies have progressed, key
challenges in replicating the requisite stimuli for development have
arisen. Mimicking the “tactile, kinaesthetic and vestibular
concomitants of maternal speech, movement and physiology”29 is
critical to support neuroplasticity and prenatal sensory
competence.29,30 This is fundamental, as prenatal plastic changes and
fine-tuning in neural assemblies that are required for speech
perception and understanding, among other functions, are stimulus or
learning induced.29-31 Conversely, the harms of inappropriate or absent
stimuli are highlighted by a 2014 review finding that noisy,
high-frequency environments disrupt functional organisation of
auditory cortical circuits, possibly increasing the risk for disorders of
hearing, language and attention.32
Embryo quality and epigenetics
In terms of maximising embryo quality, the immediate
post-fertilisation culture environment is the most important
determinant.33 However, existing gamete collection and embryo
culture methods involve hormonal, physical, thermal and other
stresses, which alter epigenetic profiles, DNA methylation patterns,
and gene expression.34-35 This is reported to exceed the adaptive
capacity of embryos, lowering developmental capacity in animal
models36 and resulting in significantly increased anatomical birth
defects in children conceived by IVF and/or intracytoplasmic sperm
injection (ICSI) – with a meta-analysis pooled risk estimation of
1.37.37,38 One logical concern is epigenetic heritability of poor
outcomes. Murine models have demonstrated transgenerational
inheritance of altered epigenetic reprogramming, resulting in
adulthood obesity, anxiety disorders and memory impairment.39 The
potential risks of unfavourable transgenerational inheritance in human
populations present potentially significant challenges to the continued
culture of embryos. Ultimately, embryo culture methods are
suboptimal, and additional studies of altered gene expression are
necessary to further interrogate aberrant imprinting, and to elucidate
how previously identified candidate genes and pathways are
disrupted.33,36
Currently, research involving engineered EUTs aims to recapitulate the
microenvironment of the maternal uterus with enhanced fidelity. EUTs
already offer the ability not only to support murine embryo growth,
but to also markedly improve development rate and quality compared
to standard IVF control culture media.40 These more closely simulate
utero-embryonic metabolic interactions, and provide the complex
mélange of chemosensory, nutritional and immunologic signalling
factors for optimum early gestation. In addition, they provide a
high-fidelity model for study of maternal-embryonic interactions
towards maximising outcomes in ectogenesis.2,9,25
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Ethics and attitudes
Motherhood
A wealth of literature demonstrates complex debate on whether
mother-child relationships and female identity will be damaged by
ectogenesis, or whether it will liberate women to escape gender
constraints and procreate, similarly to men, without compromising
health or socio-economic position. Significant division of opinion
surrounds ectogenesis and termination. Ultimately, all embryos are
potential candidates for extra-uterine viability. This reframes the
medicolegal understanding of abortion, dissociating termination of
pregnancy from termination of offspring/motherhood, with opinion
divided on how this might empower or disempower the parties
involved.11
Genetic studies show that miscarriage often functions as a natural
screening mechanism, involving termination of compromised or
non-viable pregnancies, e.g., in aneuploidy.41 The ethico-legal
considerations of replicating natural mechanisms in recognising and
terminating severely compromised offspring would fall under abortion
laws in many jurisdictions and may be complex in practice.
How might this affect the legality of, or requirements for, termination?
Should the decision-making capacity regarding bringing a conception
to term be shared by both parents, having both contributed gametes
equally, or revert to the state in certain jurisdictions? Might inalienable
legal rights be afforded from conception, and a legal responsibility on
parent or state be proposed to bring all conceptions to term? How
might viability, disease burden, quality of life, cost or legal capacity
issues be assessed? In quality of life cases, how might medical, parental
or legal opinion be interpreted?
Societal demand
In addition, it may be argued that there is an ethical imperative for
state-funded pursuit of ectogenesis. Regarding healthcare in terms of
distributive justice, it is argued that natural inequalities may generate a
prima facie right to restitution (e.g., state-funded infertility treatment). In
the Cambridge Quarterly of Healthcare Ethics, Smador argues that
reproduction is a societal demand, which unequally imposes risk on
women. 
The health-related risks and social detriment of pregnancy may
constitute a recognisable health-oriented need and natural injustice. 
Smador thus contends an imperative on the state to redress this prima
facie right to restitutive justice by pursuing ectogenesis research and
availability.42
A pilot study in Israel, of mostly Jewish women, revealed majority
support for: ectogenesis for wombless women (74.5%), foetus-saving
ectogenesis (65%) and women’s right to freely choose ectogenesis to
avoid the risks and burdens of pregnancy (59%). Men, single people,
secularists, and academic degree holders were found to have a more
positive attitude towards ectogenensis.43
Fiscal considerations
Private investment and commercial markets
Considerable return on developmental costs is conceivable in
commercial reproductive and infertility markets. Conventional IVF is
high cost, with suboptimal pregnancy rates per embryo transfer, while
surrogacy carries ethico-legal concerns. The perfected artificial womb
could provide better health outcomes, at higher success rates, while
avoiding time lost through failed embryo transfers.44 The potential
market for ectogenesis is estimable from the high-growth sectors of
surrogacy – over $2 billion USD in India alone19 – or the international
IVF market, valued at $9.3 billion in 2012, and an anticipated $21.6
billion by 2020.45 In addition, commercially available ectogenesis could
be marketable as avoiding the morbidity, potential mortality,
socioeconomic losses, career discrimination46,47 and direct medical costs
associated with vaginal and caesarean birth in the US – $32,093 and
$51,125, respectively.48
State interest – prematurity and environmental factor morbidity
The human and state-borne financial costs of prematurity and morbidity
due to environmental exposures are conceivably significant enough to
support state-level interest in an alternative that is either financially
competitive, or carries such medical advantage as to compensate
cost–benefit ratios. On a ‘per child’ basis, there is wide scope for
strategic early transfer to the artificial womb to undercut the relative
opportunity cost of US care at superior medical outcomes, with a 2013
review finding mean preterm-associated costs as high as $326,953.49
The annual societal economic burden of prematurity in the US alone
was $26.2 billion in 2005, including direct medical costs of between
$4.62 and $13.38 billion and special education costs of approximately
$370 million.50
Conclusion
We have examined the impacts of, latest research in, and challenges to
partial and total ectogenesis, in addition to fiscal and ethico-legal
considerations. As discussed, additional research is needed in a number
of areas, particularly regarding poor outcomes in embryo culture. There
is time in anticipation of such technologies to prepare regulatory
ethico-legal policies towards best practice. Finally, stakeholder
engagement is called for to see the integration and implementation of
existing partial ectogenesis technologies and development of total
ectogenesis sooner rather than later.
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A brief history of antibiotic discovery
The discovery of antibiotics revolutionised
medicine by drastically improving the efficacy
of treatment of infectious disease, which was
the greatest contributor to mortality statistics in
the pre-1900s era. The Centers for Disease
Control and Prevention (CDC) in the United
States (US) reported a rapid decline in
infectious disease mortality from 1900 to 1999,
crediting the development of antibiotics as a
major contributor to this phenomenon.1
Antibiotics remain some of the most effective
agents in a physician’s arsenal against infectious
disease, and have helped to pave the way for
groundbreaking advances in other fields of
medicine, such as surgery, transplantation
medicine, intensive care and oncology.
The development of the very first antibiotic
began with Alexander Fleming’s discovery of
penicillin in 1928,2 catalysing an age of
antibiotic discovery – in particular the beta
lactams, one of the main classes of antibiotics
utilised in clinical practice to this day.3 The
golden era of antibiotic discovery, from the
1940s to the 1960s, saw an explosion of new
antibiotics discovered through systematic
screening of soil microorganisms for
antimicrobial activity.4 Roughly two-thirds of
‘natural product’ antibiotics (natural substances
produced by microorganisms) were isolated
from soil Actinomycetes.5,6 However, this
method of antibiotic discovery was restricted to
Antibiotics in the 21st century:
a fight against a familiar foe
Abstract
Antibiotics form the cornerstone of treatment against infectious disease and have helped to
drastically reduce mortality rates since the turn of the twentieth century. Through the years,
antibiotic development has progressed through different phases of discovery techniques, but
has now reached a dipping point in its productivity for a multitude of reasons, both scientific
and financial. Furthermore, antimicrobial resistance (AMR) threatens to undo all the progress
achieved by these miraculous drugs that were discovered, no less, from the culture of other
soil microorganisms. Recent strides in technology and legislation hope to drive resurgence in
the field. This is exemplified by teixobactin, a promising new antimicrobial compound, which
has been hailed as one of the most exciting scientific discoveries of 2015. This article explores
the historical journey of antibiotic discovery, the issues surrounding AMR, the challenges
faced by antibiotic research and development (R&D), and the new and innovative strategies
being employed to overcome these hurdles.
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cultivable soil microorganisms and dwindled during the 1970s as
a result.4 As new discoveries became scarce, scientists began
utilising semi-synthetic methods to modify pre-existing antibiotic
scaffolds, altering their activity and improving their
pharmacokinetic properties.7,8
Synthetic approaches came to the forefront of antibiotic
discovery in 1995, when the first complete bacterial genome
(Haemophilus influenzae) was sequenced.9 The advent of
genomics facilitated the exploration of a multitude of new genes
and, in turn, the foundation for a target-based approach to
screen for new classes of antibiotics.8 Major pharmaceutical
companies quickly adopted these high-throughput screening
techniques; however, roughly two decades later, they have seen
limited success.8 To date, the only clinically-approved antibiotic
discovered via high-throughput screening is bedaquiline, an
anti-tuberculosis agent.10 The collective failure of target-based
screening to identify novel antibiotics has been implicated as one
of the reasons why many pharmaceutical companies have
withdrawn from antibiotics research and development (R&D).
Currently, only four large multinational pharmaceutical
companies retain their antibiotic R&D divisions (GlaxoSmithKline,
AstraZeneca, Merck and Pfizer) and as a result, the last two
decades have seen a significant void in the discovery of novel
antibiotics.11
FIGURE 1: Representation of the 20-year
discovery void in the antibiotic research
and development timeline. The 1940s to
the 1960s represents the period of
greatest productivity in terms of
antibiotic discovery, which was catalysed
by the discovery of penicillin.29
Table 1: The ESKAPE pathogens.
E Enterococcus faecium
S Staphylococcus aureus
K Klebsiella pneumoniae
A Acinetobacter baumannii
P Pseudomonas aeruginosa
E Enterobacter spp
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Antibiotic resistance
Since the dawn of antibiotic discovery, experts have voiced
concerns regarding the threat of antimicrobial (antibiotic)
resistance (AMR), most notably Fleming, who foretold the
development of penicillin resistance in his Nobel Prize acceptance
speech.12,13 Today, AMR is a serious global health issue; the World
Health Organisation (WHO) recently described it as the “single
greatest challenge in infectious diseases today”.14 The CDC
estimates that every year over two million people become
infected with antibiotic-resistant bacteria and at least 23,000 die
as a result.15 In addition to the mortality and morbidity associated
with AMR in the US, it also generates an economic burden of $20
billion USD in excess healthcare costs.16 In the past, AMR was
confined to hospital-acquired infections and
immunocompromised patients; however, it has now begun to
spread into community-acquired infections.4
AMR can be classified into two different types: intrinsic and
acquired. Intrinsic AMR refers to inherent characteristics of a
microorganism that render it resistant to antibiotics, which do
not change in response to antibiotic selective pressure. In
contrast, acquired AMR is the product of microbial evolutionary
change, conferring a survival advantage on resistant organisms17
that has been accelerated by the selective pressure of antibiotic
drugs used by humans. The main contributors to this selective
pressure are the medical and agricultural sectors, which widely
misuse and overuse antibiotics.4,18 Acquired AMR is exemplified
by the cautionary tale of the development of methicillin-resistant
Staphylococcus aureus (MRSA) around the 1960s, which was
fuelled by the uncontrolled use of methicillin in hospitals. The
modifiable nature of acquired AMR suggests that the rate at
which resistance develops can be controlled via infection
prevention efforts, efficient infection diagnostics, and antibiotic
stewardship during treatment.
The rapid evolution of AMR is a result of bacterial genetic
plasticity, allowing for spontaneous and consistent acquisition of
mutations through horizontal gene transfer (HGT) and
chromosomal mutations. These genetic changes manifest
through modification of target proteins, enzymatic inactivation of
drugs and prevention of target access. The frequency of
mutations can be increased in response to loss of DNA repair or
proofreading and the induction of pro-mutagenic pathways.19
HGT facilitates the rapid spread of resistance genes between
species via mobile genetic elements such as plasmids, leading to
the emergence of multi-drug resistant (MDR) strains of bacteria
dubbed ‘superbugs’. The ‘ESKAPE’ pathogens are responsible for
most MDR infections.20 The most worrisome pathogens exhibit
pan-drug resistance, resulting in minimal therapeutic options;
these include Acinetobacter baumannii, Pseudomonas aeruginosa,
carbapenem-resistant Enterobacteriaceae and the recently
identified New Delhi metallo-β-lactamase-1-expressing
Enterobacteriaceae.4,15
Challenges in antibiotic development
In an effort to address the concerning lack of progress in
developing novel antibiotics against MDR infections, the
Infectious Diseases Society of America launched the 10x’20
FIGURE 2: Mechanisms of antimicrobial
resistance (AMR). The acquisition and
spread of AMR is driven by: (A)
mutagenesis; or, (B) horizontal gene
transfer in response to an external stress,
such as the use of antibiotics in medicine
or agriculture.18
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Initiative for the development and approval of 10 new antibiotics
by 2020.21 A recent update reported that only two new
antibiotics (telavancin and ceftaroline fosamil) had been
approved for marketing in the US, and these numbers were part
of a downward trend.11 Antibiotic R&D is a formidable task that
requires substantial monetary investment to develop a new
compound without any guarantee of success. Ironically, despite
their life-saving capabilities, antibiotics are inherently less costly,
are administered for a shorter duration than many drugs used to
treat chronic medical conditions, are curative by nature, and tend
to be held in reserve in an effort to delay AMR development.
These factors mean that antibiotics generate less net return on
investment and are logically less appealing investments for
pharmaceutical companies.7,22,23,24 The field of antibiotic
development currently relies on the efforts of small
pharmaceutical and biotechnology companies, which often lack
the resources to develop potential drugs in large-scale clinical
trials, therefore impeding much-needed progress.18
Researchers face equally formidable obstacles in the search for
new antibiotics. Breakthroughs have become elusive due to
over-mining of natural products and unsuccessful synthetic
approaches. In the last decade, the focus of the field has been
limited to targeting resistant strains of gram-positive organisms
such as MRSA and vancomycin-resistant Enterococci (VRE).25
Recent data suggest that resistance rates in these gram-positive
pathogens have stabilised or decreased, but the incidence of
drug-resistant tuberculosis and gram-negative strains has been
increasing.26,27,28 The emergence of new resistant gram-negative
pathogens is particularly worrisome due to their intrinsic
resistance to many antibiotics, making drug design problematic.7
Gram-negative organisms have an outer membrane that is
impermeable to amphipathic drugs. Additionally, their inner
membranes and efflux pump systems also deter hydrophilic
molecules from entering the bacteria. One notable example is the
enterococcus species, which is inherently resistant to beta-lactams
such as penicillins, cephalosporins and carbapenems. The ESKAPE
pathogens, most notable for causing life-threatening MDR
infections, are predominantly gram-negative pathogens, and
physicians are sorely in need of therapeutic agents to counteract
these life-threatening infections.
Strides in the right direction
Economic incentives and new collaborative efforts are needed to
address the commercial failure of antibiotics. Government
initiatives encouraging pharmaceutical companies to undertake
antibiotic R&D have been launched on both sides of the Atlantic.
In 2011, the US Congress introduced the Generating Antibiotic
Incentives Now (GAIN) Act, which detailed new incentives to
advance antibiotic development.29 The European Commission
founded a public–private collaboration, the Innovative Medicines
Initiative (IMI), with initial funding of €223.7 million, to be used
to tackle AMR and to speed the delivery of new antibiotics to
patients.30 The IMI has also funded a multinational public–private
consortium, Driving Re-Investment in R&D and Responsible
Antibiotic use (DRIVE-AB) to develop alternative economic
strategies allowing for sustainable development of novel
FIGURE 3: A comparison of the two methods of culturing
microorganisms from soil for antibiotic discovery. The traditional
method involves directly culturing soil onto culture medium,
which yields only 1% of organisms present in the soil. The new
iChip-based technology involves seeding soil dilutions to
approximate one bacterial cell in a single agar-filled chamber
and placing it back in the soil, which greatly increases the
yield.4
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antibiotics, while balancing appropriate usage of said resources.23 A
recent review on AMR commissioned by the UK Government has
proposed the formulation of a global innovation fund to reward
groups developing new antibiotics with lump sums.24
Innovative solutions are needed to address the scientific bottleneck
facing antibiotic development. Scientists have taken to expanding
their field of research on a macroscopic level by exploring other
ecological niches in search of antibiotic agents. Promising new
compounds have been sourced from deep sea sediment bacteria,
marine flora and fauna, and bacterial symbionts of insects, fungi
and myxobacteria.31-37 Other novel research avenues to overcome
AMR include targeting molecular mechanisms of AMR, virulence
factors, antimicrobial peptides, and bacteriophages, as well as
repurposing genomic-based antibacterial screening with new tools
such as combinatorial chemistry.19,38-41
One untapped resource postulated to be a new avenue for
antibiotic discovery is that of uncultivable soil microorganisms.42
Data suggests that the number of discovered antibiotics represents
only 10% of the screened bacterial strains and only 1% of all
microorganisms.43
A recent success story is teixobactin, the first new class of antibiotics
with a novel mechanism, which was discovered using new
technology for culturing soil microorganisms – iChip44 – a
multichannel device that allows the diffusion of nutrients and
growth factors from the soil into separated chambers to allow for
growth of previously uncultivable bacteria.45 A soil sample is diluted
down to approximately one bacterial cell per given chamber and
placed back into its original environment. The growth recovery
using the iChip technology is approximately 50% and significantly
greater than the 1% yield from soil that will grow on a nutrient Petri
dish using traditional culture methods.44
Teixobactin was isolated from a new species of β-proteobacteria
named Eleftheria terrae, which is related to Aquabacteria. It is a
depsipeptide molecule that acts as a cell wall inhibitor by binding
two precursors of bacterial cell wall polymers: lipid II
(peptidoglycan) and lipid III (teichoic acid).44 Structural analysis of
teixobactin demonstrated a unique chemical scaffold unlike existing
antibiotics, a highly desirable trait for new antibiotics. Teixobactin
exhibits excellent activity against gram-positive pathogens
extending to drug-resistant strains, but has no activity against
gram-negatives. 
There is an intriguing lack of development of resistance to
teixobactin during in vitro and in vivo testing;44 however, despite
these promising results, teixobactin has yet to undergo clinical trials
in humans, so its success remains to be proven despite the initial
enthusiasm about its potential. The authors have postulated that the
reason behind the lack of resistance development is due to
teixobactin’s unique targets; lipids are essential to cell wall synthesis
and are synthesised from organic precursors, whereas proteins are
encoded by genes that can easily mutate in response to selective
pressure.44
Post-antibiotic era?
The threat of AMR and the diminishing antibiotic pipeline has led
many experts to ponder whether a post-antibiotic era is
imminent, in which common infections and minor injuries
FIGURE 4: Postulated mechanism of
action of teixobactin. Teixobactin (TEIX) is
produced by a gram-negative bacterium
and is exported across the outer
membrane. In target gram-positive
organisms, teixobactin’s targets – lipid II
(precursors of peptidoglycan [PG]) and
lipid III (precursor of wall teichoic acid
[WTA]) – are readily accessible on the
outside. Binding to multiple targets within
the cell wall pathways interrupts the
formation of a functional cell wall.44
RCSIsmjstaff review
Page 78 | Volume 9: Number 1. 2016
References
1. Centers for Disease Control and Prevention (CDC). Achievements
in Public Health 1900-1999: Control of Infectious Diseases.
[Internet]. [Accessed 2015 August 6]. Available from:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm4829a1.htm.
2. Fleming A. On the antibacterial action of cultures of penicillium,
with special reference to their use in the isolation of B. influenzae.
Br J Exp Pathol. 1929;10(3):226-36.
3. Kardos N, Demain AL. Penicillin: the medicine with the greatest
impact on therapeutic outcomes. Appl Microbiol Biotechnol.
2011;92(4):677-87.
4. Arias CA, Murray BE. A new antibiotic and the evolution of
resistance. N Engl J Med. 2015;372(12):1168-70.
5. Weber T, Welzel K, Pelzer K, Vente A, Wohlleben W. Exploiting
the genetic potential of polyketide producing streptomycetes. J
Biotechnol. 2003;106(2-3):221-32.
6. Baltz RH. Genetic manipulation of antibiotic-producing
Streptomyces. Trends Microbiol. 2009;12(5):520-7.
7. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st
century. Perspect Medicin Chem. 2014;28(6):25-64.
8. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad
bugs: confronting the challenges of antibacterial discovery. Nat
Rev Drug Discov. 2007;6(1):29-40.
9. Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF,
Kerlavage AR et al. Whole-genome random sequencing and assembly
of Haemophilus influenzae Rd. Science. 1995;269(5223):496-512.
10. Lewis K. Platforms for antibiotic discovery. Nat Rev Drug Discov.
2013;12(5):371-87.
11. Boucher HW, Talbot GH, Benjamin DK Jr, Bradley J, Guidos RJ, Jones
RN et al. 10x’20 progress – development of new drugs active
against gram-negative bacilli: an update from the Infectious
Diseases Society of America. Clin Infect Dis. 2013;56(12):1685-94.
12. Fleming A. Penicillin. Nobel Lecture. December 11, 1945.
13. Barriere SL. Clinical, economic and societal impact of antibiotic
resistance. Expert Opin Pharmacother. 2015;16(2):151-3.
14. World Health Organisation (WHO). WHO report finds systems to
combat antibiotic resistance lacking. [Internet] [Accessed 2015
August 6]. Available from:
http://www.who.int/mediacentre/news/releases/2015/antibiotic-resi
stance-lacking/en/.
15. Centers for Disease Control and Prevention (CDC). Antibiotic
resistance threats in the United States, 2015. [Accessed 2015
August 6]. 13p. Available from:
http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
16. The Alliance for the Prudent Use of Antibiotics (APUA). The cost
of antibiotic resistance to U.S. families and the health care
system. [Internet] [Accessed 2015 August 7]. Available from:
http://www.tufts.edu/med/apua/consumers/personal_home_5_1
451036133.pdf.
17. Hall BG, Barlow M. Structure-based phylogenies of the serine
beta-lactamases. J Mol Evol. 2003;57(3):255-60.
18. Jabes D. The antibiotic R&D pipeline: an update. Curr Opin
Microbiol. 2011;14(5):564-9.
19. Culyba MJ, Mo CY, Kohli RM. Targets for combating the
evolution of acquired antibiotic resistance. Biochemistry.
2015;54(23):3573-82.
20. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB et
al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious
Diseases Society of America. Clin Infect Dis. 2009;48(1):1-12.
21. Infectious Diseases Society of America. The 10x20’ Initiative:
pursuing a global commitment to develop 10 new antibacterial
drugs by 2020. Clin Infect Dis. 2010;50(8):1081-3.
22. Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S et al.
The global threat of antimicrobial resistance: science for
intervention. New Microbes New Infect. 2015;6:22-9.
become lethal.46 In the past, antibiotic development just barely
kept pace with the rate of bacterial evolution, and the lengthy
lack of productivity in the pipeline certainly has left a sizeable
gap between the two. 
In order to close this gap, collaborative efforts are necessary, as
the problem has now become too large for one sector to handle
on its own. 
Government and health organisations have begun taking action
towards combating AMR development via public health
prevention and antibiotic stewardship. Concerted efforts have
been made in legislation and funding towards revitalising the
antibiotic discovery industry. The research community has also
stepped forward with a variety of new approaches to tackling the
elusive issue of novel antibiotic discovery. Only time will tell
whether AMR can be held at bay long enough to allow for these
efforts to come to fruition, and the hope is that human
innovation can indeed make up for lost time and allow us to
continue in this age-old battle against the microbes.
RCSIsmjstaff review
Volume 9: Number 1. 2016 | Page 79
23. Harbarth S, Theuretzbacher U, Hackett J. Antibiotic research and
development: business as usual? J Antimicrob Chemother.
2015;70(6):1604-7.
24. The Review on Antimicrobial Resistance. Securing new drugs for
future generations: the pipeline of antibiotics. [Accessed 2015
August 8]. Available from:
http://amr-review.org/sites/default/files/SECURING%20NEW%20
DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20W
EB_0.pdf.
25. Loffler CA, MacDougall C. Update on prevalence and treatment
of methicillin-resistant Staphylococcus aureus infections. Exp Rev
Anti Infect Ther. 2007;5(6):961-81.
26. European Centre for Disease Prevention and Control.
Communication from the Commission to the European Parliament
and the Council. Action plan against the rising threats from
Antimicrobial Resistance. [Accessed 2015 August 8]. Available from:
http://ec.europa.eu/dgs/health_food-safety/docs/communication_a
mr_2011_748_en.pdf.
27. Daxboeck F, Budic T, Assadian O, Reich M, Koller W. Economic
burden associated with multi-resistant gram-negative organisms
compared with that for methicillin-resistant Staphylococcus aureus
in a university teaching hospital. J Hosp Infect.
2006;62(2):214-18.
28. European Medicines Agency. The bacterial challenge: time to
react. A call to narrow the gap between multidrug-resistant
bacteria in the EU and the development of new antibacterial
agents. [Accessed 2015 August 8]. Available from:
http://ecdc.europa.eu/en/publications/Publications/0909_TER_Th
e_Bacterial_Challenge_Time_to_React.pdf.
29. Infectious Diseases Society of America (IDSA), Spellberg B, Blaser
M, Guidos RJ, Boucher HW, Bradley JS, et al. Combating
antimicrobial resistance: policy recommendations to save lives.
Clin Infect Dis. 2011;52(Suppl. 5):S397-428.
30. European Commission. Combating antibiotic resistance:
NewDrugs4-BadBugs (ND4BB). [Accessed 2015 August 8].
Available from:
http://www.imi.europa.eu/sites/default/files/uploads/documents/
Press%20Releases/IMIpressRelease6thCallFINAL.pdf.
31. Blister B, Bischoff D, Strobele M, Riedlinger J, Reicke A, Wolter F
et al. Abyssomicin C – a polycyclic antibiotic from a marine
Verrucosispora strain as an inhibitor of the p-aminobenzoic
acid/tetrahydrofolate synthesis pathway. Angew Chem Int Ed
Engl. 2004;43(19):2574-6.
32. Laport MS, Santos OC, Muricy G. Marine sponges: potential
source of new antimicrobial drugs. Curr Pharm Biotechnol.
2009;10(1):86-105.
33. Burgess JG, Jordan EM, Bregu M, Mearns-Spragg A, Boyd KG.
Microbial antagonism: a neglected avenue of natural products
research. J Biotechnol. 1999;70(1-3):27-32.
34. Donia MS, Ravel J, Schmidt EW. A global assembly line for
cyanobactins. Nat Chem Biol. 2008;4(6):341-3.
35. Partida-Martinez LP, Hertweck C. Pathogenic fungus harbours
endosymbiotic bacteria for toxin production. Nature.
2005;437(7060):884-8.
36. Piel J. Metabolites from symbiotic bacteria. Nat Prod Rep.
2009;26(3):338-62.
37. Wenzel SC, Muller R. The biosynthetic potential of myxobacteria
and their impact on drug discovery. Curr Opin Drug Discov
Devel. 2009;12(2):220-30.
38. Waldor MK. Disarming pathogens – a new approach for
antibiotic development. N Engl J Med. 2006;354(3):296-7.
39. Pastagia M, Schuch R, Fischetti VA, Huang DB. Lysins: the arrival
of pathogen-directed anti-infectives. J Med Microbiol. 2013;62(Pt
10):1506-16.
40. Bragg R, van der Westhuizen W, Lee JY, Coetsee E, Boucher C.
Bateriophages as potential treatment option for antibiotic
resistant bacteria. Adv Exp Med Biol. 2014;807:97-110.
41. Steckbeck JD, Deslouches B, Montelaro RC. Antimicrobial
peptides: new drugs for bad bugs? Expert Opin Biol Ther.
2014;14(1):11-14.
42. Wilson MC, Mori T, Ruckert C, Uria AR, Helf MJ, Takada K et al.
An environmental bacterial taxon with a large and distinct
metabolic repertoire. Nature. 2014;506(7486):58-62.
43. Watve MG, Tickoo R, Jog MM, Bhole BD. How many antibiotics
are produced by the genus Streptomyces? Arch Microbiol.
2001;176(5):386-90.
44. Ling LL, Schneider T, Peoples AJ, Spoering AL, Engels I, Conlon BP
et al. A new antibiotic kills pathogens without detectable
resistance. Nature. 2015;517(7535):455-9.
45. Nichols D, Cahoon N, Trakhtenberg EM, Pham L, Mehta A,
Belanger A et al. Use of iChip for high-throughput in situ
cultivation of “uncultivable” microbial species. Appl Environ
Microbiol. 2010;76(8):2445-50.
46. Appelbaum PC. 2012 and beyond: potential for the start of a
second pre-antibiotic era? J Antimicrob Chemother.
2012;67(9):2062-8.
Naomi O’Sullivan
RCSI medical student
Watch this space: 
bringing medicine beyond
Earth’s boundaries
Abstract
Since the first manned flight by Yuri Gagarin in 1961, the human race has strived to push the
boundaries of manned space travel. Originally driven by curiosity, in more recent years the
new goal is to extend the range of human habitat beyond Earth’s limits. This will require
extended duration space flights. However, humans evolved in the presence of gravity and
Earth’s particular atmosphere. Leaving this protective environment poses a myriad of
challenges to the human body, including microgravity, solar proton radiation, prolonged
confinement and isolation, absence of natural light and circadian rhythm changes. Key effects
identified include loss of bone density and muscle strength, adverse psychological changes
and increased cancer risk. Future missions will routinely demand complex and physically
demanding tasks, and astronauts will be unable to receive additional resources or
communications from Earth in a timely manner. It is essential that effective countermeasures
be developed to maintain or enhance human performance in microgravity. Increasing private
sector investment in commercial space travel also means that future passengers will be a
more diverse population that may be less tolerant to space travel than current astronauts.
This increases the likelihood of life-threatening in-flight surgical or psychological emergencies.
With current flights including only one crew member with limited medical training, changes
will need to be made to medical protocols to ensure mission success, such as prophylactic
appendectomies and the inclusion of emergency physicians in future crews.
Royal College of Surgeons in Ireland Student Medical Journal. 2016;1:80-4.
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Introduction
Driven by innate curiosity, fear of the unknown and potential
commercial gain, humans have long strived to push the boundaries of
manned space travel since that first flight by Yuri Gagarin in 1961.
Recently, we have identified a new goal: to extend the range of
human habitat beyond Earth through colonisation of other planets
and prolonged space travel. However, leaving the protective cocoon
that we evolved in, no longer cushioned by the presence of gravity
and a precise balance of gases, poses a myriad of challenges to the
human body – as demonstrated in the book (turned major motion
picture) The Martian by Andy Weir.1 These include microgravity,
radiation, prolonged confinement and isolation, and changes in
circadian rhythm. Key effects identified include loss of bone density,
decreased muscle strength and endurance, adverse psychological
changes, and increased cancer risk due to high-energy radiation.
Unshaken by these dangers, we are rapidly making the advances in
research and technology necessary to make extraterrestrial
colonisation a reality. Missions will routinely require astronauts to
perform complex and physically demanding tasks, so it is essential to
minimise adverse effects, particularly in light of the fact that astronauts
will be unable to receive additional resources or communications from
earth in a timely manner. With increasing private sector investment in
commercial space travel, the passengers of future flights will also be a
more diverse population, potentially less tolerant of space travel than
the robust and rigorously trained athletes of today.
Cardiovascular adaptations
The cardiovascular system appears to adapt the most appropriately to
microgravity. The most frequently documented changes are related to
shifts in body fluids and mild arrhythmias.2-4 During space flight, lack
of gravity-induced hydrostatic forces lead to a cephalad shift and
equilibration of fluid from lower extremities to the trunk and upper
extremities.2 This manifests as nasal congestion and the classic “puffy
face/bird leg” appearance of astronauts.3 Fluids shifting towards the
head distend the baroreceptors of the central vasculature, resulting in
suppression of the renin-angiotensin-aldosterone system (RAAS) and a
10% reduction in total blood volume.5,6 These effects decrease over
time, but remain present for the duration of the flight.7 Increases in
heart rate and premature atrial and ventricular contractions have also
been reported in 30% of astronauts during extravehicular activity,
launch and orbit, thought to be due to catecholamine hyperactivity.8
So far, crew members have tolerated these episodes well, but
passengers on future flights will likely be much less conditioned. This
should be noted when developing future preflight medical
evaluations.
Musculoskeletal adaptations
One of the best-understood consequences of space flight is the impact
of microgravity on the musculoskeletal system. Bone and muscle are
active, dynamic organs that quickly respond to the physical forces
exerted upon them.1 Space flight neutralises the gravitational loading
required for skeletal remodelling and muscle growth,3,6,9 leading to
significant loss in bone density and widespread muscle atrophy.3
Suboptimal nutrition, reduced vitamin D due to low levels of natural
light, and higher ambient levels of CO2 lead to respiratory acidosis
and increased bone resorption.10,11
Postural muscles atrophy most due to their relatively unloaded state.6
After two weeks of space flight, muscle mass decreases by 20%,
extending to 30% by three to six months.12,13 The loss of bone density
is much more concerning, beginning immediately upon arrival in
space, with a 60-70% increase in urine and faecal calcium loss within
the first few days.10 This continues with a 1-2% loss per month in
weight-bearing bones;9,10 hence, osteopaenia could become a limiting
factor in mission duration.14 Future missions will inevitably involve
strenuous physical work and extravehicular excursions, so increased
risk of fracture is a real concern.11
Countermeasures focus on the prevention of bone loss with exercise
and dietary measures, including low-salt and high-calcium diets, and
vitamin D and protein intake.12 Pharmacological agents are avoided
due to the potential for serious side effects that the crew may not be
equipped to deal with.15 In-flight exercise programmes lack the impact
forces associated with Earth’s gravity and are insufficient.7 Additionally,
the current two-hour daily exercise regimen consumes valuable
oxygen, food, water and crew time, and will only increase with longer
flights. One alternative proposal is to use intermittent artificial
gravity;16 recent studies indicate that human subjects may undergo
daily exposure to artificial gravity without suffering debilitating motion
sickness, and periodic exposure is effective in maintaining muscle
mass.17 However, this is a costly and difficult engineering task.
Radiation exposure
Perhaps the most sinister health concern is exposure to radiation
beyond Earth’s orbit, which is vastly different to the ionising type to
which humans are usually exposed,18 and is thought to produce
distinct biological damage. Astronauts incur substantial but poorly
understood risks of carcinogenesis and degenerative disease. Solar
flares are particularly concerning due to their unpredictable nature,
while high energy (HZE) ions are the main contributor to the risk due
to their high ionisation power.18,19 During a three-year mission to
Mars, every cell nucleus in the body would be hit by a proton or
secondary electron every few days, and a HZE ion once a month. This
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would culminate in a whole-body dose of radiation equal to
approximately 1 Sievert or more. The risk of cancer is significantly
increased by this exposure, and has prompted studies on how the risks
– particularly of tumourigenesis – might be minimised.19
Radiation exposure also has significant impacts on the human
reproductive system, particularly in females. Flights to date have been
considerably shorter than the average menstrual cycle length, so no
on-shuttle studies have been conducted to determine the impact on
the hypothalamic-pituitary-ovarian axis. The main concern is that
anovulation or hypothalamic amenorrhoea and reduced oestrogen
levels (which contribute to risk of osteoporosis) could occur.19-21
Radiation exposure, combined with the increased retrograde
menstruation during space flight, may predispose to the development
of endometriosis.22
The risks of these effects can be largely controlled by oral
contraceptive or hormone replacement therapy. Due to radiation
levels associated with any space flight, and consensus that no embryo
could appropriately adapt to microgravity, pregnancy in space is
currently not feasible.23
More research needs to be carried out on shielding options, including
potential radioprotective drugs.
Psychological adaptations
NASA has predicted that psychological issues are all but inevitable,
and pose a serious threat to mission success.21 Future crews must
adhere to a strict and demanding schedule while confined in a
spacecraft, removed from earthly conveniences and daily routines. To
date, no mission has been terminated prematurely due to behavioural
disturbance, but this may be largely due to the current duration of
flights, frequency of contact with ground control, and strict astronaut
selection criteria.24
The longest prior simulated space mission lasted a mere 240 days;25
the ambitious Mars 520 project confined a multinational crew of six
healthy males to a 550m2 chamber on Earth for 520 days.26 While
unable to mimic the effects of microgravity, radiation and real threat
to life, the project isolated participants from Earth’s light-dark cycles,
limited their access to consumable resources, simulated
communication delays, and assigned daily maintenance work,
experiments and exercise identical to that predicted on a real mission
to Mars.
Investigators noted disruptions to circadian rhythm and modest
increases in depressive symptoms and psychological distress, but
arguably the most interesting observation was an increase in
crew-perceived conflicts with ground control as the mission
progressed.24 The development of an ‘Us vs Them’ attitude is a
well-documented form of displacement during space flight: the team
transfers intra-group tension onto a remote individual.27,28 The most
extreme case of frustration resulted in crew cutting contact with mission
control entirely for over 24 hours.24 Longer-duration flights are expected
to increase stress and the severity of the displacement response.
Proposed countermeasures include allowing more autonomy in
planning work schedules, and greater involvement of mission control in
pre-flight training exercises.24,29 This may also help to address the
frequently reported feelings of sedentariness and monotony resulting
from hypostimulation and restricted social contacts.29
The consensus is that more emphasis needs to be placed on
personality and identification of behaviour predisposing to certain
adaptations to prolonged confinement. Individuals’ insight into their
own capabilities, mental endurance, and response to stressors must be
taken into account.29 Biological markers such as polymorphisms
involved in sleep-wake cycle, circadian rhythm and cognitive
regulation should also be used to identify those at increased risk of
neurobehavioural vulnerability to sleep restriction.24,30
Encouragingly, not all psychological changes experienced by
astronauts are negative. Numerous astronauts report experiencing a
“transcendental, religious experience or sense of the unity of
mankind” while in space.31 This positive phenomenon enabled
astronauts to experience change as normal and beneficial, and to
believe that events would work out as well as could reasonably be
expected.29 However, this salutogenic phenomenon is, in the majority
of cases, related to the perception of Earth from space.24 With the
longer duration flights to Mars, the inability to see Earth could have
detrimental effects on psychological well-being.
Surgery in microgravity
Life-threatening surgical conditions that may arise without warning in
healthy crew members include traumatic injuries, appendicitis,
diverticulitis, cholecystitis and pancreatitis.32 As missions move further
from Earth, telemetric medical support and traditional
communications travelling at the speed of light will be greatly
delayed. For example, two-way contact on Mars would take a
minimum of 44 minutes, which will pose great challenges to real-time
robotic surgery and support from mission control in medical
emergencies.33
While no surgeries have yet been performed on humans in space, the
first animal laparotomy was performed in 1967 and since then
haemorrhage, large vessel repair and wound closure were not found
to be significantly more difficult than during terrestrial procedures.34,35
However, restricted resources and limited crew medical training,
including inability to provide basic perioperative and postoperative
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care,36 still pose significant challenges. Immune dysregulation and the
documented increased pathogenecity of bacteria in space could also
greatly increase the likelihood and severity of postoperative
infections.37 If significant operative complications occurred requiring
critical care support, there would almost certainly be loss of mission or
of life. Support for prophylactic appendicectomies and
cholecystectomies is growing. Appendicitis and cholecystsitis are
common conditions and prophylactic appendicectomy has been
mandatory for the Australian Antarctic Programme for those spending
winter in Antarctica since 1950.38 No cases of cholecystitis or
appendicitis have been documented in space thus far, but this is
largely due to the relatively young age and lower BMIs of crew
members, combined with intensive medical screening;35 future
astronauts will likely be in less optimal condition and will undergo
more lenient screening. Arguably, prophylactic surgery could be
beneficial and necessary in preventing the catastrophic loss of mission
or life; however, this is fraught with significant ethical issues. Having
the surgery may become a significant advantage for candidates being
considered for a position on a flight, leading to peer, corporate and
public pressure to comply. Conversely, suffering operative
complications may disqualify a candidate entirely from the flight.
Regardless of whether this becomes mandatory, changes will need to
be made to medical and surgical protocols to ensure mission success.
Currently, one crew member receives limited medical training and has
some minor surgical skills (such as suturing).36 At the minimum, future
flights will need a physician astronaut with basic surgical skills and the
ability to manage acute illness. Emergency physicians are likely the
most suitable candidates for this position.
Conclusion
This past year proved monumental for space exploration, imparting
an even greater sense of urgency to efforts to extend our habitat
boundaries beyond Earth’s limits. The Mars Reconnaissance Orbiter
identified hydrated salt minerals on Mars and SpaceX continued
their success in developing fully and rapidly reusable launch vehicles
that will drastically lower space flight costs.36,39 Perhaps most
significantly, International Space Station astronauts consumed the
first ever meal of space-grown lettuce, bringing the possibility of
self-sustainable astronauts closer to reality.40 The uniquely
challenging medical setting that space flight presents will
undoubtedly further terrestrial medicine through spin-off
technologies, such as telemedicine, and greater understanding of
human physiology. However, if future missions are to be successful,
it is clear that current medical protocols must change. At a
minimum, emergency physicians must be included in all crews,
prophylactic surgeries must be seriously considered, and greater
efforts need to be directed into truly effective and affordable
radiation countermeasures.
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Introduction
Amidst the furore surrounding ‘anti-vaxxer’ campaigns, and the
issues surrounding public funding of healthcare, the overworking
of junior doctors, and the use of medical marijuana, a 15-year war
has been fought behind the scenes in the world of science and
medicine. The issue of access to and sharing of scientific research
has become divisive. The open access (OA) movement advocates
for freely accessible and reusable research, while traditional
publishers claim copyright on the material they publish, since they
absorb the costs of maintaining online repositories and expert
review boards. Now, as more and more government grants require
free and open access to the information provided by these articles,
the issue is receiving more public focus. The OA movement has
extended to medicine, focusing notably on science research and
pharmacology, but also on the education of trainee doctors, with a
surprising Irish influence.
For the scientist: open access research
The key battle that is being fought focuses on whether the sale of
scientific knowledge in the form of journal subscriptions is valid
despite reduced costs due to digitisation and the fact that much of
this research has direct benefits to the public. One answer to this
problem has been the advent of the OA philosophy, which
espouses unrestricted access to research articles along with the
rights to re-use these articles.1,2 Publishers assert that their
subscription fees are legitimate because they provide the resources
to publish these articles widely, they ensure high-quality research
via a free-market approach, and they provide a long-standing
reputation, conferring legitimacy to any papers published in their
journals.3
However, OA journals argue that restricting access to academic
research that is already being funded from public grants is not
only disingenuous, but also impedes progress and discovery. By
putting information behind a paywall, only those individuals or
institutions that can afford a subscription can use that article for
their own research, creating a social hierarchy of access to
information.3
The OA movement has extended to
medicine, focusing notably on science
research and pharmacology, but also 
on the education of trainee doctors, 
with a surprising Irish influence.
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Further complicating the situation, journal subscription fees have
risen by more than three times the inflation rate over the last 30
years, despite a reduction in operating costs due to digitisation.4 In
fact, the average annual price for a health sciences journal
subscription is $1,694 USD, which is still far below the average for
a chemistry journal subscription, which will cost an individual on
average $4,942.5 It seems that the current journal publishing elite
– only five companies, which publish 50% of all research6 – are
taking advantage of their privileged status. Thus, in an effort to
provide freely-accessible quality research to everyone, OA journals
like PLoS and BioMed Central (as well as thousands of others) have
sprung up and not only offer this information for free, but allow
anyone to use the research, figures or data freely under Creative
Commons licenses. This movement has also encouraged the
development of OA-friendly research tools and platforms like
Mendeley, ResearchGate, Overleaf, Figshare and others, which
allow not only the free sharing of this information, but an OA
approach to collaboration, leading to thousands of articles that
would not otherwise have been produced.
In 2008, the US National Library of
Medicine in the National Institutes of
Health developed ClinicalTrials.gov, a
repository of the results for every trial
performed on every drug that is
approved by the Food and Drug
Administration in the US.
Of course, someone must cover the costs of OA publishing, so
most OA journals charge publishing fees to the authors, thus
putting the onus on the producer of the research (known as “Gold
OA”).7 While this has the benefit of ensuring that OA journals are
not inundated with requests to publish, it can at times be
predatory, leading to exploitation of authors.8 For example, a
number of vanity presses have popped onto the scientific
landscape, leading to largely unreviewed papers and articles being
published under the name of OA, but in fact lacking the necessary
scrutiny that is required of quality scientific research.9 It also means
that even if the OA journal is legitimate, well-reviewed and well
produced, the Gold OA approach can limit what an early-career
scientist or student can realistically publish because of a lack of
funding. 
For example, Elsevier, the third largest OA publisher, has fees
ranging from $500 to $5,000 for its Gold OA journals.10 Further
complicating the issue is that many OA journals accept
manuscripts from a broad range of disciplines, leading to questions
about the quality of the editorial process and how likely the ‘peers’
are to be from the same specialty.9
The saving grace is that those OA journals which are
well-established and have instituted legitimate peer-review systems
are considered to have the same scientific quality and impact as
subscription journals, especially in the field of biomedicine.11 In
short, while OA is far from perfect, it provides a tenable and
credible alternative to traditional subscription journals.
For the physician: open access pharmaceuticals
This push for open access is not isolated to the publishing of
scientific research, but has also spread to the world of drug
development. The information garnered from drug trials has
always been the property of the development company, giving
them the prerogative to disclose that information as they see fit.
Of course, pharmaceutical companies will suppress or minimise the
trials they perform that do not support the adoption of their drug,
as this makes financial sense. However, the problem that arises is
that these unpublished trials may have direct benefit to the
general public and the scientific community. In 2008, the US
National Library of Medicine in the National Institutes of Health
developed ClinicalTrials.gov, a repository of the results for every
trial performed on every drug that is approved by the Food and
Drug Administration in the US.12 Even then, only 13.4% of all drug
trials in the US were reported to ClinicalTrials.gov in a span from
January 2008 to September 2012.13 The purpose was to provide
OA for all trials, with complete reporting of side effects and
complications, not just those that were most common, as decided
by drug companies.
The need for this repository is clear – despite OA in the repository,
the negative side effects of drugs are reported in published articles
only 45% of the time.14 Although compliance with laws to submit
data to ClinicalTrials.gov has improved, it is still far from ideal,
especially considering that only summaries of the trials (not actual
patient-level data) are submitted to the repository.13
Pharmaceutical companies have a responsibility to provide any and
all information to those to whom they advertise and sell, especially
those physicians who will prescribe and recommend their drugs.
In fact, there are additional benefits to providing the information
in an open fashion. Jay Bradner of the Bradner Lab at the
Dana-Farber Cancer Institute at Harvard Medical School developed
JQ1, an anti-BRD4 chemical, which targets large solid tumours.15
However, rather than keep the molecule to himself and seek
financial gain, he sent it out to his colleagues – up to 70 labs
throughout the world. 
Their contributions were small at first: one group performed
crystallography to reveal the chemical’s structure;16 another
recorded the chemical converting tumour cells back to normal
cells.17 At this time, over 450 labs have used JQ1 in their own
research and the amount of literature published about JQ1 has
doubled every year for the seven years since they began sharing
the molecule, leading to eight human clinical trials and more
knowledge about their own chemical than could have been
achieved by their own lab in that time. 
Of course, the downside has been that in openly sharing both
information and the chemical probes themselves, the venture has
been an expensive lesson in sharing (since Dr Bradner’s lab
covered the costs of distribution), despite the benefits that have
been received from that sharing.
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For the student: free open access medicine
Finally, the movement towards OA has even invaded the world of
education, with a unique Irish influence. Free OA medical education
(or meducation), also known as FOAM, was first conceived in Dublin
in 2012 (over a pint of Guinness) with the purpose of providing
both an online curriculum and medical education that is freely
available to all. It hearkens back to the Hippocratic Oath, which
advocates for freely teaching medicine to all interested parties.18 It
has been bolstered by the unique progress afforded by social media,
with blogs, YouTube videos, Twitter feeds and Facebook pages
dedicated to giving students the opportunity to access sophisticated
resources providing asynchronous learning without having to spend
anything (except a monthly internet bill). In fact, FOAM resources
have become some of the most frequently visited medical websites
on the internet, with KevinMD, Medscape and iTeachEM ranking
among the top medical education websites, and blogs like Burnt
Orange Scrubs, Life in the Fast Lane, and The Presenting Complaint
among some of the most visited websites for medical students in
the world.18,19 Conferences focused on FOAM have even begun to
thrive, with the Social Media and Critical Care Conference (SMACC)
now in its fourth year and being hosted in Dublin this year. In short,
the OA approach has now made positive impacts in the world of
medical education, providing quality resources to facilitate student
learning and further entrenching the OA movement in a younger
generation of physicians.
Conclusion
There are still some significant hurdles to completely adopting a free
and open approach to research and medicine, especially when it
comes to funding the publication of research. However, the benefits
far outweigh the detriments; most notably, the increased rates of
discovery, the provision of medical information to the public, and
the delivery of high-quality education resources to any student
hoping to improve their learning. As medical students, we have a
duty to consider and ultimately adopt an OA approach, where we
consider sharing our own research and investigation. It is only with
this perspective that we can advance our professional development
and improve the quality of care of our patients.
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In medical practice today, increasing attention is being given to the
art of communication, to expressing (and better still, feeling)
empathy, and viewing a person as more than their physical or
psychological presenting complaint; that is, moving from a
dehumanising approach – as exemplified by describing a patient as
‘the appendicectomy in bed 4’ – to an understanding and
acknowledgement of the person and his or her experience, values,
feelings and personal situation.
There has been a trend away from the paternalistic approach of the
doctor, to a more collaborative, ‘patient-centred’ approach to
consultation. A more egalitarian approach encourages the physician
to see patients as having agency and a legitimate role in decisions
about their treatment, to follow their lead, and to appreciate
experiences and problems from the patient’s point of view –
including understanding their expectations and life circumstances
more broadly.1,2
Communication is especially sensitive and
difficult in the context of palliative and
end-of-life care for the physician, 
the patient and the patient’s family. 
For this reason, discussions about 
dying, and the patient and family’s
wishes, occur infrequently.
Malpractice in medicine
With medicine becoming increasingly litigious, malpractice claims
provide one window into the impact of poor communication.
Levinson et al. have found that physicians who have not had legal
claims made against them are more likely during their consultations
to use humour, ask patients for their opinions, spend more time
Empathy
is the 
new black
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with patients (than their sued colleagues), educate patients about
what to expect with a given diagnosis and treatment plan, and
encourage them to ask questions.3 Similarly, the emotional states
of patients are just as important as their physical states, with
individuals citing a lack of clear explanations, sympathy or
honesty, or a reluctance to apologise, as further reasons for
pursuing legal action against a doctor.4 There has been a shift, at
least in principle, in many major hospitals from defensive denial
and legal protection to admission of fault, apology, and
compensation. 
Similarly, levels of depression have been
shown to decrease when the doctor
communicates clearly and sympathetically
the severity of a diagnosis, the life
expectancy, and the impact a diagnosis is
likely to have on someone’s life.
This is partly because a protracted legal battle is not only
traumatic for the patient or family, but also very expensive and
distracting for the hospital.4,5 Taking a non-punitive approach
also creates an environment in which a doctor is more likely to
disclose an error, rather than trying to conceal or deny it. The
majority of patients and physicians favour knowing what has
gone wrong and why. Additionally, many hospital policies
advocate full disclosure, investigation, explanation, apology, and
some form of compensation. Unfortunately, however, these
approaches are still uncommon.5
Assessing patient satisfaction by way of malpractice claims is,
however, focused on reputational and financial risk. It is one
means of retrospectively assessing a person’s psychological state,
and level of comfort and satisfaction with consultation and
treatment, but is by no means ideal. It is the result of a failed
procedure or medical error and/or poor handling of a case, and
does not necessarily speak to the ethical dimensions of honesty
and the physician’s care for the patient. 
A more appropriate measure is to examine the person’s
emotional state and responses during or immediately following a
consultation.6 Evaluation of this approach suggests that patients
experience lower levels of anxiety when they are prepared for a
diagnosis, have the people they want with them when they are
told the diagnosis, receive written information as well as clear
verbal communication on the day of the consultation, have time
to ask questions and discuss how they are feeling, and to be
reassured. 
In one study, even one minute of compassion shown by the
physician in a consultation was shown to decrease the levels of
anxiety participants felt.7 Similarly, levels of depression have
been shown to decrease when the doctor communicates clearly
and sympathetically the severity of a diagnosis, the life
expectancy, and the impact a diagnosis is likely to have on
someone’s life.6
Communication at the end of life
Communication is especially sensitive and difficult in the context
of palliative and end-of-life care for the physician, the patient,
and the patient’s family. For this reason, discussions about dying,
and the patient and family’s wishes, occur infrequently. When
they do, there are serious shortcomings. Multiple studies have
identified key themes of importance to dying patients by
interviewing the patients themselves, their family members and
physicians.8-10 These focused on what was important to patients
and whether the same concerns applied equally to their doctors
and other caregivers. These themes included being
straightforward with all the information imparted, using clear
and understandable language, having a willingness to discuss
dying and to use the words ‘death’ and ‘dying’ as opposed to
using euphemisms, delivering news sensitively, choosing an
appropriate time and place to break bad news, listening to
patients, and encouraging questions.8-10 This requires the
physician to balance the need to give honest and distressing
advice without broaching a discussion of death when the patient
is not ready, and potentially causing greater distress or
hopelessness.10
Apart from the emotional and psychological effects, poor
communication has ramifications regarding the choice a patient
makes about their treatment. When a patient has an accurate
understanding of their diagnosis and prognosis, they are more
likely to choose a therapy that focuses on comfort and palliative
measures rather than life-extending interventions.11 The latter
patients often accept aggressive and distressing interventions,
which, when controlled for known prognostic factors, do not
increase their survival rate.11
A programme of purposefully driven
cultural change, involving everyone from
the consultants to the cleaners, drove
expectations of professional behaviour
using evidence, videos, workshops and
other strategies. 
Teaching communication and empathy
Most medical schools now supplement the academic record and
the standardised aptitude tests with some form of interviewing in
an effort to identify those candidates who have, or at least
exhibit, qualities such as motivation, ethical values, resilience,
maturity, and social and communication skills. Variations such as
the ‘multiple mini interview’ (MMI), which use multiple stations
to better assess a candidate’s ‘soft skills’, are becoming more
common. A typical MMI might use a series of trained
interviewees or actors from diverse backgrounds, and videos,
which candidates are asked to interpret. All of these measures are
designed to select for high-demand courses those students who it
is hoped will be well-rounded, empathetic and collaborative
practitioners.
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However, notwithstanding these efforts to filter out unsuitable
applicants and select those with the most promising interpersonal
as well as academic skills, effective and empathetic
communication is not guaranteed. In fact, it has been shown that
levels of empathy decline as medical students progress through
medical school, jeopardising the quality of care they are likely to
be able to offer as practising doctors.12
Reaching a consensus on the definition of empathy has been
difficult. However, most agree that to be empathetic one must
possess interpersonal sensitivity and be able to put oneself ‘in the
patient’s shoes’.13 There is, however, no consensus on whether
empathy should be defined as an emotional or a cognitive
quality, and whether it is a skill that one can acquire or is an
attitude one possesses. Some view empathy as an innate quality,
an aspect of personality, and therefore difficult to teach or to
predict.14
A well-known effort to increase ‘patient satisfaction’ is that of the
Cleveland Clinic in the USA. Of the range of patient satisfaction
scores, communication was particularly poor: 14% for doctor
communication skills and 16% for nurse communication skills. In
the author’s words:15
“Patients did not want to be in the hospital. They were afraid,
sometimes terrified, often confused, and always anxious. They
wanted reassurance that the people taking care of them really
understood what it was like to be a patient. Their families felt the
same way. Patients also wanted better communication: they
wanted information about what was going on in their
environment and about the plan of care; they wanted to be kept
up to date even on minute activities. And they wanted better
co-ordination of their care. When nurses and doctors did not
communicate with one another, patients were left feeling that no
one was taking responsibility for them”. (p 3)
A programme of purposefully driven cultural change, involving
everyone from the consultants to the cleaners, drove expectations
of professional behaviour using evidence, videos, workshops and
other strategies. The intention was to ‘make everyone a caregiver’
and to redesign the operations around patient needs rather than
organisational efficiency or clinicians’ convenience. From 2008 to
2012, the hospital’s ranking on a US government patient survey
of 4,600 hospitals rose from the 55th to the 92nd percentile.15
A caution, however, is needed. The risk in teaching
communication strategies and skills is that the health professional
simply learns some new phrases and uses them without feeling,
either because the feeling is lacking – that is, they are not able to
show empathy (which, in itself, raises some serious questions
about their suitability to practise) – or because time, exhaustion
and practical demands override their inclination to communicate
well.
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The current migration to Western Europe is unparalleled. In the
summer of 2015, Europe experienced the highest influx of refugees
since World War II.1 In 2015, an estimated 60 million people were
displaced globally, with approximately 50% of these people under
18 years of age. The main reason for this large influx is that Syria
has become the world’s top source of refugees as a consequence of
the Syrian Civil War.2 In addition to the Syrian refugees, large waves
of migrants and refugees from other countries in Asia, Africa and the
Balkans are migrating to Europe in the hopes of escaping conflict,
bad governance and poverty.3
Response in the European Union
In response to this large wave of refugees, many European countries
have agreed to accept migrants and refugees. The number of
asylum applications received in 2015 by European Union (EU)
nations more than doubled compared to 2014. In 2015, there was
an estimated total of 1,117,890 asylum applications from stateless
people across the EU.4 The majority of applications are from people
originating from Syria and Afghanistan.5 Germany is currently the
recipient of the largest number of asylum applications – with
476,620 applications received in 2015 – followed by France,
Sweden, Italy and the United Kingdom.6
This influx of migrants and refugees to Europe has, however, created
tension within the EU. Many countries do not agree to what extent
Europe as a whole should respond to the refugee crisis due to the
political and economic implications of taking in large numbers of
migrants and refugees. While many nations support the EU quota
plan to relocate refugees currently in Italy and Greece, other
countries like the Czech Republic, Slovakia, Romania and Hungary
have rejected the plan (Figure 1).7 Ireland has taken a more
moderate approach, reflecting its size and means. 
The Irish Government has established an Irish Refugee Protection
Programme, in which Ireland has agreed to accept up to 4,000
displaced persons in response to the current migration crisis.8
However, Ireland estimates the cost of hosting migrants to be €12
million per 1,000 migrants.9 Therefore, taking in large numbers of
migrants and refugees could potentially put enormous strain on
economic resources.
A global responsibility
JESSICA SUDDABY examines the challenges and opportunities involved
in refugee and migrant healthcare in Europe.
FIGURE 1: EU Resettlement Plan. NB: The UK and Denmark are not
taking part. Source: Dept. of Foreign Affairs, European Commission.
G
er
m
an
y
Fr
an
ce
Sp
ai
n
Po
la
nd
N
et
he
rla
nd
s
Ro
m
an
ia
Be
lg
iu
m
Sw
ed
en
A
us
tr
ia
Po
rt
ug
al
C
ze
ch
 R
ep
.
Ir
el
an
d
Fi
nl
an
d
Sl
ov
ak
ia
Bu
lg
ar
ia
C
ro
at
ia
Li
th
ua
ni
a
Sl
ov
en
ia
Es
to
ni
a
La
tv
ia
Lu
xe
m
bo
ur
g
C
yp
ru
s
M
al
ta
N
um
b
er
 o
f 
re
fu
g
ee
s
45000
40000
35000
30000
25000
20000
15000
10000
5000
0
EU Resettlement Plan
RCSIsmjperspective
Page 92 | Volume 9: Number 1. 2016
In addition to the Syrian refugees, large
waves of migrants and refugees from
other countries in Asia, Africa and the
Balkans are migrating to Europe in the
hopes of escaping conflict, bad
governance and poverty.
Migrant and refugee healthcare
In addition to political and economic concerns, migrant and
refugee health has become a growing issue. Its importance on the
global health radar has become evident: the “right to health of
refugees and other displaced people” was declared one of five key
areas of global health on which the M8 Alliance, a collaborative
network of academic institutions with 23 members from 16
different countries, called for action at the 2015 World Health
Summit (WHS) in Berlin.10 In the statement, the M8 Alliance
determined that the immediate health problems of refugees, and
the long-term mental health and well-being of these millions of
men, women, and children, were neglected areas of global health
that must be addressed in co-operation with refugee agencies and
the humanitarian sector.10 The following discussion is based on
major topics discussed at the Migrant and Refugee Health
workshop at the WHS 2015.
Infection and disease in refugee camps
One major concern associated with the overall health of migrants
and refugees is disease in refugee camps. The United Nations High
Commissioner for Refugees (UNHCR) was not prepared for a
refugee crisis of this scale. Thus, many refugee camps are crowded
and undersupplied, providing conditions for the onset of chronic
malnutrition and the spread of infection. Measles, hepatitis A,
leishmaniasis, poliomyelitis, meningitis and scabies, diseases that
have been virtually eradicated in developed countries, have spread
through vulnerable populations in Syria and refugee camps in
neighbouring countries.11 In addition, migration itself contributes
to higher infection rates as vectors move further, faster, and in
greater numbers than ever before. One route often used by
migrants is from East Africa, through Sudan and Libya, to North
Africa and eventually to Europe.12 This has led to the introduction
of microbes rarely seen in developed countries such as Borrelia
recurrentis, Rickettsia prowazekii, and Bartonella quintana, which
cause infectious diseases such as louse-borne relapsing fever
(LBRF), epidemic typhus, and trench fever, respectively.12 Thus, it is
important to address the issues of crowding and poor hygiene in
these camps to reduce the spread of infectious diseases.
Migrant and refugee access to healthcare
Even if migrants and refugees make it to their host country, there
are many challenges, both formal and informal, to gaining access
to healthcare. One formal challenge is legal access. While in some
European countries, migrants and refugees are fully entitled to
healthcare, other European countries provide minimal rights to
healthcare, which usually means that migrants and refugees may
only access emergency services.13,14 In Ireland, asylum seekers are
given medical cards for the period during which their application
for refugee status is being considered, which gives them access to
medical care free of charge.15 Individuals granted refugee status
are regarded as ordinary residents and fall under the usual rules for
entitlement to health services.16 In Germany, however, the law
restricts healthcare for asylum seekers to instances of “acute
diseases or pain”, meaning that only absolutely unavoidable
medical care is provided.16,17 In 2005, legal restrictions to access to
healthcare for migrants and refugees at the time of their arrival
were found to exist in 43% of European nations, compared to
healthcare available to citizens in the host country.18 These
countries included Austria, Denmark, Estonia, Finland, Germany,
Hungary, Luxembourg, Malta, Spain, and Sweden.18 In all of these
countries, except for Austria, the restrictions were entitlements to
emergency healthcare only.18 As migrant and refugee health
continues to be a growing topic of interest in global health affairs,
governments and politicians will need to reopen the discussion
about the legal extent to which migrants and refugees will be
ensured access to healthcare.
The United Nations High Commissioner
for Refugees (UNHCR) was not prepared
for a refugee crisis of this scale. Thus,
many refugee camps are crowded and
undersupplied, providing conditions for
the onset of chronic malnutrition and 
the spread of infection.
Cultural barriers to healthcare for migrants and
refugees
Informal barriers to health for migrants and refugees are largely
cultural and include inadequate language services and cultural
training. For instance, in Ireland there is a translation service called
Rotext; however, many healthcare professionals are not even aware
of it.19 A great deal can be done on a healthcare professional level
to improve language services for refugees and migrants by having
translators who can aid in the communication between the
physician and the patient. It is important that the translator does
not merely translate literally, but attempts to communicate some
of the feelings and nuances that would otherwise be lost in
translation, so that the physician can better serve the patient. It is
also critical to provide cultural training for healthcare professionals
working directly with migrants and refugees. The awareness of the
cultural determinants of health – including shared conventions,
understandings, practice, ideas, symbols and artefacts of a given
culture – has impacts on clinical care and informs clinical
practice.20 In addition, by providing language services and cultural
training for migrants and refugees, informal barriers to healthcare
can be reduced. In Germany, the government spent €2 billion on
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language training for migrants and refugees, a significant step in
reducing cultural barriers.21
Although the current refugee crisis presents many challenges for
European health systems, in many ways it can be viewed as an
opportunity for European nations to test the strengths and
weaknesses of their own health systems.
At the WHS 2015, the M8 Alliance took clear stances on the issues
of migrant and refugee healthcare in Europe. The M8 Alliance
asserted that refugees should have access to healthcare services
equivalent to that of the host population.10 Refugee policies should
prioritise the integration of new refugees into the new country’s
health and social systems.10 In addition to the immediate health
concerns discussed, they also declared it critically important to be
aware of the long-term mental health and well-being of the
millions of men, women and children that have been displaced. 
This will require action from a healthcare perspective as well.
Ultimately, the M8 Alliance feels that the migrant and refugee crisis
in Europe is a global health issue that requires the co-operation of
the international community and humanitarian sector at large to
respond in a co-ordinated manner.
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Introduction
The past few decades have seen extensive advances in surgical
techniques as technology adapts to the ever-demanding needs and
expectations of patients.1 One such medical advance is the use of
robotic arms and devices to assist in surgery, including one of the
most common surgical robots used in gynaecological surgeries, the
da Vinci® Surgical System (Intuitive Surgical, Inc.; Sunnyvale, CA,
USA).1 The Mayo Clinic defines robotic surgery as the “use of
advanced surgical tools to perform minimally invasive surgery for
complex procedures with increased precision, flexibility and control
compared to traditional surgical methods”.2 Initially, robotic surgery
was introduced to compensate for limitations in human dexterity
and to reduce surgical complications.3 However, a majority of the
potential benefits of robotic surgery are not being realised to the
fullest extent in Ireland as a result of the lack of acclimatisation into
surgical theatres.4,5 The high cost of operating and maintaining a
robot, as well as the extensive training involved, have often
outweighed the potential benefits for its utilisation in the wider
context of surgery.5 Therefore, the question arises as to whether the
use of robots in surgery is here to stay for the long term or is a
waste of money.
THE FUTURE OF SURGERY OR
a robotic waste 
of money?
SAMY BESHAY wonders if robotic surgery is here to stay, 
or just an expensive surgical white elephant.
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Cost-effectiveness analysis
The Health Service Executive (HSE), which runs the public healthcare
system in Ireland, has determined that the clinical benefits of robotic
surgery compared to traditional methods are negligible and not
cost-effective. Performing surgery using the da Vinci® Surgical System
has been found to consistently cost more than traditional
laparoscopic procedures,6 operating at an approximate cost of €1.45
million with hundreds of thousands more in annual maintenance fees
and licensing agreements.6,7 In addition to these high fixed costs,
robotic procedures are marred by increased operating times, which
increase the overhead costs of a hospital.8
The high cost of operating and
maintaining a robot, as well as the
extensive training involved, have often
outweighed the potential benefits for its
utilisation in the wider context of
surgery. Therefore, the question arises as
to whether the use of robots in surgery is
here to stay for the long term or is a
waste of money.
In the United States, the surgical system is used for a wide range of
operations in both urology and gynaecology.5,9-10 However, for
nearly all operations, robotic surgery consistently costs several
thousand dollars more when compared with local best practice.11 A
recent study published in the Journal of the American Medical
Association (JAMA) found that robotically assisted hysterectomy was
not more efficient compared to the traditional laparoscopic
methods, and the only notable variation between the two was the
substantially increased cost associated with the robotic
technology.12
In a prospective cohort study by Desille-Gbaguidi et al.,11 robotic
surgery was shown to cost 2.6 and 2.7 times as much as
laparoscopy for endometrial and cervical cancers, respectively. The
significant increases in cost associated with robotic surgery were
attributed to the time and labour of preparation, anaesthesia,
incubation and equipment set-up, which increased overhead costs
and reduced the availability of the operating room,11 with a
non-significant reduction in average hospital stay. However, upon
performing further analyses, it was shown that reducing hospital
stay duration by one day in a given patient, and performing two
daily operations using the robot, may allow robotic surgery to be
the most cost-effective treatment option.11
The increased cost of robotic surgery is echoed in a case-control
study by Sarlos et al.13 in the context of hysterectomy. Another
study found that robotic surgery increased operating time, leading
to an increase of approximately €2,000 when compared to
laparoscopy.14 While Desille-Gbaguidi et al. reported set-up time to
be a major contributor to the cost of the da Vinci® Surgical
System, Sarlos et al. determined that preparation time at their
practice had decreased with each successive surgery.12,13 With
improved training, costs associated with set-up may be
minimised.14 The robotic system reportedly offered surgeons better
ergonomic control and a wider range of motion when compared
to current gold standards, and greater perceptual awareness, but it
was disadvantaged by preventing access to the patient during the
procedure.14
Surgical training involved with robotic technology
While experienced surgeons cannot readily use a robotic system,
training curricula that integrate didactic and experiential sessions
exist for all surgical disciplines, particularly within gynaecology and
urology.15 Expertise-based trials have shown that the learning curve
for experienced open and laparoscopic surgeons is approximately
eight to 12 cases, assuming a completion of 100 previous
surgeries.16 For a naïve surgeon, it is estimated that 80-100 cases are
needed before sufficient expertise is achieved with the robotic
system.15 Hanly et al. had also demonstrated that with more
experience, set-up time decreased by 30% and operative time
lowered by 20% at their practice, minimising the elevated overhead
costs associated with a robotic surgical system.17 Moreover,
specifically training an Irish surgeon on the robotic technologies is
arduous and tedious, often requiring a visit overseas to the United
States for training in multiple facilities.18 The surgeon will also require
mentor supervision during his or her first 15 to 20 procedures with
the robot to gain the essential knowledge and expertise, after he or
she returns to Ireland, a process that can take several months or even
years.18 This not only decreases the amount of surgeries that an Irish
surgeon will perform, but also increases waiting times and limits the
amount of surgeons available at a given hospital.18
Context of Irish healthcare – 
integration into Irish hospitals
The implementation of robotic surgery has been severely limited in
Ireland where there are only three systems in the entire country:
one actively used in the public healthcare system at the Cork
University Maternity Hospital8 and two in the private sector.7,18
These surgical robots are primarily used in gynaecological care in
hysterectomy procedures. Regardless of whether or not the use of a
surgical robot has improved patient outcomes in gynaecological
surgeries, it is undoubtedly a heavy burden on the publicly funded
healthcare system in Ireland. A study by Teljeur et al. found that in
Ireland, the cost of a robot-assisted hysterectomy is nearly €3,300
more than the existing mix of both open and traditional
laparoscopic surgery.7
In countries such as the United States, where the da Vinci® Surgical
System is thriving with over 2,000 robots in use, it is simple to
maximise a robot’s use.19 A high volume of patients ensures that
the substantial investment cost of the robot and its lifespan are
capitalised upon and that the costs of licence agreements are
compensated for. However, in smaller countries such as Ireland,
where the demand is much lower and there are significant constraints
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on the public healthcare system, it is much more difficult to capitalise
on the investment in a surgical robot. The single surgical robot in the
Irish public healthcare system is used primarily for hysterectomies and
averages around 100 cases per year, a quarter of the number of cases
a typical robot in the United States would see.12
Robotic surgery in Ireland has
not fully developed and there is 
very little infrastructure to
support its development.
Possible suggestions to increase this number would include allowing
the robot to perform non-gynaecological procedures, or putting a
referral system in place that allows tertiary facilities to access the
robot. In either sense, robotic surgery in Ireland has not fully
developed and there is very little infrastructure to support its
development.7
Conclusion
Although robotic surgery may improve the functional design and
visualisation for surgeons, in the patient-centred world of medicine,
if it does not equate to more efficient outcomes, it is not practical to
use in the wider context of surgery. Moreover, in times of scarce
resources, healthcare investments should be directed towards
interventions that demonstrate both positive patient outcomes and
cost-effectiveness. As Prof. Lord Darzi, an RCSI graduate and
world-renowned surgeon and inventor of surgical methods, once
stated regarding the efficiency of robotic surgical techniques:
“Healthcare systems all over the world are facing completely
different pressures compared with 20 years ago … the whole way in
which we provide healthcare has got to change. The world is crying
out for low-cost, high-impact technologies that can be employed
widely across the globe”.20 For the time being, it is evident that
more research is required before robotic surgery is fully integrated
into the Irish healthcare system. As it stands, robotic surgery is,
indeed, a waste of money.
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Introduction
In an ever-evolving healthcare environment, industrialised countries
are constantly faced with new and difficult challenges. Foremost
among these is the changing age profile of western populations.
Against this backdrop, there is a strong argument for a single
specialty assuming the role of perioperative physicians, a concept
much discussed in anaesthetic conferences. There are pros and cons
to anaesthetists filling the role – from a healthcare perspective and
from the perspective of the specialty of anaesthesia. However, their
unique skillset makes them ideal candidates, if certain practical
barriers can be overcome.
An ageing population
In most industrialised countries life expectancy is increasing, while
the number of live births is decreasing, with the result that in these
countries the population is ageing.1 The most recent census showed
that Ireland is no exception, with an increase in the number of
over-85s and a relative decrease in the under-14 category.2 The
United States faces a similar situation.3
Because people are living longer with existing chronic conditions,
the ageing patient tends to have more comorbidities, making their
management more complex. Patients who are higher risk due to
their age or comorbid diseases have the highest mortality rates.4
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This results in a rise in the number of high-risk patients
presenting for surgery. To complicate matters further, there is
increasing pressure to reduce the number of surgical inpatients
and to perform more surgical procedures as day cases.5,6
Postoperative complications have been shown to negatively
impact long-term survival more than either comorbid disease or
intraoperative adverse events;7 therefore, it is imperative that
perioperative care also extends for a period beyond discharge. In
this context, it is clear that patients need optimal preoperative
management in order to maximise their chances of a positive
outcome.
On this background, there is a strong argument for a single
physician taking the lead in the care of the patient, from the
decision to undergo surgery until a specified time postoperatively.
Mantz et al. (2010) observed that “perioperative care may have a
major impact on long-term postoperative mortality and major
complications in surgical patients by decreasing the rate of
individual decisions”.8 This is the proposed realm of the
perioperative physician.
Streamlining of medical practice in the
perioperative period is reported to
improve “co-ordination and management
of surgical patients and has been shown
to increase quality, reduce complications,
... and improve the patient’s perception 
of the surgical experience”.
The perioperative physician
The perioperative physician takes charge of the patient from the
time of the decision to have surgery, managing the patient
through the preoperative phase, in which the health of the
patient is optimised and comorbidities are controlled as best as
possible, and then through the surgery. The same physician
follows up after discharge to monitor recovery, ensuring that day
cases do not become re-admissions and that postoperative
complications are kept to a minimum. This specialist is not a lone
doctor, but the co-ordinator of a multidisciplinary team,
membership of which will vary based on individual patient needs.
There is evidence that a single co-ordinator for the perioperative
period improves the co-ordination and management of surgical
patients, and has multiple benefits to the patient and hospital in
terms of cost reduction, positive outcome and patient
satisfaction.9,10 In addition, a single specialty performing the role
leads to standardised practice, which results in fewer mistakes.11
This streamlining of medical practice in the perioperative period
is reported to improve “co-ordination and management of
surgical patients and has been shown to increase quality, reduce
complications, increase the efficiency and cost-effectiveness of
perioperative care, and improve the patient’s perception of the
surgical experience”.10,11
An example of this process in practice is the American Society of
Anesthesiologists’ Surgical Home model, in which a single physician
co-ordinates a patient-centred, multidisciplinary team to guide the
patient throughout the entire surgical experience.10 Reviews of this
model of care are heartening in that they report positive outcomes
in many areas, including patient satisfaction and cost reduction.11
Longer hospital stays increase the healthcare burden in a number of
ways. The longer a patient remains in hospital, the higher their
chances of developing a hospital-acquired infection, which in turn
increases mortality.12 Increased length of stay for an individual
patient reduces the amount of bed space available for new patients,
as well as increasing the financial burden on the healthcare system.
Limiting the amount of time patients spend in hospital by
proactively avoiding preventable complications reduces the financial
burden on healthcare systems, as patients require fewer
re-admissions and, ultimately, fewer hospital days.7,8 Various
specialties have already offered their services privately as
perioperative physicians.13 Here we will discuss the merits of the
anaesthetist performing the role.
The anaesthetist as a perioperative physician
The anaesthetist already takes part in perioperative medicine.14 While
the surgeon’s primary concern is dealing with the disease process, the
anaesthetist’s concern is keeping the patient alive for the duration of
surgery and managing the patient’s physiological response to the
insult, both intra- and postoperatively. The anaesthetist already needs
to be intimately familiar with the patient’s medical history in order to
provide optimal analgesia and to predict possible complications
during surgery; becoming involved in the care of the patient from an
earlier stage and taking responsibility for their management heightens
pre-operative knowledge of the patient and their medical history. This
in turn aids the anaesthetist in avoiding complications intra- and
postoperatively, while making them the most suitable physicians to
undertake post-surgical follow up.
Anaesthetists’ roles as intensivists make them ideal candidates. On a
daily basis they manage very ill patients with multiple comorbidities,
with the result that they have a wealth of experience managing
complex cases and optimising physiological function in patients
who require intricate medical management. As part of this role they
liaise with members of virtually every specialty in the hospital,
managing patients as part of multidisciplinary teams. The
perioperative physician is merely an extension of this role. In
addition, some feel that the unique training, skills and experience of
anaesthetists mean that they are natural candidates for the role,
more so than any other specialist.13 They already have crucial
experience in risk assessment and quality improvement,15 areas vital
to the field of perioperative care; the importance of risk assessment
in particular cannot be overestimated, and has been highlighted as
a means of minimising surgical risk through anticipation of
patient-specific complications and optimisation of organ function
prior to surgery.16
Advocates for the concept of anaesthetists expanding to the role of
perioperative care feel that they should embrace the role,17 and that
not to do so would be to limit the scope of practice and sphere of
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influence of the anaesthetist in the medical environment.13 On the
other hand, if anaesthetists were to take on the role of perioperative
physician, it could mean a loss of focus in their current role as
anaesthetists, intensivists and pain managers, potentially detracting
from care in those areas. Compounding this, a recent report by the
College of Anaesthetists of Ireland revealed significant shortages of
manpower at all levels, from specialist anaesthetist trainees to
consultant, and an over-reliance on non-training NCHDs to run
services.18 Expanding the role of an already stretched service to
include broader perioperative care may place too much strain on an
already overloaded specialty. Anaesthetists would add significant
value to the healthcare service as perioperative physicians, but only
if sufficient resources were made available to make further positions
available at all levels.
Practical issues
There are a number of practical issues that could come into play in
expanding perioperative care. Clear definitions of where the role
begins and ends would need to be agreed upon in order to
optimise patient care. Follow-up of patients postoperatively by the
perioperative physician is also a difficult question, particularly in the
ambulatory setting, as the speed of recovery is bound to be quite
variable. This could create an unsustainable care burden if a large
number of patients required extended postoperative management.
The importance of developing objective criteria and the need to
develop evidence-based guidelines in order to receive certification,
are crucial to developing the role.10 Currently, there is no training
scheme or college that covers the full scope of the perioperative
physician.13 It is necessary to define what core knowledge, skills,
and experience are expected of the perioperative physician, and at
what stage of the training, from basic to advanced, the
competencies should be achieved.13
Conclusion
In the context of an industrialised country with an ageing
population and pressure to increase the number of surgical
procedures as day cases, there can be little doubt as to the value a
perioperative physician would provide to all parties involved. There
are compelling arguments for anaethetists to take on this role, not
least as it would be an expansion of their current role in surgical
care. There are a number of practical issues that would need to be
resolved in order to facilitate incorporation of the role into the
perioperative process, but it is certainly an idea that merits further
exploration.
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Introduction
Marijuana, also known as cannabis, consists of dried leaves, stalks,
flowers and seeds of the Cannabis sativa plant.1
∆9-Tetrahydrocannabinol (THC) and cannabidiol are the primary active
components in cannabis and are thought to act on cannabinoid
receptor sites CB1 and CB2 to produce psychoactive effects on mood,
perception and psychomotor performance. Cannabis plants contain
over 60 cannabinoids, which act additively, synergistically, or
antagonistically with THC and cannabidiol, modifying the drug’s
effects.1,2 To determine whether legalising marijuana could provide
adequate funding for addiction services, this paper discusses available
literature pertaining to the financial benefits, health implications and
societal impact that legalisation has, paying particular attention to
Colorado, USA, where the effects of legalisation can be observed and
used to estimate the effect it would have in Ireland.
Medical uses
Claims exist that cannabis can effectively treat numerous diseases; some
of the potential uses include treatment of muscle spasticity in multiple
sclerosis (MS), as a neuroprotective agent against neurodegenerative
diseases, in the treatment of chronic pain, in the treatment of cancer,
and in a palliative setting.3-12 The illicit uses of marijuana are thus not the
only considerations when looking at the issue of legalisation.
Reducing spasticity in MS sufferers with cannabis has had positive results
in placebo-controlled trials, but is accompanied by acute cognitive
effects as well as dizziness, nausea, headache and fatigue.3-5 Studies of
patients with MS using cannabis also showed a decrease in cognitive
performance compared to non-users.6,7 In an attempt to circumvent side
effects and enhance therapeutic effects, oromucosal and oral
preparations of THC and cannabidiol have been developed to treat
muscle spasticity in patients with MS, and have shown positive results
clinically.8 In Ireland, MS advocacy groups successfully campaigned for a
change in the Misuse of Drugs Act 1977 to allow cannabis-based drugs
to be made available by prescription.9,10 Using cannabinoids as
neuroprotective agents has shown potential in vivo and in vitro for
epilepsy, and may be effective in treating neurodegenerative diseases,
including Huntington’s, Parkinson’s, and Alzheimer’s diseases.4,11,12 Use of
cannabidiol and other cannabinoids that act as CB2 receptor agonists
could inhibit the inflammatory processes involved in neurodegenerative
diseases.13 In Alzheimer’s disease, there is evidence that cannabidiol
prevents degenerative pathways that lead to neuronal death; however,
these patients may be concerned by the prospect of cognitive decline as
seen in MS trials.6,7,14
The use of cannabinoids as anti-proliferative and apoptogenic agents
has shown promise against a variety of tumour types. There is some
evidence that cannabinoids can specifically target tumour cells,
making them exceptionally desirable for use as anti-cancer agents.
Palliative uses of cannabinoids in cancer and other life-altering
conditions increases the profile of cannabis-based drugs as potential
therapeutic agents.15 Studies investigating the use of marijuana to
treat pain are subject to intense scrutiny.16,17 Some conclude that there
is little or no benefit in using cannabis over conventional pain
medication and that the psychological side effects are unacceptable;18
however, cannabinoids have the potential to act synergistically with
opiates and benzodiazepines to allow for a reduction in doses, limiting
the associated side effects of these drugs.4
Although not a comprehensive list of the possible medical indications
of marijuana-based medicines, the above examples illustrate the
potential benefits that may exist. Further research is needed to isolate
and fully develop selective molecules targeting the endogenous
cannabinoid system to balance therapeutic effects with side
effects.4,11,12,18
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Impact of substance use
In Ireland, arguably the most important public health concerns are
associated with the use of alcohol and tobacco, both legally
available to the adult population. The cost of alcohol to Irish
society is in excess of €3.5 billion per year, including €1.2 billion
across a range of healthcare services. Alcohol is the most common
substance for which addiction treatment is sought in Ireland.19 Just
as with alcohol, driving under the influence of cannabis is
associated with a riskier driving style and increased reckless
behaviour;20 therefore, legalisation of cannabis could easily result in
an increase in dangerous driving and road traffic accidents, with
an associated increase in hospital admissions. The use of tobacco
and marijuana are strongly linked in young people, with use of one
increasing the likelihood of use of the other.21,22 Smoking is a
major cause of morbidity, costing those who smoke an average of
10 quality years of life, and is responsible for one in 10 deaths.23
The average treatment cost in Ireland for a smoking-related illness
is €7,700, with an estimated health expenditure on
smoking-related illness of €500 million in 2009.24 Studies show
that young adults perceive quitting smoking tobacco preferable to
quitting marijuana, and that the desire to quit one does not
correlate to the desire to quit the other.21,22 The likelihood of
smoking tobacco is increased if one’s mother smoked while
pregnant, and there have been suggestions of increased
probability of marijuana use due to enhanced receptor expression
in the foetus, which contributes to addiction in later life.25 The
propensity for users to continue using cannabis, and for this use to
increase the likelihood of future generations using cannabis, is a
cause for concern, as it could potentiate a rise in consumption
levels over time. Studies show that of those who experiment with
marijuana, 9% become addicted, increasing to almost 17% if
marijuana use begins in the teen years, and up to 50% if it is
smoked daily. 
Quitting is made more difficult due to the low cost and high
availability of the drug, even though withdrawal is less severe than
with other drugs.26-28 A survey of young people aged 15 to 24 in
Europe discovered that 42% of Irish participants had used
cannabis, with an EU average of 31%. Some 72% of Irish
participants considered it easy to obtain cannabis, and 25%
believed that regular cannabis use posed no health risks.29
Marijuana use has been shown to influence the academic
achievement of users and is linked to impaired cognition, memory,
and problem solving, lower levels of life satisfaction, lower IQ (with
frequent adolescent use), and increased risk of chronic psychosis
where predisposition exists.6,26,27,30 Although it is difficult to
ascertain the far-reaching effects that some of these impairments
could impose, it is certain that there would be direct demand on
the healthcare system as a result of increased prevalence of
psychosis in the population.
Current addiction treatment
In Ireland, the three substances for which addiction treatment is
sought most are alcohol, marijuana and heroin. In 2011 cannabis
overtook heroin as the second most sought addiction treatment.19
Treatment for alcohol addiction consists of multi-tiered
intervention strategies, ranging from identification of the problem
and providing advice to reduce harm, to provision of specialist
healthcare from multidisciplinary teams. Due to the complex
nature of alcohol addiction, and high levels of comorbidity that
accompany it, treatment costs escalate as severity increases.
However, there is evidence that alcohol addiction treatment results
in savings to the healthcare system of five times the amount that is
initially invested.31 Quitting marijuana without formal treatment is
associated with increased use of alcohol and tobacco, but not with
uptake of new substance use.32 Simple interventions such as
motivating users to quit by highlighting usage-related problems
has been shown to significantly increase the chances of a
permanent change in behaviour in a study of young women aged
18 to 24, particularly where there have been previous attempts to
quit.33 It is reasonable to assume that such interventions would
produce similar effects in males. The potential for this form of
intervention to have low associated costs, and for it to be available
from frontline services such as GPs and addiction helplines, has
considerable appeal.
Potential revenue
Financially, there is the potential benefit of tax revenue from the
legalisation of marijuana. In 2012, cannabis herb, plants, and resin
received by the forensic science laboratory in Ireland for testing
was valued at €71.8 million, accounting for over 60% of the value
of controlled drugs reported by the laboratory.34 Annual costs for
tackling drug crime in Ireland are approximately €30 million, only
a fraction of this being spent on marijuana.35 In the 2014 tax year,
the state of Colorado generated $34.8 million USD through
application of sales taxes and licensing fees for medical and retail
marijuana.36 In 2011 Ireland had a population of 4.5 million
people; similarly, in 2010 Colorado had an estimated population of
five million. The comparable demographics in terms of population,
age and gender profiles mean that it could be possible to generate
similar revenue in Ireland.37-39
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Results of legalisation
Direct observation of the effects of legalising marijuana is an invaluable
tool in determining whether it is advisable to legalise marijuana in other
areas. Since the legalisation of marijuana in Colorado, the perception of
risk associated with the use of marijuana has decreased compared to
states where medical marijuana is not available.40 The changing
attitudes towards risk are seen in the increase in levels of risky use,
particularly among males. Availability of the drug legally has increased
the odds of use to 1.92 times the usage seen in prohibition states.
Before legalisation of marijuana in Colorado, the number of fatal car
crashes where the driver tested positive for marijuana was decreasing,
but it began to increase after legalisation. No equivalent increase was
seen in prohibition states.41-43 In Colorado the use of marijuana increased
after commercial legalisation; however, introduction of medical
marijuana resulted in no significantly increased use due to limited
patient numbers qualifying for prescriptions. The usage by adolescents
was also seen to decrease where medical marijuana was available,
possibly due to an association with the chronically and terminally ill.42,44
Conclusion
Legalising marijuana to pay for addiction treatment is a stopgap
measure. Development of cannabis-based drugs that minimise
psychological impairment and psychoactive properties has considerable
appeal, and creating avenues for research and regulation is preferable
to legalisation permitting herbal preparations of unknown
concentration. Legalising marijuana for recreational use introduces an
addictive and intoxicating product, which impairs cognitive function,
to the general public. Significant costs are already incurred by society
due to the use of alcohol and tobacco, and as such the introduction of
a new addictive agent makes little sense. Factoring in the rising
requests for cannabis addiction treatment, which is already the second
most requested addiction treatment in Ireland, arguments for
legalisation are significantly undermined, with the prospect of
commercial availability threatening to further exacerbate the problem.
Although the revenue that would be generated is potentially
significant, a fine balance would be required to prevent the associated
health and safety concerns, rendering any income generated obsolete.
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How did you get involved in sports medicine inthe
first place?
I suppose sport has always been a passionate interest; it’s something
I have always wanted to work in. I studied in Trinity and at the time
our anatomy professor, Moira O’Brien, was one of the pioneers of
sports medicine in Ireland. At that stage there was no real
run-through sports medicine training so her advice to me was to
choose something else – be that orthopaedics, emergency medicine
or general practice – and to do sports medicine on top of that. So
that’s what I did: general practice training, and then parallel to that
I did my sports medicine training in Bath University. After I stopped
playing rugby I started helping my local club, then the Ulster U21s,
then the Ireland U18s. Things have kind of just snowballed as the
years have gone on. I suppose I now have what would be called a
portfolio career; I still do some general practice, but sports medicine
has become an ever-increasing part of my job.
So you played rugby until you were finished with
your GP training?
Yeah, I trained in England and then came back to Northern Ireland
and was doing locum GP work for a couple of years, and at that
stage, well, the rugby packed me in as much as I did it. It became
too difficult managing the demands of the job, training and most of
all the pain post games!
What makes sports medicine different from other 
fields you might also have an interest in, such as 
general practice?
It’s a relatively new discipline. I think we are still finding our feet a bit
on how we position ourselves. What’s happened in the UK is that a lot
of what developed as sports medicine is now repositioning itself as
‘exercise medicine’, because I think that’s where we will have the
population benefit. The benefits of exercise are so well documented,
and similarly, lack of physical fitness is associated with so much
morbidity, that that is where the big ‘wins’ are to be had. The difficulty
is influencing those in decision-making positions because it probably
seems less pressing than a lot of other health priorities. I think that to
have a cohort of well-qualified doctors there to advise not just on
sports injuries and musculoskeletal medicine, but also on the wider
picture, such as exercise in people with chronic conditions such as
diabetes, asthma, or cardiovascular disease, is essential.
So you think it’s moving in a health promotion kind 
of direction?
Yes, health promotion, but also for someone who has a chronic
medical condition: what are they able to do? How do they fulfill
their potential? Similarly then, in terms of exercise for the nation:
how do we advise on that? Just simple things like the fact that girls
reach peak bone mass by age 13/14 and that is done through
skeletal loading, so should we have primary school children
bouncing up and down on their feet for five minutes every
morning? Simple little interventions like that. ... It essentially covers
all of medicine. Then you have team medicine, which covers
everything as well, so even within sports medicine there are loads of
specialist areas, which is an attraction.
What do you think about the issues surrounding
concussion?
It’s changed unbelievably quickly. I would have had a keen interest
dating back to 2007/2008 but a lot of that was watching what was
happening in the States – they are probably three or four years
ahead of us in what they’ve experienced with regard to concussion.
In many ways the explosion in interest has been a really good thing
because the media interest has driven the public interest in it. We
have been able to do a huge amount of work trying to educate
people and I think it’s now on people’s radar and they are willing
and interested to learn more about it. When we started our
education initiatives back in 2009, really very few people came
along to anything we tried to do while now, regularly, we’ll have
one hundred plus people at our workshops, so that’s been great!
The evidence would say that we’ve become very much better at
‘recognise and remove’, and our threshold for diagnosis has
dropped significantly. Players are now reporting symptoms earlier
because they realise how important it is that they report any
symptoms they are experiencing – even seemingly trivial or
short-lasting ones. Also, coaches, parents and teachers are
becoming more vigilant, looking out for signs of concussion and
picking these up, so we’re becoming good at that. And I think we
Committed to sport
DANIEL O’REILLY interviews Dr Michael Webb, Medical Director of Ulster Rugby.
Dedicated to the team
Dr Michael Webb is the Medical Director of Ulster Rugby and an assistant team doctor to the Ireland senior rugby
team. He is the current Chairman of the Pro12 Doctors Group and has worked extensively as a team doctor
within rugby for both the Ulster and Ireland teams at all levels since 2000. He is also a part-time general
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have also gotten really good at keeping people out for the
requisite period of time. Actually, one of the issues we’ve come
across now is the medical clearance to go back to sport, and as a
medical community we are lagging behind a little bit. One big
concern is that concussion doesn’t become such a divisive topic
that children or their parents get put off participation in sport.
Because the benefits of contact sport so far outweigh any potential
risks. It would be very sad if people were turned away from sport
because of a perceived risk of long-term problems that in real
terms is relatively low. And certainly the risk now would seem to
be lower than it was five years ago because the condition is likely
to be managed so much better now than it was even then.
Do you think it will change how contact sports 
are played?
We are already seeing a change in how these sports are played.
It’s interesting – Brian McLaughlin (Ulster Head coach
2009-2012) took a session in my local club this year with
U12s/U14s and he was talking about how guys came to the ruck,
and he was talking about injury prevention. He was saying: “You
lead with your shoulder and your hip and keep your head well
out of the way”, so that was really fascinating for me to see.
Coaches are already taking it on board. That is one big positive
thing.
I also think there is an onus on the lawmakers of sports to remain
aware of trends and keep on top of that, and implement good
evidence-based rule changes. I am sure that all sport will
continue to evolve with regard to safety. In fairness, sports realise
that for the PR side of each individual sport, player welfare is key.
... I know certainly within world rugby, every meeting they have,
player welfare is the first thing on their agenda. And that is being
driven not only by concussion but also by the desire to make the
overall game as safe as possible.
Do you think rugby is at risk of diminishing popularity?
Rugby is still a contact sport, and that’s why a lot of people like
watching it. It’s also why a lot of people like playing it as well. I
don’t think you need to disbar contact completely but there is no
point in having any needless risk. I think how you prepare for
games is important, certainly how you train. I don’t think there is
any point doing hours and hours of pointless contact training –
straight away you can drop your exposure to risk of injury way
down there. There are lots of interventions you can introduce
that, when put together, can make a big difference.
Do you think strength and conditioning has changed
the nature of injuries?
Statistics would actually show that serious injuries in rugby
haven’t gone up, which almost belies the public perception. I
think over the past 10-15 years we have become better at
managing injuries, and perhaps if we hadn’t done that then
maybe the injuries incidence would have risen a bit. There’s no
doubt that players have become bigger and faster, but that’s
probably maxed out now. The World Cup has taught us a lesson
– if you look at New Zealand, they have taken the view that they
are looking to be a little bit more mobile and lose a bit of the
excess weight. For me, that’s really exciting and that’s the way
rugby should go.
With the doping scandal in the IAAF, do you think that’s
changing the way you do your job as someone who is
involved in sports medicine? Do you think it is going to
be more of an issue?
It’s a big part of our job. My biggest fear with our professional
players isn’t deliberate doping, it’s guys making an inadvertent
mistake over something or another – taking a supplement, or
taking a cough or cold remedy with pseudoephedrine in it. That’s a
bigger concern. I think within rugby in Ireland there is no evidence
of any sort of systemic doping. However, you’d need to be naïve to
say there’s no risk. We know that within the general population
there is quite a prevalent use of anabolic agents for aesthetic
purposes. These are not professional athletes. Clearly if there is a lot
of this in local gyms, the fear would be that 16-, 17- or 18-year-old
kids, who want to be bigger to be a bit better at rugby, could make
poor life choices and be tempted to take anabolic or other banned
agents. It’s so important that this cohort are well educated about all
the potential risks of getting involved in this, so that they
understand why it would be a huge mistake to do so.
What do you think is coming down the line as far as
sports medicine as a career is concerned?
I think a lot of it is probably hampered by health economics and
the problem is that, for example here in Northern Ireland, the
health budget is going up every year but it’s not keeping pace with
inflation and currently the NHS is really struggling. It’s hard to
position yourself against cancer services or children’s heart services,
and there is an endless list of very deserving medical causes, who
are all fighting for the same piece of the pie. There is a problem
there for sports medicine to develop in any big way. I think
hopefully it can continue to steadily evolve. We need policy makers
who have the vision to see the benefits of prevention that will come
with a fitter population.
And are you involved in any research yourself at the
moment?
We have a schools injury audit running up here where we are
following all our senior rugby-playing schools. This is the second
year of the study. The research group encompasses some
orthopaedic surgeons and sports medicine doctors in Belfast and
researchers from the University of Ulster. Ulster Rugby and the IRFU
are part funding it along with support from the MITRE charity. It’s
an injury audit of schoolboy rugby players – and again, we talked
about it earlier – and the aim is to establish the injury patterns
within the game so that we can use good, objective evidence to
inform lawmakers who want to make the game as safe as possible.
It’s one of the biggest studies of its kind that’s ever been done in
the world and already we’ve gleaned some really interesting
information, which is very exciting.
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In April of 2015 an earthquake struck the small mountainous
country of Nepal, killing over 9,000 people. The government was
going through a political upheaval and the $4.1 billion USD
earthquake reconstruction fund sat in the bank, while thousands of
families faced the winter with nothing more than a sheet of plastic
for shelter.1 Although the Nepali people are resilient and resourceful,
the situation was bleak for many. Nepal was my home for 12 years
while my dad worked as a missionary doctor in a rural hospital. In
May, I had the opportunity to go back for two weeks with my dad
and brother to lend a hand in the rebuilding process.
Rebuilding
When we arrived in Kathmandu, we met with friends who work for
an NGO, Human Development Community Services (HDCS), which
my dad used to work with. HDCS had been working on earthquake
relief for several weeks, so they were able to offer insight into the
current situation. Later that morning, we headed off toward Besi
Sahar, a town eight hours from Kathmandu, close to the epicentre
of the quake. When we got there we met with the HDCS hospital
administrator and the mayor of the district. They advised us to go to
a village close to the epicentre, where 30 houses had been
completely destroyed.
Two weeks after the earthquake, there was not a large need for
medical aid or food; the main issue was shelter. The earthquake
destroyed over half a million homes.2 Families slept under tarps, in
chicken coops or anywhere that provided shelter from the elements
and fast-approaching monsoons. My former high school track and
field team had raised some money for earthquake relief, with which
we bought roofing tin and building supplies for all 30 houses in the
village. This all took several days, but soon we were able to load up
a truck and head off, arriving after several hours on dirt roads. The
destruction was widespread and devastating, and although the
newer brick and cement houses had survived, almost all of the mud
and stone houses had collapsed. Distributing the supplies took all
day, but everyone in need got enough to build a temporary house.
The next morning a man asked for help to build a home that would
survive the monsoon and the winter. Until then, his wife and
12-year-old daughter had been sleeping under a tarp. It took us two
days to put up his bamboo house, which will last several years until
they can rebuild their own house.
Reflection
Being able to give back in a small way to the place that helped to
shape who I am today was an amazing opportunity. It reminded me
why I want to be a doctor, and of the great needs of many around
the world.
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Turkey is one of the biggest hosts for Syrian refugees, with 1.9
million people seeking refuge there in 2015.1 This became very
apparent to me in August 2015 when I was on holiday there. I
contacted a humanitarian NGO that is very active in aiding Syrian
refugees, the International Blue Crescent (IBC) Relief and
Development Foundation. I was assigned to a city called Gaziantep,
where many child-friendly spaces (CFS), and primary and secondary
schools, have been opened for Syrian refugees. Together with its
German partner Malteser International, IBC is running a temporary
field hospital (TFH) in Kilis, a town 3km away from the warzone in
Syria.
Growing up in Gaziantep
I accompanied a Syrian psychologist to a CFS in Gaziantep. This
particular programme ran a morning and afternoon shift five days a
week, with approximately 40 children in each, divided based on
age. Learning exercises with a focus on psychosocial support were
organised to educate these children, whose education had been
interrupted by the devastating civil war. Group activities and games
focused on expressing emotions, making new friends, building
self-confidence, and showing artistic skills and other talents. The
teachers attempted to convert the fear and anxiety these children
were experiencing into hope for the future. Although interacting
with children was a tremendous experience, it was also an
emotionally challenging one.
Crisis in Kilis
Initially, I took a public minibus from Gaziantep to Kilis, but due to
the proximity to the Syrian border the IBC arranged for a car to
drive me to the hospital. The TFH, with a capacity to accommodate
48 inpatients, receives conflict-affected patients for postoperative
care. Intensive physiotherapeutic care of war-injured patients is
provided, in addition to psychosocial support for patients and
relatives. The determination and faith of patients, particularly in the
physiotherapy room, was truly admirable and eye opening.
Patients were surprisingly open to sharing their stories. One woman
had been injured by barrel bombs dropped by air forces. She lost
one of her three daughters when her house collapsed, but was
miraculously able to deliver her fourth baby at the TFH despite
injuries to both her legs. The TFH provided her with much-needed
medical and psychosocial support in the form of daily consultations
and stress-relieving exercises. Another story that was particularly
touching was that of a 10-year-old boy who had lost his arm in the
war. This extremely smart and sociable young boy was attending
school to learn to write with his left hand in order to fulfil his dream
of becoming a doctor, but expressed a desire for a prosthetic arm to
be able to play with his siblings again.
Reflection
Apart from getting a closer view of the hardship associated with
such crises, and an opportunity to help where possible, this was also
a valuable learning experience, as I had the chance to practise in my
mother tongue of Arabic, improve my communication skills, and be
supervised in performing some basic medical procedures. This
experience also opened my mind to Turkish culture and the
generosity of Turkish people and, importantly, emphasised the role
medical professionals play in such trying conditions.
Fostering
hope
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When I first considered travelling to Shanghai, with its population of
14.35 million people,1 I wondered how the medical system coped
with the massive population. Given that breast cancer is one of the
world’s top ten causes of death for women and, together with
cardiovascular and cerebrovascular disease, contributed to 70% of
all female Chinese fatalities in 2010, I decided to observe breast
cancer patient care.2,3
I was placed in the Comprehensive Breast Health Center at the
Ruijin Hospital in Shanghai, where I had the opportunity to shadow
the chief resident of breast cancer surgery team one.
Multidisciplinary team meetings
Each morning began with patient rounds, followed by
multidisciplinary team meetings, where – to maximise efficiency and
deal with time constraints – each physician used a tablet to cast a
vote for the next treatment for the specific patient case. Treatments
receiving the highest number of votes were employed.
Operating theatre
The Ruijin Hospital has an entire floor of operating theatres
dedicated to breast-related surgery, ranging from mastectomies to
central line insertions and breast reconstructions using silicone
implants. Surgeons performed up to five to six procedures per day
and discharged patients back to the ward, where medical students
(including myself) performed dressing changes and monitored for
postoperative infections or drainage tube complications. Typically,
patients remained for up to three days before being discharged
home.
Outpatient clinic
The chief resident and I worked in a small room with connections to
other rooms, facilitating communication with other physicians.
Patients returning for bandage changes saw a nurse or medical
student, then had a consultation with the physician. As the patients
came into the room, they handed the physician their medical and
payment card before quickly explaining their medical concern.
Breast examinations were completed while the patient was standing
and lifting their shirt, not lying down. The entire hospital visit often
lasted less than five minutes.
Reflection
Seeing how the Shanghai physicians efficiently handled an
overwhelming number of patients (and their families) was an
incredible experience. During a consult, other patients or family
members often waited just outside, or even entered the room and
bombarded the physician with questions and concerns. I was not
accustomed to this sort of interaction, but the chief resident was
extremely patient with the women and often handled multiple
appointments at the same time. Additionally, the physicians and
students all spoke English and were eager to teach and answer any
questions, demonstrating an abundance of grace, patience and
understanding, which I wish to emulate in the future.
The mass
approach
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Neurosurgery is often seen as an impossibly technical and emotionally
distant specialty. Two surgical memoirs produced on either side of the
Atlantic give an insight into the challenges and rewards of a
neurosurgical career. Do No Harm: Stories of Life, Death and Brain Surgery
by British neurosurgeon Henry Marsh describes his meandering career in
hindsight as he prepares to retire. When the Air Hits Your Brain: Tales from
Neurosurgery by Frank Vertosick Jr is an autobiographical take on
becoming an American neurosurgeon, from his time as a medical
student through to the end of his residency. While both books address
the same central theme, their tone and approach could not be more
different.
Matter-of-fact
In Do No Harm the style is matter-of-fact and anecdotal. Each chapter is
named after a different neurosurgical condition, wherein Marsh outlines
his own experience with managing the disease and weaves elements of
his personal and professional life into his factual accounts of each case.
These can be harrowing, hilarious or, more often, a mixture of both, as
Marsh recounts struggles against disease, discusses bureaucracy in the
NHS, and muses on a surgical life. As a narrator Marsh is painfully
honest, sharing both his triumphs and his failures. In a notable exception
to the condition-oriented titles of his chapters, ‘Hubris’ recounts an early
experience with the consequences that can arise from major neurological
surgery and shows how profoundly affected a doctor can be by a case
gone wrong. Marsh’s journey into neurosurgery is certainly not typical,
with a prior degree in politics, philosophy and economics, a short stint as
a porter, and an early diversion into anaesthetics all featuring in his
portfolio. This contributes to his likeability as a narrator, as he displays
the myriad of experiences and how they brought him to the profession
he finally entered.
The trainee’s perspective
When the Air Hits Your Brain is from the beginning more jovial in tone.
Written from the perspective of Vertosick as a trainee, it betrays the
naivety and immaturity of his early coping mechanisms with difficult
cases. Vertosick writes with a distinctly American voice, outgoing and
with an ascerbic wit, describing his younger self as confident to the point
of arrogance. His description of medical students as falling into three
categories – “Slackers, Keeners and Wild Cards” – may strike close to
home for many a student in our own College, while his rules of
neurosurgery may compete with the famous rules of Samuel Shem’s
‘House of God’ as the finest medical guidelines committed to print. His
own pursuit of what he views as perfection, “the surgical psychopath”, is
described in detail, and his description of his reaction to an unsuccessful
aneurysm surgery performed by one of his senior colleagues may make
even the most hardened, cynical student cringe. However, as the book
develops, his professional goals are altered by a number of cases. When
one finally emerges from the book it is with a sense of how Vertosick
developed as both a surgeon and a person through his training.
Something to offer all readers
So why compare these two memoirs? Beyond the profession of the men
writing them, do these books have anything in common? I have already
underlined the differences in tone and perspective that make both books
intriguing reads in very different ways. Ultimately, both books stress the
importance of compassion in the pursuit of a medical career. Both
describe the self-doubt that can emerge from managing difficult cases,
the consequences of one’s actions as a medical professional, and working
in a high-stress environment. In spite of both narrators’ chosen niche,
there are lessons in these books for readers in both medical and
non-medical careers, and both are engaging from front to back. When
the Air Hits Your Brain is rightly regarded as a medical classic, while Do No
Harm has featured on scores of non-fiction writing awards lists.
As a final note, one other reasonably famous neurosurgeon, Harvey
Cushing, remarked: “I would like to see the day when somebody would
be appointed surgeon somewhere who had no hands, for the operative
part is the least of the work”.1 Upon finishing both these books, the
reader comes away with the impression that there is a great deal more
to surgery than performing procedures, and that almost eight decades
on from Cushing’s death, his thoughts are as true as ever.
A tale of two theatres
DANIEL O’REILLY looks at two very different takes on a neurosurgical career.
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Oestrogen receptor gene mutations in
endocrine-resistant breast cancer
Benjamin Lau
RCSI medical student
Introduction
Breast cancer is the most common form of cancer in females. The
majority of breast cancers express the oestrogen receptor; oestrogen
exposure drives cell growth and division in the breast, and is therefore a
major risk factor for tumour development.1 Tamoxifen, a selective
oestrogen receptor modulator (SERM), is effective in treating oestrogen
receptor positive breast cancer due to its anti-oestrogen actions in
mammary tissue.2 However, metastatic disease may recur after the
tumour develops drug resistance.3 Mutations in the ligand binding
domain of ESR1, the gene coding for the oestrogen receptor, have
previously been found in metastatic breast tumours.4 This experiment
explored the possibly of resistance due to mutations in ESR1.
Methods
Genomic DNA was extracted from tamoxifen-resistant LY2 cells and
cells of their parent cell line MCF7, which are tamoxifen sensitive, using
a DNeasy Blood & Tissue Kit (Qiagen; Manchester, UK). Specifically
designed primers were used to target each of the eight exons in the
ESR1 gene, which were amplified by polymerase chain reaction (PCR).
Agarose gel electrophoresis was used to confirm that the PCR products
were the correct size. The PCR products were then purified using a
MinElute PCR Purification Kit (Qiagen), quantified by a Nanodrop 2000
Spectrophotometer (Thermo Fisher Scientific; Wilmington, USA) and
sent to GATC Biotech for sequencing. The results of sequencing were
compared using the bioinformatics tool BLAST.5
Results
All exons were amplified by PCR with the exception of exon 1,
which did not yield a specific PCR product even after redesigning
primers. Sequencing was successful except exon 4, which was not
sequenced accurately. A heterozygous point mutation at
nucleotide 336 resulting in an alanine to guanine substitution at
amino acid 112 was detected in exon 8, changing the codon
from ACA to ACG. However, both codons encode the amino acid
threonine, and therefore the mutation was non-functional.
Conclusion
There was no functional mutation found in the ESR1 gene of the
LY2 cells. Experimentation with alternate methods is needed to
produce a suitable PCR product for exon 1. Further investigation
into alternate mechanisms, such as cross-talk between the
oestrogen receptor and other growth factor receptors or ligands, is
needed to determine the cause of endocrine resistance in breast
cancer cells.3
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FIGURE 1: Images of the MCF7 PCR products on
electrophoresis gels. Columns on the left show a
reference ladder with increments of 100 base pairs.
FIGURE 2: Images of the LY2 PCR products on
electrophoresis gels. Columns on the left show a
reference ladder with increments of 100 base pairs.
FIGURE 3: Comparison of MCF7 and LY2 sequences in
exon 8 with the point mutation highlighted.
Image by Catherine Tennant.
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